



US009085616B2

(12) **United States Patent**
Aderem et al.

(10) **Patent No.:** **US 9,085,616 B2**
(45) **Date of Patent:** ***Jul. 21, 2015**

(54) **TOLL-LIKE RECEPTOR 5 LIGANDS AND METHODS OF USE**

(75) Inventors: **Alan Aderem**, Seattle, WA (US);
Fumitaka Hayashi, North Quincy, MA (US); **Kelly D. Smith**, Seattle, WA (US);
David M. Underhill, Seattle, WA (US);
Adrian Ozinsky, Seattle, WA (US)

(73) Assignees: **THE UNIVERSITY FOR SYSTEMS BIOLOGY**, Seattle, WA (US);
UNIVERSITY OF WASHINGTON, Seattle, WA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 715 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/191,093**

(22) Filed: **Jul. 26, 2011**

(65) **Prior Publication Data**

US 2012/0269855 A1 Oct. 25, 2012

Related U.S. Application Data

(63) Continuation of application No. 12/546,593, filed on Aug. 24, 2009, now abandoned, which is a continuation of application No. 10/125,692, filed on Apr. 17, 2002, now Pat. No. 7,915,381.

(60) Provisional application No. 60/285,477, filed on Apr. 20, 2001.

(51) **Int. Cl.**

A61K 39/39 (2006.01)
C07K 14/21 (2006.01)
C07K 14/195 (2006.01)
C07K 14/24 (2006.01)
C07K 14/255 (2006.01)
A61P 31/04 (2006.01)
C07K 14/25 (2006.01)
C07K 14/20 (2006.01)
C07K 14/32 (2006.01)
C07K 14/33 (2006.01)
A61K 39/02 (2006.01)
A61P 37/04 (2006.01)
C07K 14/28 (2006.01)
C07K 14/245 (2006.01)
A61K 39/00 (2006.01)

(52) **U.S. Cl.**

CPC **C07K 14/195** (2013.01); **C07K 14/255** (2013.01); **A61K 39/00** (2013.01); **A61K 2039/55516** (2013.01); **C07K 2319/00** (2013.01)

(58) **Field of Classification Search**

CPC **C07K 14/195**; **C07K 14/255**; **C07K 2319/00**; **A61K 2039/55516**; **A61K 39/00**
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,194,254 A	3/1993	Barber et al.
5,420,109 A	5/1995	Suto et al.
5,612,035 A	3/1997	Howell
5,614,192 A	3/1997	Vandenbark
5,618,533 A	4/1997	Flavell et al.
5,677,427 A	10/1997	Goldenberg et al.
5,817,308 A	10/1998	Scott et al.
5,837,825 A	11/1998	Meinersmann et al.
6,030,624 A	2/2000	Russell et al.
6,130,082 A	10/2000	Majarian et al.
6,548,295 B2	4/2003	Andre et al.
6,610,298 B2	8/2003	Hasan et al.
6,610,661 B1	8/2003	Carson et al.
6,685,935 B1	2/2004	Pawelek et al.
6,703,487 B2	3/2004	Bird et al.
6,740,487 B1	5/2004	Schwartz et al.
6,753,166 B2	6/2004	Sims et al.
6,797,813 B2	9/2004	De Waal Malefyt et al.
2003/0232055 A1	12/2003	Medzhitov

FOREIGN PATENT DOCUMENTS

WO	WO-02/09748	2/2002
WO	WO-02/085933	10/2002

OTHER PUBLICATIONS

Adachi et al., *Immunity* (1998) 9:143-150.
Aderem and Ulevitch, *Nature* (2000) 406:782-787.
Ahlers et al., *J. Immunol.* (1997) 158:3947-58.
Blackburn et al., *Nature Structural Biology* (2000) 7:847-849.
Bowie et al., *Science* (1990) 257:1306-1310.
Brem et al., *J. Neurosurg.* (1991) 74:441-446.
Brightbill and Modlin, *Immunology* (2000) 101:1-10.
Brightbill et al., *Science* (1999) 285:732-736.
Brostoff et al., *Immunol. Ser.* (1993) 59:203-218.
Cario and Podolsky, *Infect. Immun.* (2000) 68:7010-7017.
Chaudhary et al., *Blood* (1998) 91:4020-4027.
Ciacci-Woolwine et al., *Infect. Immun.* (1998) 66:1127-1134.
Ciacci-Woolwine et al., *Infect. Immun.* (1999) 67:5176-5185.
Collins et al., *PNAS* (1995) 92:8036-8040.
Cookson et al., *The American Association of Immunologists* (1997) 158:4310-4319.
Das Gracas Luna et al., *Res. Microbiol.* (2000) 151:575-582.
De Vries et al., *Appl Environ Microbiol* (1998) 64(12):5033-5038.

(Continued)

Primary Examiner — Robert A Zeman

(74) *Attorney, Agent, or Firm* — Morrison & Foerster LLP

(57) **ABSTRACT**

The invention provides methods to elicit an immune response with an immunomodulatory flagellin polypeptide having toll-like receptor 5 (TLR5) binding, and further comprising an ADCC targeting molecule.

8 Claims, 18 Drawing Sheets

(56)

References Cited**OTHER PUBLICATIONS**

Dorland's Medical Dictionary, definition of immunomodulator and immunomodulation, retrieved online at <<http://www.mercksource.com>> on Jun. 27, 2007.

Eaves-Pyles et al., *J of Immunol* (2001) 167:7009-7016.

Eaves-Pyles et al., *The Journal of Immunology* (2001) 166:1248-1260.

Eroshkin et al., *Comput Appl Biosci* (1993) 9:491-497.

Feghali and Wright, *Frontiers in Bioscience* (1997) 2:D12-D26.

Felix et al., *Plant Journal* (1999) 18(3):265-276.

Fujita and Yamaguchi, *J. Gen. Microbiol.* (1973) 76:127-134.

Gewirtz et al., *The Journal of Clinical Investigation* (2001) 107:99-109.

Goodlett et al., *Anal Chem* (2000) 72:1112-1118.

Gomez-Gomez and Boller, *Mol. Cell* (2000) 5:1003-11.

Hayashi, *Nature* (2001) 410(6832):1099-1103.

Herlyn and Birebent, *Ann Med* (1999) 31:66-78.

Ibrahim et al., *J. Clin. Microbiol.* (1985) 22:1040-1044.

Joys and Schodel, *Infect. Immun.* (1991) 59:3330-3332.

Joys and Street, *Infect. Immun.* (1993) 61:1146-1148.

Joys, *Journal of Biological Chemistry* (1985) 260(29) 15758-15761.

Kopp et al., *Current Opinion in Immunology* (1999) 11:13-18.

Kuwajima et al., *Bacteriol.* (1988) 170:3305-3309.

Kuwajima et al., *PNAS USA* (1989) 86:4953-4957.

Lazar et al., *Molecular and Cellular Biology* (1988) 8(3):1247-1252.

Logan et al., *J. Bacteriology* (1989) 171:3031-3038.

Major, *J Receptor and Signal Transduction Res* (1995) 15:595-607.

McDermott et al., *Infect. Immun.* (2000) 68:5525-9.

McEwen et al., *Vaccine* (1992) 10:405-411.

McSorley et al., *J. Immunol.* (2000) 164:986-993.

Means et al., *Cytokine Growth Factor Rev.* (2000) 11:219-232.

Medzhitov et al., *Nature* (1997) 388:394-397.

Medzhitov et al., *Mol. Cell* (1998) 2:253-268.

Mellentin-Micelotti et al., *Anal Biochem* (1999) 272:P182-190.

Mimori-Kiyosue et al., *J. Mol. Biol.* (1997) 270:222-237.

Muzio et al., *J. Immunol.* (2000) 164:5998-6004.

Namba et al., *Nature* (1989) 342:648-654.

Newton et al., *Vaccines* (1990) 90:439-445.

Newton et al., *Science* (1989) 244:70-72.

Ozinsky et al., *PNAS USA* (2000) 97:13766-13771.

Peel et al., *J. Gen. Microbiol.* (1988) 134:2171-2178.

Roberts and Vellacio, *The Peptides: Analysis, Synthesis, Biology*, Eds., Gross and Meinhofer (1983) 5:341, New York, NY, Academic Press, Inc.

Rock et al., *PNAS USA* (1998) 95:588-593.

Samakovlis et al., *Biochem. Biophys. Res. Commun.* (1992) 188:1169-1175.

Samatey et al., *J. Struct. Biol.* (2000) 132:106-111.

Samatey et al., *Nature* (2001) 410:331-337.

Scanga and Legros, *Drugs* (2000) 59(6):1217-1221.

Sebastiani et al., *Genomics* (2000) 64:230-240.

Sequence alignment for SEQ ID No. 8, 44-50.

Smith et al., *Nature Immunol* (2003) 4(12):1247-1253.

Steidler et al., *Infect Immun* (1998) 66:3183-3189.

Steiner et al., *J. Clin. Invest.* (2000) 105:1769-77.

Stocker and Newton, *Int. Rev. Immunol.* (1994) 11:167-178.

Sutton and Lee, *Aliment Pharmacol* (2000) 14:1107-1118.

Sztein et al., *Journal of Infectious Diseases* (1994) 170(6):1508-1517.

Underhill et al., *Nature* (1999) 401:811-815.

Uniprot/Swissprot Database, Accession No. FLIC_SALRU, 2 pages.

Urban et al., *Cell* (1988) 54:577-592.

Van Asten et al., *Journal of Bacteriology* (1995) 177(6):1610-1613.

Von Herrath and Whitton, *Ann Med* (2000) 32:285-292.

Wei et al., *Nucleic Acids Research* (1986) 14:8227.

Wilson and Czarnick, Eds., *Combinatorial Chemistry* (1997) 11:235, New York, NY, John Wiley & Sons.

Wolff, Ed., *Burger's Medicinal Chemistry and Drug Discovery* (1995) 15:619-620, New York, NY, John Wiley & Sons.

Wyant et al., *Infect. Immun.* (1999) 67:3619-24.



Wyant et al., *Infect. Immun.* (1999) 67:1338-46.

Xu et al., *The American Association of Immunologists* (1998) 160:1285-1289.

Youngkin, *Nat Med* (2001) 7(1):18-19.

Zhang et al., *Anal Biochem* (1999) 268:134-142.

Zuck et al., *PNAS USA* (1999) 96:11122-11127.

**FIG. 1A****FIG. 1B**




FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4A

MKVNTNIISLKTQEYLRKNNEGMTQAQERLASGKRINSSLDD
AAGLAVVTRRMNVKSTGLDAASKNSSMGIDLLQTADSALSSMS
SILQRMRLABQSSNGSFSDEDRKQYTAEFGLIKELDHVAD
TTNYYNNIKLLDQTATGAATQVSIQASDKANDLINIDLFNAKG
LSAGTITLGSGSTVAGYSALSVADADSSQEATEAIDELINNI
SNGRALLGAGMSRLLSYNVSNNVNNQSIATKASASSIEDADMAA
EMSEMTKYKILTQTSISMLSQANQTPQMLTQLINS

FIG. 4B




FIG. 4C




FIG. 5A




FIG. 5B




FIG. 5C





FIG. 5D

**FIG. 6**

C.jejuni	1	MGFRINTNVAALNAKANADLNSKSLDASLSRLSSGLRINSAADDA SGMAIADTLRSQANT
H.pylori	1	MAFQVNTNINAMNAHVQSA LTIQNALKTS LERLSSGLRINKAADDA SGMTVADS LR SQASS
V.cholerae	1	MTINVTNVSAMTAQRYLT KATGELN TSMERLSSGNRINSAKDDAAGLQI SNRL TAQSRG
P.aeruginosa	1	MALTVENTNIASLNTQRNLN SSASLNT SLQRLSTGSRINSAKDDAAGLQIANRLTSQVNG
R.sphaeroides	1	-MT ITINTNIGAIAAQANMT KVNDQF TAMTRLSTGLRINAKDDAAGMAI GEK MTAQVMG
P.mirabilis1	1	MAQVINTN YLS LV TQNNLNKSQGT LGSAIERLSSGLRINSAKDDAAGQAIANRFTSNVNG
P.mirabilis2	1	MAQVINTN YLS LV TQNNLNRSQ SALGNAIERLSSGMRINSAKDDAAGQAIANRFTSNVNG
S.typhimurium2	1	MAQVINTN SL SL LTQNNLNKSQ SALGTAIERLSSGLRINSAKDDAAGQAIANRFTANIKG
S.typhimurium1	1	MAQVINTN SL SL LTQNNLNKSQ SALGTAIERLSSGLRINSAKDDAAGQAIANRFTANIKG
S.marcesens	1	MAQVINTN SL SL MAQNNLNKSQ SSLGTAIERLSSGLRINSAKDDAAGQAI SNR FTANIKG
E.coli	1	MAQVINTN SL SL ITQNNLNKNQ SALSSS IERLSSGLRINSAKDDAAGQAIANR FTSNIKG
S.flexneri	1	MAQVINTN SL SL ITQNNLNKNQ SALSSS IERLSSGLRINSAKDDAAGQAIANR FTSNIKG
T.pallidumA	1	--MI INHNM SA MF AQ RT LGHT WVGKIEKLSSGYRINRAGDDA SG LA VSEK MR SQIRG
T.pallidumB	1	--MI INHNM SA MF AQ RT LGNT NLSVQKNMEKLSSGLRINRAGDDA SG LA VSEK MR SQIRG
L.pneumophila	1	--MI INHNL SA VNAHR SLKF NELAVDKTMKALSSGMRINSAADDA SG LA VSEK LR TQVNG
B.burgdorferi	1	--MI INHNT SA IN ASRMNGINAA NLSKTQEKLS SGYRIN RA SD DAAGMGVSGKINAQIRG
B.subtilus	1	--MR INHNI A AL NTLNRLSSNN SA SQKN MEKLSSGLRINRAGDDAAGLAI SEK MR GQIRG
C.difficile	1	--MR VNTN VS ALI ANNQ MGRNV SGQSK SMEKLSSGLRIKRAADDAAGLAI SEK MR AQLKG
R.meliloti	1	-MT SIL TNN SA MA AL STLRSISS MEDTQSR ISSGLR VG SA SDNAA YW SI ATT MR SDNQ A
A.tumefaciens	1	-MA SIL TNN NA MA AL STLRSIAS DLSTTQDR ISSGL KV SA SDNAA YW SI ATT MR SDNKA
R.lupini	1	-MA S VL TN IN AM SA LQ TLRSISS NMEDTQSR ISSG MR VG SA SD NAA YW SI ATT MR SDNAS
L.monocytogenes	1	--MK VNTN II SL K TQ EYLRKN EGMTQ AQ ERLASGKRINS SL DDAAGLA W VT RM NVKSTG
B.claridgeiae	1	MG TSLL TN K SA MT AL QTLRSIDAN LD R SKDR VS TGLRIS NA SENTAY W SI SS MMR HD SNT
consensus	1	m intNv al aq nl k q 1 slerlssGlrinsa ddaagmaia rl sqvrg

FIG. 7AA

C.jejuni	61	LGQAISNGND AIGIL QTA D KAMDE QLKILDT I KTKAT QAAQD --G QSL KTR TM L Q ADINR
H.pylori	61	LGQAIA NTNDGMGI IQVADKAMDE QLKILDTVKVKAT QAAQD --G QT TESRKA IQSD IVR
V.cholerae	61	LDVAMRN ANDGIS IAQTAEGAM NESTSIL QMRDLALQ SANG-- TNSASERQALNE ESVA
P.aeruginosa	61	LNVA TKNANDGIS LAQTAEGAL QOSTN ILQMRDLSLQ SANG-- SNSD SERTAL NGEAKQ
R.sphaeroides	60	LNQAIRNAQ DGKNLVD TTEGAH VEVSS MLQRLRELAVQ SSND-- TNTAAD RGS LAAEGKQ
P.mirabilis1	61	LTOASRN ANDGIS IAQTTEGAL NEINN NLQRIRELTVQAKNG -- TNSNSD ITS IQNE VKN
P.mirabilis2	61	LTOASRN ANDGIS VSQTTEGAL NEINN NLQRIRELTVQAKNG -- TNSNSD INS IQNE VNQ
S.typhimurium2	61	LTOASRN ANDGIS IAQTTEGAL NEINN NLQRIRELTVQAKNG -- TNSQSD LDS IQAE ITQ
S.typhimurium1	61	LTOASRN ANDGIS IAQTTEGAL NEINN NLQRIRELTVQAKNG -- TNSQSD LDS IQAE ITQ
S.marcesens	61	LTOASRN ANDGIS LAQTTEGAL NEVND NLQIRRLTVQAQNG -- SNSTSD LKS IQDE ITQ
E.coli	61	LTOAARN ANDGIS VAQTTEGAL SEINN NLQRIRELTVQATTG -- TNSDSD LDS IQDE IKS
S.flexneri	61	LTOAARN ANDGIS VAQTTEGAL SEINN NLQRIRELTVQASTG -- TNSDSD LDS IQDE IKS
T.pallidumA	59	LNQASTNA SGVNF IQVTEAYLQETTD IM QRIRELA IQANG -- IYSAED RM QIQVE VSQ
T.pallidumB	59	LNQASTNAQ NGISF IQVAESYLQETTD VI QRIRELSVQ SANG-- IYSAED RM YIQVE VSQ
L.pneumophila	59	LRQAERN TE DGMSFIQTAEGF LEQTSN IIQIRIVLA IQTSNG -- IYSNED R QLVQVE VSA
B.burgdorferi	59	LSQASRN TSKAINF IQTTEGN LN VEKVLVRMKELAVQ SGNG-- TYS DADRG SIQIE IEQ
B.subtilus	59	LEMASKNSQ DGIS LIQTAEGAL TE THAILQRVREL V VQAGNTGTQDKATD L QSIQDE ISA
C.difficile	59	LDQAGRN VQDGIS VVQTAEGALEETGN IL TRMRTLAVQA SN ET--NSKDERAKIAGE MEQ
R.meliloti	60	LSAVQD ALGLGA AKVDTAYS GMESAIEV VKEIKAKLVA ATED----- GVDKAKIQEE ITQ
A.tumefaciens	60	LGAVSD ALGMGA AKVDTASAGMDAAIKV TD IKAKVVAAKEQ ----- GVDKTKVQEE VSQ
R.lupini	60	LSAVQD AI GLGA AK VD TASAGMDAVID VVKQIKNKL V TAQES ----- SADKTKIQGE VKQ
L.monocytogenes	59	LDAASKN SSMGID LLQTAD SALSS SSILQMRQLAVQ SSNG-- SFSD EDRK QYTA EFGS
B.claridgeiae	61	MSAIVDA INL KEQVGIA DTA I GLT KEALDDIQKSMV SAREK----- GSDDIAKIQD SIIG
consensus	61	l qatrnandgisilqtaegal e ilqirdl vqa ng tqs dr iq ei q

FIG. 7AB

C.jejuni	119	LME ELDN IA NT TSFNGKQLLSGN FINQ EFQIG ASSN-QTVKATIGATQSSKIGLTRFETG
H.pylori	119	LIQGL DN IGN TT YNGQALLSGQFTNKEFQVG AYSN-QS IKASIG STTS DKIGQVRI ATG
V.cholerae	119	LQDEL NR IAETTSF GGR KLLNGS FGEAS FQIG SSSG-EA IIMGLTSVR ADDFR-----
P.aeruginosa	119	LQKEI DR ISNTTFFGRKLLDGS FGVAS FQVG SAAN-EI ISVGID EMSAES LN GT YF KAD
R.sphaeroides	118	LIAE INR VAESTTFNGMKVLDGS FTG KLQIG ADSG-QT MAINVD SAATD IGA -----
P.mirabilis1	119	VLDE INR ISEQTQFNGVKVLSGEK SEM IQVG TNDN-ET IKFNLDKID NDT LG VASDKLF
P.mirabilis2	119	RLDE INR VSEQTQFNGVKVLSGEK SKMT IQVG TNDN-EV IEFNLDKID NDT LG VASDKLF
S.typhimurium2	119	RLNE IDR VSGQTQFNGVKVLA-QD NLT IQVG ANDG-ET IDIDLKQINSQ TL GLD SLNVQ
S.typhimurium1	119	RLNE IDR VNGQTQFSGVKVLA-QD NLT IQVG ANDG-ET IDIDLKQINSQ TL GLD TLNVQ
S.marcesens	119	RLSE INR ISEQTDFNGVKVLS-SD QKL TIQVG ANDG-ET TDIDLKKIDAKQ LGMD TFD VT
E.coli	119	RLDE IDR VSGQTQFNGVNVLS-KD GSM KIQVG ANDG-ET TTIDLKKIDS DT LN LAGFNVN
S.flexneri	119	RLDE IDR VSGQTQFNGVNVLA-KD GSM KIQVG ANDG-QT TTIDLKKIDS DT LG LNGFNVN
T.pallidumA	117	LVAE VDRI ASSAQFNGMNL LTGRFSRTEG----- ENVIGGSMW FH
T.pallidumB	117	LVAE IDRI ASHAQFNGMNL TG RF ARETG----- ENTVTASM WFH
L.pneumophila	117	LVDE VDRI ASQAEFNKFLFEGQ FARGS----- R---VASM WFH
B.burgdorferi	117	LTDE INRI ADQAYNQMHML SNKSASQNV RTAEELGMQ PAKINT PASLSGSQ ASWT ILRVH
B.subtilus	119	LTDE IDGISNR TEFNGKLLDGT YKVD TATP ----- ANQKNL VFQ
C.difficile	117	LRSE VDRI ADSTKFNGEN LLS- SDKKIALQVG ----- AEAVSNNV IEVS
R.meliloti	115	LKDQ LT IAEAA S FGENWLQAD LSGGPV TKSVVGGFVRD SSGAVS VKKVDYS LN TD TVL
A.tumefaciens	115	LLDQ LKS IGTSASFNGENWL VSSAN--- ATKT VVSGFVR DAGT VS VKT TDY ALDANS ML
R.lupini	115	LQEQLKGI VDSAS FGENWLKGD LS- TTTTKS VVGSFV RE-GGT VS VKTIDYAL NASKVL
L.monocytogenes	117	LIKE LDHVAD TTNNIKLLDQ TATGA ATQVS ----- IQASDKAN DLINID
B.claridgeiae	117	NMKN ISNA VQSAS FGGKNIL SNGGQ TVGMAAGYR REGTA VYVD MID VGGSE LN FGT IGSD
consensus	121	lmeidria t fngmkll g qig v i v igl l

FIG. 7BA

C.jejuni	178	GRISTSGEVQFTLKNYNGIDDFQFQKVVISVGTGLGALADEINKNADKTG----	VRAT
H.pylori	178	ALITASGDISLTFKQVDGVNDVTLESVKVSSAGTGIGVLAEVINKNSNRTG----	VKAY
V.cholerae	171	MGGQSFIAEQPKTKEWGP-----	
P.aeruginosa	178	GGGAVTAATASGTVDIAIG-----	
R.sphaeroides		-----	
P.mirabilis1	178	DTKEKKGVTAAG-----	
P.mirabilis2	178	DAKTEKKGVTAAG-----	
S.typhimurium2	177	KAYDVKDTAVTTKAYANNGTLDVSGLDDAAIKAAATGGTNGTASVT----	GGAVKFD
S.typhimurium1	177	QKYKVSDDTAATVTGYADTTIALDNS-----TFKASATGLGGTDEKI----	DGDLKFD
S.marcesens	177	TKSAKAGAEIATG-----	
E.coli	177	GEGETANTAATLKDMLVGLKLDNTGVTAGVNRYYIADKAVASSTDILNAVAGVDGSKVSTE	
S.flexneri	177	GGGAVANTAASKADLVAANATVVGNKYTVSAGYDAKASDLLAGVS--D--	GDTVQAT
T.pallidumA	157	IGANMDQMR-----VY-----	
T.pallidumB	157	IGANMDQRT-----AY-----	
L.pneumophila	153	MGPNNQNR-----FY-----	
B.burgdorferi	177	VGANQDEAIA-----VN-----	
B.subtilis	159	IGANATQQIS-----VN-----	
C.difficile	160	LINTKGVLT-----RN-----	
R.meliloti	175	FDTTGN---TGILDKVYN-----	
A.tumefaciens	172	YTEG-----	
R.lupini	173	VDTRATGKTGILTAYTG-----	
L.monocytogenes	163	LFNAKGLSAG-----	
B.claridgeiae	177	GTIDMSQGVLGIGFGTSKG-----	
consensus	181		

FIG. 7BB

C.jejuni	234	FTVETRGIAAVRAGATSDTFAINGVKIGKVDYKDGANGALVAAINSVKDTTGVEASIDA
H.pylori	234	ASVITTSDVAVQSGSLNLTNGIHLGNIADIKKNSDGRLLVAAINAVTSETGVEAYTDQ
V.cholerae	190	-----PTARDLKFEFTKK
P.aeruginosa	197	-----ITGGSVNVKVDM
R.sphaeroides		-----
P.mirabilis1	191	-----AG-----VTDKAKINA
P.mirabilis2	191	-----DA-----IDANALGIS
S.typhimurium2	230	ADNNKYFVTIGGFTGADAAKNG--DYEVNVA TDGTVTLAAGATKTTMPAGATTKTEVQEL
S.typhimurium1	225	DTTGKYYAKVTVTG--GTGKDG--YYEVSVDKTNGEVTLAAVTPATVTTATATALSCKMYSA
S.marcesens	190	-----T-----KITVDS--DA
E.coli	237	ADVGFGAAAPGTPVEYTYHKDTNTYTASASVDATQLAAFLNPEAGGTTAA TVSIGNGTTA
S.flexneri	231	INNGFGTAASATNYKYDSASKS-YSFDTT TASAADVQKYLTPGVGDTAKGTITIDG---S
T.pallidumA	169	-----IGTMTAVA
T.pallidumB	169	-----IGTMTAAA
L.pneumophila	165	-----IGTMTSKA
B.burgdorferi	189	-----IYAANVAN
B.subtilus	171	-----IEDMGADA
C.difficile	172	-----VNSANIDA
R.meliloti	190	-----VSQASVTLPPNV
A.tumefaciens	176	-----T--
R.lupini	192	-----LNANTVTVDINK
L.monocytogenes	173	-----
B.claridgeiae	196	-----DEGEDVVVGKGIGA
consensus	241	

FIG. 7CA

C.jejuni	294	NGQLLLTSREGRGIKIDGNIGGGAFINADMKENYGRLSLVKNDGKDILISGSNLSSAGFG
H.pylori	294	KGRNLRSIDGRGIEIK-----TDSVSNGPSALTMVNGGQDLTKGSTNYGRLSLT
V.cholerae	203	DG----EAVVLDIIAKDGD-----DIEELA-----TYINGQTD
P.aeruginosa	210	KGNETAEQAAAKIAAAVND-----ANVGIG-----AFSDGDTI
R.sphaeroides		-----
P.mirabilis1	202	AATLDMVSLVKEFNLDG-----KPVTDK-----FIVTKGGKD
P.mirabilis2	202	GSKKYVTGISVKEYKVDG-----KVSSDK-----VVLNDGSDDD
S.typhimurium2	288	KDTPAVVSADAKNALIAGGV-----DATDANGAELVKMSYTDKNGKTIEGGYALKAGDK
S.typhimurium1	281	NPDSDIAKAALTAAGVTG-----TASVVKMSYTDNNGKTIDGGLAVKVGDD
S.marcesens	199	T-----KQADADVTLAKG-----QTLVSG-----TDADGKSA
E.coli	297	QEQKVI IAKDGSLTAADDG-----AALYLDGTGNLSKTN-AGTDTQAKLS
S.flexneri	287	-AQDVQISSDGKITASNG-----DKLYIDTTGRLTKNKGASLTEASLS
T.pallidumA	177	LG-----
T.pallidumB	177	LG-----
L.pneumophila	173	LK-----
B.burgdorferi	197	LFSGEGAQAQAQAPVQEGA-----
B.subtilus	179	LGIKEADG-----
C.difficile	180	MS-----
R.meliloti	202	NGTSEYTVGAYNVDDLID-----ASATFDGDYANVGAGALAGDYVVKVQG
A.tumefaciens	177	-----
R.lupini	204	GGVITQASVRAYSTDEMLS-----LGAKVDGANSNVAVGGGSAFVKVDGS
L.monocytogenes	173	-----
B.clarridgeiae	209	FSAAHATYKGLEDTLRN-----AEADLAKAIAKYGESPEDEPGKAI
consensus	301	

FIG. 7CB

C.jejuni	354	ATQFISQASVSLRESKGQIDANIADAMGFGSANKGVVLGGYSSVSAYMSSAGSGFSSGSG
H.pylori	344	RLDAKSINVVSAS-----DS-----HLGFTAIGFGESQV
V.cholerae	232	LFKASVDQEGKLQ-----Q-----IFVAEPNIEGNFN
P.aeruginosa	243	SYVSKAGKDGSGA-----ITSASVSGVVIADT
R.sphaeroides		-----
P.mirabilis1	235	YVATKSDFFELDAT-----GTK--LGLKASAT
P.mirabilis2	235	YIVSKSDFTLKSG-----TTTGEVEFTGSKT
S.typhimurium2	342	YYAADYDEATGAI-----KAKTTSYTAADGT
S.typhimurium1	327	YYSATQDKDG-SI-----SIDTTKYTADNGT
S.marcesens	227	YFIATKDDATGDV-----AYTKAKVADDGKV
E.coli	341	DLMANNANAKTVI-----TT-DKGTFTANTT
S.flexneri	330	TLAANNTKATTID-----IGGTSISFTGNST
T.pallidumA	179	-----VRNGVDESIMSIE
T.pallidumB	179	-----VRDVGDESILNID
L.pneumophila	175	-----LVKADGR-PIAIS
B.burgdorferi	216	QOEGAQQPAPVTA-----PSQGGVNSPVNVT
B.subtilus	187	---SIAALHSVND-----LDVTKFADNAADT
C.difficile	182	-----VS---GSI
R.meliloti	247	SWVKAVDVAATQGEVVYDD-----GTTKWGVDTTIVTGAPATNVA
A.tumefaciens	177	--PGTIDANS-----GILNATGATTTVG
R.lupini	249	WVKGSVDAAAASITASTPVAGK-----FAAAYTAAEAGTAAAGDAIIVDETNNGAGAV
L.monocytogenes	173	-----TITLGSGSTVAGYS
B.claridgeiae	250	IEKAKQAVETAKTG-----LKDGQEAYNKAKG
consensus	361	m

FIG. 7DA

C.jejuni	414	YSVSGGKNYSTGFANAIAISAASQLSTVYNVSAGSGFSSGSTLSQFA-----T-----
H.pylori	374	AETTVNLRDVTGNFNANVKASGANYNANVIAASGNQSLGSG-----
V.cholerae	258	ISGGLATELGLN-----
P.aeruginosa	269	GSTGVGTAAGVAPSA-----
R.sphaeroides		-----
P.mirabilis1	259	TEFKVDAGKDVKTLN-----
P.mirabilis2	261	TKFTADAGKDVKVLN-----
S.typhimurium2	368	TKTAANQLGGVDGKTEVVVTIDGKTYNAS-----
S.typhimurium1	352	SKTALNKLGGADGKTEVVVTIDGKTYNAS-----
S.marcesens	253	TDSGTDAG-----
E.coli	366	KFDGVDISVDASTFANAVKNETYATVG--VTLPATYTVNNGTAASAYLVDGKVS KTP--
S.flexneri	356	TPDTITYSVTGAKVDQAAFDKAVSTSGNNVDTTAGYSVNGTTGAVTKGVDSVYVDNNEA
T.pallidumA	192	--TADSAN-----
T.pallidumB	192	--DPEKAN-----
L.pneumophila	187	--SPGEAN-----
B.burgdorferi	242	--TTVDAN-----
B.subtilus	210	--ADIGFD-----
C.difficile	187	--GTEAAS-----
R.meliloti	286	APASIAATIDITIAAQ-----
A.tumefaciens	198	AKTYTQISVLDMNVG-----
R.lupini	302	NLTQSVLTMDVSSMS-----
L.monocytogenes	187	ALSVADAD-----
B.claridgeiae	277	EFQTVLDGMTLADFTELKG-----
consensus	421	

FIG. 7DB

C.jejuni	462	-----MKTTFAGVKDETAGVTTLKGAMAVMDIAET A TT
H.pylori	414	-----VTTLRGAMVVIDIAES A MK
V.cholerae	270	-----GGPGVKTTVQDIDITSVGGSQNAVGI IDAAL K
P.aeruginosa	284	-----TAFAKTNDTVAKIDISTAKALSRRAGRDRT T AIK
R.sphaeroides		-----
P.mirabilis1	274	-----VKDDALAT LDKA IN
P.mirabilis2	276	-----VKDDALAT LDNA IS
S.typhimurium2	396	-----KAAGHDFKAQPELAEAAAKTTENPLQK IDAAL A
S.typhimurium1	380	-----KAAGHDFKAQPELAEQAAKTENPLQK IDAAL A
S.marcesens	261	-----VKNPLAT LDKA LA
E.coli	422	-----AEYFAQADGTTSGENAATSKAIYVSANGNLTTTSESEATTNPLAAL DDA IA
S.flexneri	416	LTTSDTVDFYLQDDGSVTNG---SGKAVYKDADGKLTTDAETKAATTADPLKAL DEA IS
T.pallidumA	198	-----KSIGT IDAAL K
T.pallidumB	198	-----RAIGT LDEA IK
L.pneumophila	193	-----DVIGLAD AAL T
B.burgdorferi	248	-----TSLAKI ENA IR
B.subtilus	216	-----AQIKVV DEA IN
C.difficile	193	-----KMIIVN LDSS LA
R.meliloti	301	-----AGNLDALIAGV DEA LT
A.tumefaciens	213	-----TDDLDNALYSV ET ALT
R.lupini	317	-----STDVGSYLTGV EKA LT
L.monocytogenes	195	-----SSQEATEA IDE LIN
B.clarridgeiae	296	-----LGELHSDIQRMINTSVQNTVRD A IN
consensus	481	m id am

FIG. 7EA

C.jejuni	495	NLDQIRADIGSVQNVQVTSTINNITVTQVNVKAESQIRDVDFAAESANYSKANILAQSGS
H.pylori	433	MLDKVRSDLGSVQNMISTVNNISITQVNVKAESQIRDVDFAAESANFNKNNILAQSGS
V.cholerae	302	YVDSQRADLGAQNRLSHSISNLSNIQENVEASKRIKDTDFAKETTQLTKSQILQQAGT
P.aeruginosa	317	QIDASVPTSVAVQNRFDNTINNLNKNIQENVSAAARGRIEDTDFAAETANLTKNQVLQQAGT
R.sphaeroides		-----
P.mirabilis1	288	TIDESRKLGAIQNRFFESTINNLNNTVNNLSASRSRIILDADYATEVSNMSRGQILQQAGT
P.mirabilis2	290	KVDESRSKLGAIQNRFFQSTINNLNNTVNNLSASRSRIILDADYATEVSNMSKNQILQQAGT
S.typhimurium2	429	QVDALRSDLGAQNRFNFAITNLGNTVNNLSEARSRIEDSDYATEVSNMSRAQILQQAGT
S.typhimurium1	413	QVDTLRSDLGAQNRFNFAITNLGNTVNNLSARSRIEDSDYATEVSNMSRAQILQQAGT
S.marcesens	274	QVDGLRSSLGAQNRFFDSVINNLNSTVNNLSASQSRRIQDADYATEVSNMSRANILQQAGT
E.coli	476	SIDKFRSSLGAIQNRLLDSAVTNLNNTTNNLSEAAQSRRIQDADYATEVSNMSKAQIIQQAGN
S.flexneri	472	SIDKFRSSLGAQNRLLDSAVTNLNNTTNNLSEAAQSRRIQDADYATEVSNMSKAQIIQQAGN
T.pallidumA	209	RINKQRADLGGYQNRMEYTWGLDIAAENLQAAESRIRDANI AKQWVEYTKNQVLTQSGT
T.pallidumB	209	KINKQRADLGAQNRLEYTVIGNVAAENLQAAESRIRDVDMAKEWVDYTKNQILVQSGT
L.pneumophila	204	KIMKQRA DMGAYYNRLEYTAKGLMGAYENMQASESRIRDADMAEEVWSLTTKQIILVQSGT
B.burgdorferi	259	MISDQARANLGAQNRLESIKDSTEYAIENLKASYAQIKDATMTDEWVAATTNSILTQSAM
B.subtilus	227	QVSSQRAKLGAQNRLEHTINNLSASGENLTAAESRIRDVDMAKEMSEFTKNNILSQASQ
C.difficile	204	DINSARALLGAQNRLESTQNNLNNTVENVTAAESRIRDTDVASEMVNLSKMMNLLVQASQ
R.meliloti	317	DMTSAAASLGSISSRIDLQSDFVNKLSDSIDSGVGRLVADMMNEESTRLKALQTQQQLAI
A.tumefaciens	229	KMTSAGAKLGSLSARIDLQSGFADKLSDTIEKGVGRLVADMMNEESTKLKALQTQQQLAI
R.lupini	333	SLTSAGAEELGSIKQRIDLVDFASKLGDALAKGIGRLVDADMMNEESTKLKALQTQQQLAI
L.monocytogenes	209	NISNGRALLGAGMSRLSYNVSVNNQSIATKASASSIEDADAAEMSEMFKYKILTTQTSI
B.claridgeiae	321	VTLTAGSKIGAAVNLWNIQNFVKKLLDNVEVGIGALVDADMNAESAKLAALQVQQQLGI
consensus	541	l ra lgavqnrvd i nl enl aa sri dad a evtlnsk qilqq gs

FIG. 7EB

C.jejuni	555	YAMAQANSVHQNVLRLLQ--
H.pylori	493	YAMSQANTVQQNILRLLT--
V.cholerae	362	SILAQAKQLPNSAISLLQ--
P.aeruginosa	377	ATLAQANQLPQSVLSLLR--
R.sphaeroides		-----
P.mirabilis1	348	SVLAQANQVPQTVLSLLR--
P.mirabilis2	350	AVLAQANQVPQTVLSLLR--
S.typhimurium2	489	SVLAQANQVPQNVLSLLR--
S.typhimurium1	473	SVLAQANQVPQNVLSLLR--
S.marcesens	334	SVLAQANQSTQNVLSLLR--
E.coli	536	SVLAKANQVPQQVLSLQQG-
S.flexneri	532	SVLAKANQVPQQVLSLLQG-
T.pallidumA	269	AMLAQANTSAQSILSILR--
T.pallidumB	269	AMLAQANQATQSVLSLLR--
L.pneumophila	264	AMLARANMKPNSVLKLLQHI
B.burgdorferi	319	AMIAQANQVPQYVLSLLR--
B.subtilus	287	AMLAQANQQPQNVLQLLR--
C.difficile	264	SMLSQANQQPQGVLLQ--
R.meliloti	377	QALSIANSQNVLSLFR--
A.tumefaciens	289	QALSIANSQNVLSLFR--
R.lupini	393	QSLSIANSQNVLSLFR--
L.monocytogenes	269	SMLSQANQTPQMLTQLINS-
B.clarridgeiae	381	QALSIANQGSQNVLLALFRN-
consensus	601	ilaqanq pgnvlsllr

FIG. 7F

1

TOLL-LIKE RECEPTOR 5 LIGANDS AND METHODS OF USE

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Ser. No. 12/546,593 filed 24 Aug. 2009, which is a continuation of U.S. Ser. No. 10/125,692 filed 17 Apr. 2002 and now U.S. Pat. No. 7,915,381, which claims benefit under 35 U.S.C. §119(e) to provisional application 60/285,477 filed 20 Apr. 2001. The contents of these applications are incorporated herein by reference.

STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This invention was made with government support under grant numbers 5R37AI025032 and 5R01AI032972, awarded by the National Institutes of Health. The United States Government has certain rights in this invention.

BACKGROUND OF THE INVENTION

Cancer is the second leading cause of death in the United States, accounting for one in every four deaths. This year, it is expected that over 1500 Americans will die of cancer each day and that a million new cases of cancer will be diagnosed. The most common treatments for cancer are surgery, radiation and chemotherapy. According to the American Cancer Society, immunotherapy can be considered as the "fourth modality" in the treatment of cancer. Immunotherapy is treatment that stimulates one's own immune system to fight cancer.

Cancer is a group of diseases characterized by uncontrolled growth of abnormal cells of the body. All types of cancer involve the malfunction of genes that control cell growth and division. Some of these genes become incorrectly regulated, resulting in over- or under-production of a particular protein, while others become mutated, resulting in unusual or abnormal proteins that alter normal cellular functions. These abnormal proteins, referred to as "tumor cell antigens," should be recognized and destroyed by an individual's immune system as "foreign" antigens.

However, the immune system of a cancer patient may ignore these tumor antigens and be unresponsive to the growing tumor. Using immunotherapy approaches, such as cancer vaccines and immune system modulators, an individual's immune system can be induced to mount a potent immune response against tumor cell antigens, resulting in elimination of cancer cells. A cancer vaccine can contain a tumor cell antigen that stimulates the immune system to recognize and destroy cells which display that antigen. Treating an individual with such a cancer vaccine can result in a humoral response, which involves producing antibodies that recognize and target tumor cells for destruction and a cellular response, which involves producing cytotoxic T cells that recognize and destroy tumor cells directly, or both responses. It can be desirable to obtain both a humoral and cellular immunity response during immunotherapy because both arms of immune response have been positively correlated with beneficial clinical responses. To help stimulate either or both humoral and cellular immune responses, a cancer vaccine can be combined with an adjuvant, which is a substance that stimulates a general immune response.

2

The potency of cancer vaccines is greatly enhanced by the use of adjuvants. The selection of an adjuvant for use with a particular vaccine can have a beneficial effect on the clinical outcome of vaccination. Some vaccines are ineffective in the absence of an adjuvant. Effectiveness of a vaccine may be particularly troublesome when the vaccine is produced from self antigens such as those required for cancer vaccines or other non-infectious disease vaccines. In view of the beneficial effects of adjuvants in vaccine formulations, it is surprising that only one type of adjuvant, aluminum-salt based adjuvants, are currently in wide use in United States-licensed vaccines.

Thus, there exists a need for more and improved immunological adjuvants. The present invention satisfies this need and provides related advantages as well.

SUMMARY OF THE INVENTION

The invention provides an immunomodulatory flagellin peptide having at least about 10 amino acids of substantially the amino acid sequence GAVQNRFNSAIT, or a modification thereof, and having toll-like receptor 5 (TLR5) binding. Methods of inducing an immune response are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-B show NF- κ B activation and TNF α production in cells expressing CD4-TLR4 or CD4-TLR5.

FIGS. 2A-B show selective induction of TLR5-stimulated activation of NF- κ B by *P. aeruginosa* and *L. monocytogenes* cultures compared to LPS and lipopeptide.

FIGS. 3A-C show the purification of a TLR5-stimulating activity from *L. monocytogenes* culture supernatant.

FIGS. 4A-C (portions of SEQ ID NO:32 (including amino acids 1-11, amino acids 36-51, amino acids 120-134, amino acids 155-168, amino acids 224-240) and SEQ ID NO:32) show the identification by mass spectrometry of flagellin as a TLR5-stimulating activity.

FIGS. 5A-D show that flagellin expression in bacteria reconstitutes TLR5-stimulating activity.

FIG. 6 shows systemic induction of IL-6 in wild type mice treated with purified flagellin.

FIGS. 7AA-F show a comparison of flagellin amino acid sequences from 22 species of bacteria (SEQ ID NOS:11-33) and a consensus sequence of amino acid residues conserved across species (SEQ ID NO:34).

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to flagellin derived peptides that exhibit immunomodulatory activity and to methods of inducing an immune response through activation of toll-like receptor 5 (TLR5). The identification of active flagellin peptides and their corresponding receptor, TLR5, expands the available treatment methods for inducing an immune response. Moreover, the identification of active flagellin peptides and their cognate receptor allows the identification of immunomodulatory compounds.

In one embodiment, the invention is directed to immunomodulatory flagellin peptides that bind to TLR5 and induce a TLR5-mediated activity. The peptides can be used, for example, to effectively stimulate an immune response or ameliorate a pathological condition by administration of immunomodulatory flagellin peptides and combinations of such peptides with antigens and other immunomodulatory molecules. Full length flagellin polypeptides are also used in the methods of the invention to stimulate an immune

response. An advantage of the immunomodulatory flagellin peptides of the invention is that they provide the specificity of flagellin together with the availability of rapid and efficient methods for recombinant and chemical synthesis of peptides. The immunomodulatory flagellin peptides of the invention can therefore be combined with numerous well known modes of administration for the treatment of a wide variety of pathological conditions.

In another embodiment, the invention provides a method of inducing an immune response in an individual by administering a vaccine containing an immunomodulatory flagellin peptide of the invention and an antigen. An immunomodulatory flagellin peptide of the invention functions to stimulate an innate immune response. The innate immune response involves the production of immunomodulatory molecules that beneficially promote the adaptive immune response. The adaptive immune response includes both humoral and cell-mediated immune responses to antigen. Thus, a flagellin peptide functions to boost either or both humoral and cell-mediated immune responses against the antigen. A boost in an immune response causes a general increase in immune system activity that can result in the destruction of foreign or pathologically aberrant cells that otherwise could have escaped the immune response.

As used herein, the term "flagellin" is intended to mean a flagellin polypeptide contained in a variety of Gram-positive or Gram-negative bacterial species. The nucleotide and amino acid sequences of flagellin from 22 bacterial species are depicted in FIG. 7. The nucleotide sequences encoding the listed flagellin polypeptides are publicly available in the NCBI Genbank database. The flagellin sequences from these and other species are intended to be encompassed by the term flagellin as used herein. Therefore, the sequence differences between species is included within the meaning of the term.

As used herein, the term "peptide" is intended to mean two or more amino acids covalently bonded together. The term "flagellin peptide" is intended to mean a peptide or fragment encoded by a portion of the nucleotide sequence or having a portion of the amino acid sequence which exhibits substantially the same sequence identity to the flagellin sequences as described above and identified in FIG. 7 and binds to toll-like receptor 5 (TLR5). For example, a flagellin peptide amino acid sequence is about 65% or greater in sequence identity to a portion of the *S. Typhimurium*1 sequence, GAVQNRFSAIT, identified as SEQ ID NO:2, encoded by the nucleic acid sequence identified as SEQ ID NO:1. Therefore, flagellin peptides having amino acid substitutions that do not substantially alter TLR5 binding are included within the definition of a flagellin peptide. For example, flagellin peptides which contain one or more alanine substitutions and have substantially the same TLR5 binding activity as the flagellin peptide identified as SEQ ID NO:2 are included within the definition of a flagellin peptide. Exemplary flagellin peptides containing alanine substitutions and having substantially the same TLR5 binding activity as the flagellin peptide identified as SEQ ID NO:2 include, for example, GAVANRFSAIT (SEQ ID NO:3) and GAVQNAFNSAIT (SEQ ID NO:4). Flagellin peptides consisting of greater than twelve amino acids and having TLR5 binding activity can similarly contain amino acid substitutions, so long as such substituted peptides retain substantially the same TLR5 binding activity. Examples of such flagellin peptides containing substitutions of various amino acid residues with alanine include ADTRDLGAVQNRFSAIT (SEQ ID NO:37), VDARDL-GAVQNRFSAIT (SEQ ID NO:38) and VDTADLGAVQNRFSAIT (SEQ ID NO:39). A flagellin peptide of the invention does not include a full length flagellin polypeptide. A

flagellin peptide is intended to include molecules which contain, in whole or in part, non-amide linkages between amino acids, amino acid analogs and mimetics. Similarly, a flagellin peptide also includes cyclic peptides and other conformationally constrained structures. A flagellin peptide of the invention includes polypeptides having several hundred or more amino acid residues and can contain a heterologous amino acid sequence.

The term flagellin peptide specifically excludes fragments of flagellin described in Newton et al. *Science*, 244:70-72 (1989); Kuwajima, G., *J. Bacteriol.* 170:3305-3309 (1988); McSorley et al., *J. Immunol.* 164:986-993 (2000); and Samatey et al. *J. Struct. Biol.* 132:106-111 (2000).

As used herein, term "immunomodulatory flagellin peptide," is intended to mean a peptide or fragment having a portion of the amino acid sequence which exhibits substantially the same sequence identity to the flagellin sequences as described above and shown in FIG. 7 and binds to toll-like receptor 5 (TLR5). For example, an immunomodulatory flagellin peptide amino acid sequence is about 65% or greater in sequence identity to a portion of the *S. Typhimurium*1 sequence, GAVQNRFSAIT, identified as SEQ ID NO:2, encoded by the nucleic acid sequence identified as SEQ ID NO:1. Therefore, immunomodulatory flagellin peptides having amino acid substitutions that do not substantially alter TLR5 binding are included within the definition of an immunomodulatory flagellin peptide. For example, immunomodulatory flagellin peptides which contain one or more alanine substitutions and have substantially the same TLR5 binding activity as the flagellin peptide identified as SEQ ID NO:2 are included within the definition of a flagellin peptide. Exemplary immunomodulatory flagellin peptides containing alanine substitutions and having substantially the same TLR5 binding activity as the flagellin peptide identified as SEQ ID NO:2 include, for example, GAVANRFSAIT (SEQ ID NO:3) and GAVQNAFNSAIT (SEQ ID NO:4). Immunomodulatory flagellin peptides consisting of greater than twelve amino acids and having TLR5 binding activity can similarly contain amino acid substitutions, so long as such substituted peptides retain substantially the same TLR5 binding activity. Examples of such immunomodulatory flagellin peptides containing substitutions of various amino acid residues with alanine include ADTRDLGAVQNRFSAIT (SEQ ID NO:37), VDARDLGAVQNRFSAIT (SEQ ID NO:38) and VDTADLGAVQNRFSAIT (SEQ ID NO:39). An immunomodulatory flagellin peptide of the invention does not include a full length flagellin polypeptide. An immunomodulatory flagellin peptide is intended to include molecules which contain, in whole or in part, non-amide linkages between amino acids, amino acid analogs and mimetics. Similarly, an immunomodulatory flagellin peptide also includes cyclic peptides and other conformationally constrained structures. An immunomodulatory flagellin peptide of the invention includes polypeptides having several hundred or more amino acid residues and can contain a heterologous amino acid sequence.

An immunomodulatory flagellin peptide, polypeptide or modification thereof, of the invention binds to toll-like receptor 5 (TLR5) and induces a TLR5-mediated response. It is understood that minor modifications can be made without destroying the TLR5 binding activity, TLR5-mediated response stimulating activity or immune response modulating activity of an flagellin peptide or polypeptide and that only a portion of the primary structure may be required in order to effect activity. Such modifications are included within the meaning of the terms flagellin polypeptide and flagellin peptide so long as TLR5 binding activity, TLR5

response stimulating or immune response stimulating activities are retained. Further, various molecules can be attached to flagellin polypeptides and peptides, including for example, other polypeptides, carbohydrates, nucleic acids or lipids. Such modifications are included within the definition of the term.

Minor modifications of flagellin polypeptide and peptides having at least about the same TLR5 binding activity, TLR5 response stimulating or immune response stimulating activity as the referenced polypeptide or peptide include, for example, conservative substitutions of naturally occurring amino acids and as well as structural alterations which incorporate non-naturally occurring amino acids, amino acid analogs and functional mimetics. For example, a Lysine (Lys) is considered to be a conservative substitution for the amino acid Arg. Similarly, a flagellin peptide containing mimetic structures having similar charge and spatial arrangements as reference amino acid residues would be considered a modification of the reference polypeptide or peptide so long as the peptide mimetic exhibits at least about the same activity as the reference peptide.

As used herein, the term "amino acid" is intended to mean both naturally occurring and non-naturally occurring amino acids as well as amino acid analogs and mimetics. Naturally occurring amino acids include the 20 (L)-amino acids utilized during protein biosynthesis as well as others such as 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, homocysteine, citrulline and ornithine, for example. Non-naturally occurring amino acids include, for example, (D)-amino acids, norleucine, norvaline, p-fluorophenylalanine, ethionine and the like. Amino acid analogs include modified forms of naturally and non-naturally occurring amino acids. Such modifications can include, for example, substitution or replacement of chemical groups and moieties on the amino acid or by derivitization of the amino acid. Amino acid mimetics include, for example, organic structures which exhibit functionally similar properties such as charge and charge spacing characteristic of the reference amino acid. For example, an organic structure which mimics Arginine (Arg or R) would have a positive charge moiety located in similar molecular space and having the same degree of mobility as the ϵ -amino group of the side chain of the naturally occurring Arg amino acid. Mimetics also include constrained structures so as to maintain optimal spacing and charge interactions of the amino acid or of the amino acid functional groups. Those skilled in the art know or can determine what structures constitute functionally equivalent amino acid analogs and amino acid mimetics.

Specific examples of amino acid analogs and mimetics can be found described in, for example, Roberts and Vellaccio, *The Peptides: Analysis, Synthesis, Biology*, Eds. Gross and Meinhofer, Vol. 5, p. 341, Academic Press, Inc., New York, N.Y. (1983), the entire volume of which is incorporated herein by reference. Other examples include peralkylated amino acids, particularly permethylated amino acids. See, for example, *Combinatorial Chemistry*, Eds. Wilson and Czarnik, Ch. 11, p. 235, John Wiley & Sons Inc., New York, N.Y. (1997), the entire book of which is incorporated herein by reference. Yet other examples include amino acids whose amide portion (and, therefore, the amide backbone of the resulting peptide) has been replaced, for example, by a sugar ring, steroid, benzodiazepine or carbo cycle. See, for instance, *Burger's Medicinal Chemistry and Drug Discovery*, Ed. Manfred E. Wolff, Ch. 15, pp. 619-620, John Wiley & Sons Inc., New York, N.Y. (1995), the entire book of which is incorporated herein by reference. Methods for synthesizing peptides, polypeptides, peptidomimetics and proteins are

well known in the art (see, for example, U.S. Pat. No. 5,420,109; M. Bodanzsky, *Principles of Peptide Synthesis* (1st ed. & 2d rev. ed.), Springer-Verlag, New York, N.Y. (1984 & 1993), see Chapter 7; Stewart and Young, *Solid Phase Peptide Synthesis*, (2d ed.), Pierce Chemical Co., Rockford, Ill. (1984), each of which is incorporated herein by reference).

As used herein, the term "immune response" is intended to mean to a measurable or observable reaction to an antigen or immunomodulatory molecule mediated by one or more cells of the immune system. An immune response begins with an antigen or immunomodulatory molecule binding to an immune system cell and terminates with destruction of antigen and cells containing antigen or alteration in immune cell function. A reaction to an antigen or immunomodulatory molecule is mediated by many cell types, including a cell that initially binds to an antigen or immunomodulatory molecule and cells that participate in mediating an innate, humoral, cell-mediated immune response. An innate immune response involves binding of pathogen-associated molecular patterns (PAMPs) to cell surface receptors, such as toll-like receptors. Activation of toll-like receptors in response to PAMPs leads to the production of immunomodulatory molecules, such as cytokines and co-stimulatory molecules, that induce an immune response. A humoral response involves interaction of B cells with antigen and B cell differentiation into antibody-secreting cells. A cell-mediated response involves various subpopulations of T cells that recognize antigen presented on self-cells, including helper T cells that respond to antigen by producing cytokines and cytotoxic T cells that respond to antigen by developing into cytotoxic T lymphocytes, which mediate killing of altered self-cells. The term immune response includes measurable or observable reactions produced by any cell type that participates in the processes through which immune system cells are activated and antigen containing cells are destroyed. Such measurable reactions include, for example, production of immunomodulatory molecules, migration and proliferation.

An "immunomodulatory molecule" is a molecule that alters an immune response. An immunomodulatory molecule can be, for example, a compound, such as an organic chemical; a polypeptide, such as an antibody or cytokine; a nucleic acid, such as a DNA or RNA molecule; or any other type of molecule that alters an immune response. An immunomodulatory molecule can alter an immune response by directly or indirectly altering an activity of a cell that mediates an immune response. An immunomodulatory molecule can act directly on an immune system cell, for example, by binding to a cell surface receptor and stimulating or inhibiting proliferation, differentiation, or expression, secretion or receptor binding of immune system regulatory molecules such as co-stimulatory receptors and ligands, cytokines, and chemokines. Examples of naturally occurring molecules that act directly on immune system cells to alter an immune response include PAMPs, cytokines, chemokines and growth factors. Other examples of molecules that act directly on immune system cells to alter an immune response include molecules that alter receptor functions, such as antibodies to receptors, soluble cytokine receptors, receptor agonists and antagonists, molecules that alter the production of immunomodulatory molecules, such as inhibitors of converting enzymes and molecules involved in the intracellular transport and secretion of immunomodulatory molecules.

An immunomodulatory molecule can indirectly alter the activity of a particular immune system cell by altering the amount or activity of a molecule that regulates a cellular activity of the cell. For example, a cytokine, chemokine, or growth factor produced by an immune system cell, such as a

macrophage, can stimulate or inhibit various cellular activities of B and T lymphocytes. Immune cell functions that can be stimulated or inhibited by an immunomodulatory molecule include, for example, immune cell activation, co-activation, proliferation, production of cytokines, cellular interactions and migration. An immunomodulatory molecule can therefore act on a variety of immune cell types and can alter a variety of cellular functions. An immunomodulatory flagellin peptide, polypeptide or modifications thereof used in the methods of the invention are examples of immunomodulatory molecules useful for inducing an immune response, for example, by binding to TLR5 and inducing a TLR5-mediated increase in macrophage production of TNF α , IL-1 and IL-6. The flagellin polypeptides, peptides and modifications thereof, are also useful for indirectly inducing an immune response because immunomodulatory molecules produced by a TLR5-expressing cell in response to flagellin will alter the activities of immune system cells that respond to the particular immunomodulatory molecules produced.

An immunomodulatory molecule can mediate an immune response that is specific for a target antigen or nonspecific. A specific immunomodulatory molecule alters an immune response to a particular target antigen. Examples of specific immunomodulatory molecules include monoclonal antibodies, including naked monoclonal antibodies, drug-, toxin- or radioactive compound-conjugated monoclonal antibodies, and ADCC targeting molecules. Such immunomodulatory molecules stimulate an immune response by binding to antigens and targeting cells for destruction. An immunomodulatory molecule can be used to suppress an immune response to an antigen. For example, a tolerogenizing molecule can be used to suppress an immune response to a self-antigen.

Nonspecific immunomodulatory molecules stimulate or inhibit the immune system in a general manner through various mechanisms that can include, for example, stimulating or suppressing cellular activities of immune system cells. Nonspecific immunomodulatory molecules useful for stimulating an immune responses include, for example, agents that stimulate immune cell proliferation, immune cell activation and production of cytokines and co-stimulatory molecules. Well known immunomodulatory molecules that stimulate an immune response are, for example, interleukins, interferons, levamisole and keyhole limpet hemocyanin. Nonspecific immunomodulatory molecules useful for suppressing immune responses include, for example, agents that inhibit cytokines synthesis or processing, specific cytokine receptor blocking reagents such as soluble receptors and receptor antagonists, and cytokines that down-regulate or inhibit the production of other immunomodulatory molecules. Well known immunomodulatory molecules for suppressing an immune response include, for example, cyclosporin, rapamycin, tacrolimus, azathioprine, cyclophosphamide and methotrexate.

Immunomodulatory molecules can be contained in a mixture of molecules, including a natural or man-made composition of molecules. Exemplary natural compositions of immunomodulatory compounds include, for example, those contained in an organism such as *Bacille Calmette-Guerin* (BCM) or *Corynebacterium parvum*. Exemplary man-made compositions of immunomodulatory molecules include, for example, QS-21, DETOX and incomplete Freund's adjuvant.

As used herein, the term "adjuvant" when used in reference to a vaccine, is intended to mean a substance that acts generally to accelerate, prolong, or enhance the quality of specific immune responses to a vaccine antigen. An adjuvant can advantageously reduce the number of immunizations or the amount of antigen required for protective immunization.

As used herein, the term "antigen-specific immune response" is intended to mean a reaction of one or more cells of the immune system to a particular antigen that is not substantially cross-reactive with other antigens.

As used herein, the term "antigen" is intended to mean a molecule which induces an immune response. An antigen can be a crude mixture of molecules, such as a cell, or one or more isolated molecules. Examples of crude antigens include attenuated organisms, inactivated organisms, viral particles and tumor cells. Examples of isolated antigens include a polypeptide, lipoprotein, glycoprotein, lipid, anti-idiotypic antibody, toxoid, polysaccharide, capsular polysaccharide and nucleic acid. Such isolated antigens can be naturally occurring, recombinantly produced, or synthesized. Exemplary naturally occurring antigens include purified microbial macromolecules. Exemplary recombinantly produced antigens include cloned microbial and tumor cell antigens. Exemplary synthesized antigens include synthetic peptides and nucleic acids.

As used herein, the term "vaccine" is intended to mean a compound or formulation which, when administered to an individual, stimulates an immune response against an antigen. A vaccine is useful for preventing or ameliorating a pathological condition that will respond favorably to immune response modulation. A vaccine can contain isolated or crude antigen, and can contain one or more antigens. A vaccine can contain one or more adjuvants.

As used herein, the term "immunogenic amount" is intended to mean an amount of an immunomodulatory flagellin polypeptide, peptide or modifications thereof, or combinations thereof with one or more molecules, such as an antigen or other immunomodulatory molecule, required to effect an immune response. The dosage of an immunomodulatory flagellin polypeptide, peptide, or modifications thereof, independently or in combination with one or more molecules, will depend, for example, on the pathological condition to be treated, the weight and condition of the individual and previous or concurrent therapies. The appropriate amount considered to be an immunogenic dose for a particular application of the method can be determined by those skilled in the art, using the guidance provided herein. For example, the amount can be extrapolated from in vitro or in vivo assays as described below. Those skilled in the art will understand that the condition of the patient needs to be monitored through the course of therapy and that the amount of the composition that is administered can be adjusted according to patient response to therapy.

The term "pathologically aberrant cell" is intended to mean a cell that is altered from a normal physiological or cellular state. Such alteration can be due to changes in physiology or phenotype associated with a disease or abnormal condition of a mammalian cell or tissue. Pathologically aberrant cells include cells lacking normal control of cellular functions, such as growth, differentiation, and apoptosis, resulting in altered gene and protein expression. Cells that lack normal growth control proliferate in the absence of appropriate growth signals, resulting in damage in structure or function of surrounding tissues. Cells that lack normal differentiation undergo inappropriate phenotypic or physiological changes that do not normally characterize the cell type, resulting in damage in structure and function or surrounding tissues. Cells that lack normal apoptosis fail to undergo, or inappropriately undergo the process of cell death, resulting in damage in structure or function of surrounding tissues. Altered protein expression is an example of a phenotype change that renders such cells distinguishable from normal. For example, increased or decreased expression of a polypeptide normally

expressed on a cell, expression of a mutated polypeptide and expression of a polypeptide not normally expressed on a cell are phenotypic changes that can alter a cell from normal. Examples of pathologically aberrant cells include tumor cells and degenerating cells.

As used herein, the term “pathological condition” is intended to mean a disease, abnormal condition or injury of a mammalian cell or tissue. Such pathological conditions include, for example, hyperproliferative and unregulated neoplastic cell growth, degenerative conditions, inflammatory diseases, autoimmune diseases and infectious diseases. Pathological conditions characterized by excessive or unregulated cell growth include, for example, hyperplasia, cancer, autoimmune disease and infectious disease. Hyperplastic and cancer cells proliferate in an unregulated manner, causing destruction of tissues and organs. Specific examples of hyperplasias include benign prostatic hyperplasia and endometrial hyperplasia. Specific examples of cancer include prostate, breast, ovary, lung, uterus, brain and skin cancers. Abnormal cellular growth can also result from infectious diseases in which foreign organisms cause excessive growth. For example, human papilloma viruses can cause abnormal growth of skin cells. The growth of cells infected by a pathogen is abnormal due to the alteration of the normal condition of a cell resulting from the presence of a foreign organism. Specific examples of infectious diseases include DNA and RNA viral diseases, bacterial diseases, parasitic diseases. Similarly, the growth of cells mediating autoimmune and inflammatory diseases are aberrantly regulated which results in, for example, the continued proliferation and activation of immune mechanisms with the destruction of tissues and organs. Specific examples of autoimmune diseases include, for example, rheumatoid arthritis and systemic lupus erythematosus. Specific examples of degenerative disease include osteoarthritis and Alzheimer’s disease.

By specific mention of the above categories of pathological conditions, those skilled in the art will understand that such terms include all classes and types of these pathological conditions. For example, the term cancer is intended to include all known cancers, whether characterized as malignant, benign, soft tissue or solid tumor. Similarly, the terms infectious diseases, degenerative diseases, autoimmune diseases and inflammatory diseases are intended to include all classes and types of these pathological conditions. Those skilled in the art will know the various classes and types of proliferative, infectious, autoimmune and inflammatory diseases.

As used herein the term “toll-like receptor 5” or “TLR5” is intended to mean a toll-like receptor 5 of any species, such as the murine and human polypeptides containing the amino acid sequences set forth as SEQ ID NOS:6 and 8, respectively, encoded by the nucleic acid sequence identified as SEQ ID NOS:5 and 7, respectively. A TLR5 is activated upon binding to flagellin, an immunomodulatory flagellin peptide, or modifications thereof, and other TLR5 agonists. Upon activation, a TLR5 induces a cellular response by transducing an intracellular signal that is propagated through a series of signaling molecules from the cell surface to the nucleus. For example, the intracellular domain of TLR5 recruits an adaptor protein, MyD88, which recruits the serine kinase IRAK. IRAK forms a complex with TRAF6, which then interacts with various molecules that participate in transducing the TLR signal. These molecules and other TLR5 signal transduction pathway components stimulate the activity of transcription factors, such as fos, jun and NF- κ B, and the corresponding induction of gene products of fos-, jun- and NF- κ B-regulated genes, such as, for example, TNF α , IL-1 and IL-6. The activities of signaling molecules that mediate the TLR5 signal, as

well as molecules produced as a result of TLR5 activation are TLR5 activities that can be observed or measured. Therefore, a TLR5 activity includes binding to a flagellin polypeptide, immunomodulatory flagellin peptide, or a modification thereof, recruitment of intracellular signaling molecules, as well as downstream events resulting from TLR5 activation, such as transcription factor activation and production of immunomodulatory molecules. A TLR5 cellular response mediates an innate immune system response in an animal because cytokines released by TLR5-expressing cells regulate other immune system cells to promote an immune response in an animal. Therefore, as used herein the term “TLR5-mediated response” is intended to mean the ability of a flagellin polypeptide, immunomodulatory peptide or modification thereof to induce a TLR5-mediated cellular response. Exemplary TLR5-mediated cellular responses include activation of transcription factors such as fos, jun and NF- κ B, production of cytokines such as IL-1, IL-6 and TNF α , and the stimulation of an immune response in an animal.

A TLR5 also encompasses polypeptides containing minor modifications of a native TLR5, and fragments of a full-length native TLR5, so long as the modified polypeptide or fragment retains one or more biological activities of a native TLR5, such as the abilities to stimulate NF- κ B activity, stimulate the production of cytokines such as TNF α , IL-1, and IL-6 and stimulate an immune response in response to TLR5 binding to flagellin polypeptide, immunomodulatory peptide or modifications thereof. A modification of a TLR5 can include additions, deletions, or substitutions of amino acids, so long as a biological activity of a native TLR5 is retained. For example, a modification can serve to alter the stability or activity the polypeptide, or to facilitate its purification. Modifications of polypeptides as described above in reference to flagellin polypeptides and peptides are applicable to TLR5 polypeptides of the invention. A “fragment” of a TLR5 is intended to mean a portion of a TLR5 that retains at least about the same activity as a native TLR5.

As used herein, the term “TLR5 agonist” refers to a compound that selectively activates or increases normal signal transduction through TLR5. As used herein, the term “TLR5 antagonist” refers to a compound that selectively inhibits or decreases normal signal transduction through TLR5. A TLR5 agonist or antagonist can alter normal signal transduction through TLR5 indirectly, for example, by modifying or altering the native conformation of TLR5 or a TLR5 ligand. For therapeutic applications, a TLR5 agonist or antagonist has an EC₅₀ of less than about 10^{-7} M, such as less than 10^{-8} M and less than 10^{-9} M, although a TLR5 agonist with a higher EC₅₀ can be therapeutically useful. As used herein, the term “TLR5 ligand” refers to a compound that binds a TLR5 polypeptide with high affinity. A TLR5 ligand can further be an agonist or antagonist of TLR5, as described above, or can be a compound having little or no effect on TLR5 signaling.

As used herein, the term “detectably labeled” refers to derivitization with, or conjugation to, a moiety that is detectable by an analytical or qualitative method. A detectable moiety can be, for example, a radioisotope, such as ^{14}C , ^{131}I , ^{32}P or ^3H , fluorochrome, ferromagnetic substance, or luminescent substance.

As used herein the term “ADCC targeting molecule” is intended to mean an antigen binding protein containing a Fc receptor binding domain capable of inducing antibody-dependent cell cytotoxicity (ADCC). An ADCC targeting molecule can also contain other domains that augment induction of ADCC. The flagellin polypeptides and peptides, immunomodulatory peptides, and modifications described herein, can be domains of an ADCC targeting molecule that augment

induction of ADCC. The ADCC targeting molecule can include multiple valencies for either or both the antigen binding domain or the Fc receptor binding domain. Additionally, an ADCC targeting molecule also can have multiple different antigen binding domains combined with a single or multiple copies of an Fc receptor binding domain or combined with different Fc receptor binding domains. The antigen binding domain or domains can be derived from essentially any molecule that has selective or specific binding activity to a target antigen so long as it can be fused or attached to one or more Fc receptor binding domains while still maintaining antigen binding activity. The Fc receptor binding domain can be derived from an antibody constant region of, for example, the IgG class, including subclasses IgG1, IgG3 and IgG4. Such Fc receptor binding domains can be used in their native form or the amino acid sequence can be modified so as to enhance or optimize the Fc receptor binding or ADCC activity. Moreover, the Fc receptor binding domains can be derived from constant regions which recognize either stimulatory or inhibitory Fc receptors. The Fc receptor binding domain is located within the hinge region of an antibody constant region where the cognate receptors bound by this domain include, for example, the Fc RI, Fc RIIA and Fc RIII. Therefore, ADCC targeting molecules include, for example, antibodies selective for a target antigen and functional variants thereof as well as fusion proteins and chemical conjugates containing both an antigen binding domain and a Fc receptor binding domain in functionally active forms. ADCC targeting molecules and the use of ADCC targeting molecules in the treatment of disease are described in detail in U.S. patent application Ser. No. 09/618,176, which is incorporated herein by reference.

The term "about" when used in reference to a particular activity or measurement is intended to refer to the referenced activity or measurement as being within a range values encompassing the referenced value and within accepted standards of a credible assay within the art, or within accepted statistical variance of a credible assay within the art.

As used herein, the term "substantially" or "substantially the same" when used in reference to an amino acid sequence is intended to mean that the amino acid sequence shows a considerable degree, amount or extent of sequence identity when compared to the reference sequence. Such considerable degree, amount or extent of identity is further considered to be significant and meaningful and therefore exhibit characteristics which are definitively recognizable or known as being derived from or related to flagellin. For example, an amino acid sequence which is substantially the same amino acid sequence as an flagellin peptide, including fragments thereof, refers to a sequence which exhibits characteristics that are definitively known or recognizable as being sufficiently related to flagellin so as to fall within the classification of flagellin sequences as defined above. Minor modifications thereof are included so long as they are recognizable as an flagellin sequence as defined above.

As used herein, the term "individual" is intended to mean any animal in which an immune response can be induced by a flagellin polypeptide, peptide or modifications thereof including a human, non-human primate, cow, pig, chicken, rabbit, ferret, rat or mouse.

An immunomodulatory flagellin polypeptide, peptide or modifications thereof can be used to induce an immune response in an individual having a pathological condition, promoting the individual's own immune system to function more effectively and thereby ameliorate the pathological condition. An individual's immune system may not recognize cancer cells and other types of pathologically aberrant cells as foreign because the particular antigens are not different

enough from those of normal cells to cause an immune reaction. In addition, the immune system may recognize cancer cells, but induce a response insufficient to destroy the cancer. By stimulating an innate immune response, immunomodulatory flagellin peptide, polypeptide or modification thereof, promote humoral and cell-mediated responses to antigens on foreign cells or pathologically aberrant cells, such as cancer cells. Administered independently or in combination with an antigen, such as a tumor antigen, a flagellin polypeptide, peptide or modification thereof, can be used to boost the immune system's recognition of cancer cells and other pathologically aberrant cells, and target such cells for destruction.

Flagellin is a pathogen-associated molecular pattern (PAMP) recognized by toll-like receptor 5 (TLR5). Toll-like receptor 5 is a member of a family of at least 10 receptors involved in mediated the innate immune response. Toll-like receptors recognize PAMPs that distinguish infectious agents from self and mediating the production of immunomodulatory molecules, such as cytokines, necessary for the development of effective adaptive immunity (Aderem, A. and Ulevitch, R. J. *Nature* 406:782-787 (2000) and Brightbill, H. D., *Immunology* 101: 1-10 (2000)). Members of the toll-like receptor family recognize a variety of antigen types and can discriminate between pathogens. For example, TLR2 recognizes various fungal, Gram-positive, and mycobacterial components, TLR4 recognizes the Gram-negative product lipopolysaccharide (LPS), and TLR9 recognizes nucleic acids such as CpG repeats in bacterial DNA. TLR5 has now been identified as a receptor for bacterial flagellin.

Flagellin induces an innate immune response by binding to and activating TLR5. Activation of TLR5 by binding to flagellin induces the production of immunomodulatory molecules, such as cytokines and co-stimulatory molecules, by a TLR5-expressing cell. For example, activation of TLR5 in macrophages results in the expression of the cytokines TNF α , IL-1 and IL-6. These cytokines directly and indirectly alter the activities of immune system cells that participate in both humoral (TH2) and cell-mediated (TH1) adaptive immune responses. In this manner, an immunomodulatory flagellin peptide, polypeptide or modification thereof, acts as an adjuvant to stimulate a general immune response.

Altering the balance of TH1- versus TH2-associated cytokines can be used to favorably alter an immune response to treat certain diseases. For example, in the use of cancer vaccines, it can be favorable to induce both TH1 and TH2 responses (Herlyn and Birebent, *Ann. Med.*, 31:66-78, (1999)). Different sets of cytokines orchestrate TH1 and TH2 immune responses. For example, TH1 immune responses are associated with the cytokines IL-2, IFN- γ , and TNF α while TH2 immune responses are associated with the cytokines IL-4, IL-5, IL-6 and IL-10. TLR5 stimulates the production of cytokines associated with both TH1- and TH2-associated cytokines. For example, TNF α is associated with the stimulation of a TH1 type immune response (Ahlers, J D et al. *J. Immunol.* 158:3947-58 (1997)), and IL-6 is associated with the stimulation of a TH2 type response (Steidler, L. et al. *Infect. Immun.*, 66:3183-9, (1998)). Therefore, an immunomodulatory flagellin peptide, polypeptide or modification thereof, can be used to advantageously elicit TH1 and TH2 type immune responses.

An immunomodulatory flagellin peptide, polypeptide or modification thereof can also be used to generally alter the particular cytokines involved in an immune response in an individual. Alterations from normal levels of cytokines are observed in many disease states. For this reason, it can be desirable to increase or decrease the amounts or activities of specific cytokines involved in particular pathological condi-

tions. The cytokines produced in response to TLR5 activation can both stimulate and down-regulate the production of other cytokines. Therefore, an immunomodulatory flagellin peptide, polypeptide or modification thereof, or combination of a flagellin molecule with an immunomodulatory molecule or antigen can be used to alter levels of cytokines associated with a pathological condition. For example, an immunomodulatory flagellin peptide can increase TLR5-expressing macrophage production of TNF α , IL-1 and IL-6. TNF α and IL-1 generally function as pro-inflammatory cytokines. IL-6 generally functions as an anti-inflammatory cytokine and induces a variety of anti-inflammatory activities in immune system cells. For example, IL-6 stimulates the production of many anti-inflammatory anti-proteases. Those skilled in the art will be able to determine if a pathological condition in an individual could be ameliorated by inducing TLR5-stimulated cytokine production and will be able to determine appropriate combinations of flagellin and immunomodulatory molecules suitable for inducing a beneficial immune response.

The invention provides an immunomodulatory flagellin peptide comprising at least about 10 amino acids of substantially the amino acid sequence GAVQNRFNSAIT (SEQ ID NO:2), or a modification thereof, that binds to toll-like receptor 5 (TLR5).

The flagellin peptide identified by SEQ ID NO:2 is a peptide of *S. Typhimurium*1 flagellin which is encoded by the nucleic acid sequence identified by SEQ ID NO:1. A flagellin peptide of the invention also includes peptides from other bacterial species, such as *H. Pylori* (SEQ ID NO:12), *V. Cholera* (SEQ ID NO:13), *S. marcesens* (SEQ ID NO:20), *S. flexneri* (SEQ ID NO:22), *T. Pallidum* (SEQ ID NO:23 or SEQ ID NO:24), *L. pneumophila* (SEQ ID NO:25), *B burgdorferi* (SEQ ID NO:26), *C. difficile* (SEQ ID NO:28), *R. meliloti* (SEQ ID NO:29), *A. tumefaciens* (SEQ ID NO:30), *R. lupini* (SEQ ID NO:31), *B. clarridgeiae* (SEQ ID NO:33), *P. Mirabilis* (SEQ ID NO:16), *B. subtilis* (SEQ ID NO:27), *L. monocytogenes* (SEQ ID NO:32), *P. aeruginosa* (SEQ ID NO:14) and *E. coli* (SEQ ID NO:21), which contain amino acid sequences having 21-71% identity over the 12 amino acid sequence of SEQ ID NO:2. A flagellin peptide of the invention also includes flagellin peptides from other bacterial species, including peptides contained within the flagellin amino acid sequences shown FIG. 7. Thus, a flagellin peptide of the invention can have greater than about 65% identity, such as greater than about 75%, greater than about 85%, greater than about 95%, greater than about 98% identity with the peptide identified by SEQ ID NO:2.

A flagellin peptide of the invention is derived from a conserved region of a flagellin polypeptide. Conserved regions of flagellin are well known in the art and have been described, for example, in Mimori-Kiyosue, et al., *J. Mol. Biol.* 270:222-237, (1997). Whereas T cell receptors which mediate the adaptive immune response recognize random portions of antigen amino acid sequences, toll-like receptors recognize conserved portions of antigen amino acid sequences. Therefore, the flagellin peptides of the invention and immunomodulatory flagellin peptides used in the methods of the invention contain amino acid sequences derived from conserved regions of flagellin.

A flagellin peptide of the invention excludes a portion of flagellin described in Newton et al. (supra, 1989), which consists of an *S. meunchen* flagellin fragment containing a deletion of amino acids 207-223, portions of *E. coli* (strain K12) flagellin described in Kuwaijima et al. (supra, 1998), which consist of *E. coli* flagellin fragments containing deletions of amino acids 239-254, 259-278, 237-262, 194-379, 201-318, 218-326, 211-347, 210-299, 245-301, and 220-299,

a portion of flagellin described in Samatey et al. (supra, 2000), which consists of an *S. typhimurium* flagellin fragment lacking 52 N-terminal amino acid residues and lacking 44 C-terminal amino acid residues, and portions of flagellin described in McSorley et al. (supra, 2000) which consist of *S. typhimurium* flagellin fragments having the following amino acid sequences: RSDLGAVQNRFNNSAI (SEQ ID NO:40), DLGAVQNRFNNSAITN (SEQ ID NO:41), GAVQNRFN-SAITNLG (SEQ ID NO:42) AND VQNRFNNSAITNLGNT (SEQ ID NO:43).

An immunomodulatory flagellin peptide of the invention can contain a heterologous amino acid sequence that imparts structural or functional characteristics onto the flagellin peptide. For example, chimeric flagellin peptides or modifications can be used to impart a targeting function. Targeting of a flagellin peptide or modification to a particular site, such as a mucosal surface for example, confers additional therapeutic advantage of inducing an immune response at a site of pathological condition or a site favored for inducing an antigen-specific immune response, for example by a vaccine. Further, chimeric flagellin peptides can include a sequence that facilitates detection, purification or enhances immunomodulatory activity of the flagellin peptide. A flagellin peptide can be contained, for example, in an ADCC targeting molecule used to treat a pathological condition. A flagellin peptide can augment the effectiveness of an ADCC targeting molecule by, for example, stimulating an innate immune response through TLR5, such as the induction of cytokines such as TNF α , IL-1 and IL-6. Similarly, a flagellin peptide can contain amino acid sequences of a variety of antigen polypeptides, such as those described above in reference to antigens contained in vaccines used in the methods of the invention. A chimeric flagellin peptide containing amino acid sequences of an antigen or containing an antigenic molecule such as a carbohydrate, nucleic acid, or lipid, can be used analogously to a vaccine, as described above, as well as in a vaccine formulation, to induce an immune response in an individual. As such, a chimeric flagellin peptide can be a vaccine that induces both innate and adaptive immune system responses.

An immunomodulatory flagellin peptide of the invention can be prepared by a variety of methods well-known in the art, for example, by recombinant expression systems described below, and biochemical purification methods described below, as well as by synthetic methods well known in the art. Methods for recombinant expression and purification of polypeptides in various host organisms are described, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York (1992) and in Ansel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Md. (1998), both of which are incorporated herein by reference. Similarly, flagellin peptide modifications can be generated using recombinant mutagenesis, such as site directed mutagenesis and PCR mutagenesis, and expression of the flagellin peptide modification. Numerous methods of constructing, modifying, expressing and purifying peptides are known to those skilled in the art. A specific example of a method for purifying flagellin is described below in Example III. The choice of recombinant methods, expression and purification systems will be known by those skilled in the art and will depend on the user and the particular application for the immunomodulatory flagellin peptide or modification thereof.

A flagellin peptide of the invention induces an innate immune response in an individual by binding to an stimulating TLR5. Therefore, the invention provides methods for inducing an immune response in an individual having a pathological condition that can be ameliorated by immune

system activity. The methods involve administering an immunomodulatory flagellin peptide or modification thereof to induce an immune response, administering a combination of an immunomodulatory flagellin peptide and an antigen to induce an antigen-specific immune response, and administering a combination of an immunomodulatory flagellin peptide and an immunomodulatory molecule to modulate an immune response. The selection of a particular method for inducing an immune response will depend on the particular pathological condition to be ameliorated or prevented in an individual. As described herein, the methods are applicable to a wide variety of pathological conditions. Those skilled in the art will be able to determine if an immune response can be beneficially modulated by administering an immunomodulatory flagellin peptide or combination thereof with an antigen or immunomodulatory molecule.

The invention provides method of inducing an antigen-specific immune response in an individual. The method involves administering to an individual an immunogenic amount of a vaccine, comprising an antigen and an immunomodulatory flagellin peptide having at least about 10 amino acids of substantially the amino acid sequence of SEQ ID NO:2, or a modification thereof.

As an adjuvant in a vaccine formulation, the immunomodulatory flagellin peptides of the invention can contribute to the effectiveness of the vaccine by, for example, enhancing the immunogenicity of weaker antigens such as highly purified or recombinant antigens, reducing the amount of antigen required for an immune response, reducing the frequency of immunization required to provide protective immunity, improve the efficacy of vaccines in individuals with reduced or weakened immune responses, such as newborns, the aged, and immunocompromised individuals, and enhance the immunity at a target tissue, such as mucosal immunity, or promote cell-mediated or humoral immunity by eliciting a particular cytokine profile. An immunomodulatory flagellin peptide, polypeptide or modification thereof induces an innate immune response through activation of TLR5. The innate immune response increases the immune response to an antigen by stimulating the adaptive immune response. Therefore, a combination of an immunomodulatory flagellin peptide, polypeptide or modification thereof with one or more antigens provides an effective vaccine for inducing an immune response in an individual.

The methods of the invention for inducing an antigen-specific immune response can be used to treat individuals having a variety of pathological conditions. For example, cancer vaccines have been used effectively for treating melanoma and breast cancers. Vaccines have been used for treatment of inflammatory diseases such as asthma (Scanga C. B and Le Gros, G., *Drugs* 59(6), 1217-1221 (2000)), infectious diseases of pathogenic bacteria such as *H. pylori*, pathogenic viruses such as human papilloma virus and HIV (Sutton P. and Lee, A., *Aliment Pharmacol.* 14:1107-1118 (2000)), protozoa, autoimmune diseases such as diabetes (von Herrath and Whitton, *Ann. Med.* 32:285-292 (2000)) and degenerative diseases such as Alzheimer's disease (Youngkin, S. G., *Nat. Med.*, 7(1):18-19 (2001)). Therefore, a vaccine used in the methods of the invention for inducing an antigen-specific immune response can be administered to an individual for treatment of a variety of pathological conditions, including proliferative disease, infectious disease, inflammatory disease and degenerative disease.

A variety of antigens can be used in combination with an immunomodulatory flagellin peptide of the invention for preparing a vaccine. Microorganisms such as viruses, bacteria and parasites contain substances that are not normally present

in the body. These substances can be used as antigens to produce an immune response to destroy both the antigen and cells containing the antigen, such as a bacterial cell or cancer cell.

For example, isolated or crude antigens of microbial pathogens can be used in vaccines to treat infectious disease; isolated or crude tumor cell antigens can be used in vaccines to treat cancer; isolated or crude antigens known to be associated with a pathologically aberrant cell can be used to treat a variety of diseases in which it is beneficial to target particular cells for destruction.

A variety of substances can be used as antigens in a vaccine compound or formulation. For example, attenuated and inactivated viral and bacterial pathogens, purified macromolecules, polysaccharides, toxoids, recombinant antigens, organisms containing a foreign gene from a pathogen, synthetic peptides, polynucleic acids, antibodies and tumor cells can be used to prepare a vaccine useful for treating a pathological condition. Therefore, an immunomodulatory flagellin peptide of the invention can be combined with a wide variety of antigens to produce a vaccine useful for inducing an immune response in an individual. Those skilled in the art will be able to select an antigen appropriate for treating a particular pathological condition and will know how to determine whether a crude or isolated antigen is favored in a particular vaccine formulation.

An isolated antigen can be prepared using a variety of methods well known in the art. A gene encoding any immunogenic polypeptide can be isolated and cloned, for example, in bacterial, yeast, insect, reptile or mammalian cells using recombinant methods well known in the art and described, for example in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York (1992) and in Ansubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Md. (1998). A number of genes encoding surface antigens from viral, bacterial and protozoan pathogens have been successfully cloned, expressed and used as antigens for vaccine development. For example, the major surface antigen of hepatitis B virus, HbsAg, the β subunit of cholera toxin, the enterotoxin of *E. coli*, the circumsporozoite protein of the malaria parasite, and a glycoprotein membrane antigen from Epstein-Barr virus, as well as tumor cell antigens, have been expressed in various well known vector/host systems, purified and used in vaccines. An immunomodulatory flagellin peptide, polypeptide or modification thereof induces an innate immune response through TLR5 that can beneficially enhance an immune response to a recombinant antigen.

A pathologically aberrant cell to be used in a vaccine can be obtained from any source such as one or more individuals having a pathological condition or ex vivo or in vitro cultured cells obtained from one or more such individuals, including a specific individual to be treated with the resulting vaccine.

Those skilled in the art will be able to determine if a vaccine compound or formulation induces an innate, humoral, cell-mediated, or any combination of these types of immune response, as methods for characterizing these immune responses are well known in the art. For example, the ability of a vaccine compound or formulation to induce an innate immune response through TLR5 can be determined using methods described herein as well as other methods. Such methods for detecting an innate immune response can be generally performed within hours of vaccine administration. The ability of a vaccine compound or formulation to induce a humoral response can be determined by measuring the titer of antigen-specific antibodies in an animal primed with the vaccine and boosted with the antigen, or determining the pres-

ence of antibodies cross-reactive with an antigen by ELISA, Western blotting or other well-known methods. Cell-mediated immune responses can be determined, for example, by measuring cytotoxic T cell response to antigen using a variety of methods well known in the art. Methods of detecting humoral and cell-mediated immune responses can be generally performed days or weeks after vaccine administration.

A combination of an antigen or immunomodulatory molecule and an immunomodulatory flagellin peptide, polypeptide or modification thereof, can be tested in a variety of preclinical toxicological and safety studies well known in the art. For example, such a combination can be evaluated in an animal model in which the antigen has been found to be immunogenic and that can be reproducibly immunized by the same route proposed for human clinical testing. A combination of an antigen or immunomodulatory molecule and an immunomodulatory flagellin peptide or modification thereof can be tested, for example, by an approach set forth by the Center for Biologics Evaluation and Research/Food and Drug Administration and National Institute of Allergy and Infectious Diseases (Goldenthal, K L et al. *AID Res Hum Retroviruses*, 9:S45-9 (1993)).

Those skilled in the art will know how to determine for a particular combination of antigen or immunomodulatory molecule and immunomodulatory flagellin polypeptide modification thereof, the appropriate antigen payload, route of immunization, volume of dose, purity of antigen, and vaccination regimen useful to treat a particular pathological condition in a particular animal species.

The invention provides a method of inducing a TLR5-mediated response. The method involves administering to a TLR5-containing cell an effective amount of an immunomodulatory flagellin peptide having at least about 10 amino acids of substantially the amino acid sequence of SEQ ID NO:2, or a modification thereof.

A TLR5-mediated response can be assessed in a cell or animal because TLR5 stimulates cellular activities that stimulate the immune response that occurs in an animal. For example, flagellin binding to TLR5 induces cellular events such as an increase in the amount or activity of cytokines, such as TNF α , IL-1 and IL-6. These cytokines in turn regulate the activities of immune system cells. Therefore a TLR5-mediated response can be determined by examining an immune responses in an animal and by observing particular immune system cell activities. Determination of immune responses in an animal is discussed below. Determination of immune system cell activities can be performed, for example, by observing or measuring the amount of activity of immunomodulatory molecules produced by specific types of immune cells. Cytokine production by macrophages is an exemplary immune cell activity that can be conveniently measured using methods well known in the art and those described herein. A biological activity of a cytokine can also be assessed using methods well known in the art. TNF α activities include, for example, inducing the production of IL-1 and IL-6, activation of neutrophils and endothelial cells in inflammation, inducing acute phase reactants in liver, inducing fever. IL-1 activities include, for example, activating of endothelial cells in inflammation and coagulation, inducing acute phase reactants in liver, inducing fever and stimulating T cell proliferation. IL-6 activities include, for example, stimulating proliferation of mature B cells and inducing their final maturation into antibody-producing plasma cells, inducing IL-2 receptor expression, inducing acute phase reactants in liver, and co-stimulation of thymocytes in vitro. A regulatory effect of IL-6 is inhibition of TNF α production, providing negative feedback for limiting

the acute inflammatory response (Feghali, C. A. and Wright, T. M., *Frontiers in Bioscience*, 2, d12-26 (1997) provides a summary of cytokine activities).

The invention provides a method of inducing an immune response in an individual having a pathological condition. The method involves administering to said individual an immunogenic amount of an immunomodulatory flagellin peptide having at least about 10 amino acids of substantially the amino acid sequence of SEQ ID NO:2, or a modification thereof.

As described above, an immunomodulatory flagellin peptide can be used to beneficially boost a general immune response in an individual having a pathological condition by stimulating an innate immune response. An increased immune response can ameliorate a pathological condition as well as prevent a pathological condition in a healthy individual, or individual not having a pathological condition. Therefore, an immunomodulatory flagellin peptide can be administered prophylactically to an individual not having a pathological condition, if desired.

The invention provides another method of modulating an immune response in an individual having a pathological condition. The method involves administering to the individual a combination of an immunogenic amount of an immunomodulatory flagellin peptide having at least about 10 amino acids of substantially the amino acid sequence of SEQ ID NO:2, or a modification thereof, and another immunomodulatory molecule.

As described above, a combination of an immunomodulatory flagellin peptide with another immunomodulatory molecule can be used to advantageously induce or modulate an immune response. An immune response can be induced by combining an immunomodulatory flagellin peptide with another immunomodulatory molecule that induces an immune response in a general manner, such as an adjuvant, or can be combined with an immunomodulatory molecule that induces a particular alteration in an immune cell activity. Such immunomodulatory molecules are described herein.

Modulating an immune response is useful for promoting a more effective or more normal immune response in an individual having a pathological condition. As described above, alterations in normal cytokine levels are associated with various pathological conditions. An immunomodulatory flagellin peptide or combination with another immunomodulatory molecule can be used to modulate cytokine levels in an individual by inducing the production of immunomodulatory molecules, such as cytokines including TNF α , IL-1, and IL-6 through TLR5, and inducing the production of suppression of the same or different immunomodulatory molecules through the activity of the administered immunomodulatory molecule.

Therefore, the immunomodulatory flagellin peptides of the invention can be combined with immunomodulatory molecules that alter an immune response by stimulating or inhibiting the cellular functions of immune system cells.

A variety of immunomodulatory molecules can be used in combination with an immunomodulatory flagellin peptide or modification thereof of the invention to alter an immune response in an individual. The type of alteration desired will determine the type of immunomodulatory molecule selected to be combined with an immunomodulatory flagellin peptide. For example, to promote an innate immune response, an immunomodulatory flagellin peptide can be combined with another immunomodulatory molecule that promotes an innate immune response, such as a PAMP or conserved region known or suspected of inducing an innate immune response. A variety of PAMPs are known to stimulate the activities of

different members of the toll-like family of receptors. Such PAMPs can be combined to stimulate a particular combination of toll-like receptors that induce a beneficial cytokine profile. For example, PAMPs can be combined to stimulate a cytokine profile that induces a TH1 or TH2 immune response.

Other types of immunomodulatory molecules that promote humoral or cell-mediated immune responses can be combined with a flagellin molecule of the invention. For example, cytokines can be administered to alter the balance of TH1 and TH2 immune responses. Those skilled in the art will know how to determine the appropriate cytokines useful for obtaining a beneficial alteration in immune response for a particular pathological condition.

Immunomodulatory molecules that target antigens and cells displaying antigens for destruction can be combined with a flagellin molecule of the invention. For example, the effectiveness of monoclonal antibodies and ADCC targeting molecules that recognize a particular antigen on an unwanted cell, such as a pathologically aberrant cell can be increased when administered with a flagellin molecule of the invention. Immunomodulatory molecules that stimulate or suppress cellular activities such as proliferation, migration, activation, interaction and differentiation can be combined with a flagellin molecule of the invention. For example, IL-2 can be used to stimulate proliferation of immune system cells, certain interferons can be used to interfere with the rapid growth of cancer cells or to interfere with angiogenesis, and granulocyte-colony stimulating factor can be used to increase production of certain types of immune system cells and blood cells. A variety of immunostimulating and immunosuppressing molecules and modalities are well known in the art and can be used in combination with a flagellin polypeptide, peptide or modification thereof, of the invention. A flagellin molecule of the invention increases the beneficial effect of an immunomodulatory molecule by inducing TLR5-mediated production of immunomodulatory molecules that function in concert with a selected immunomodulatory molecule to produce a desired cytokine profile or cellular activity, or prime the adaptive immune response to respond to the selected immunomodulatory molecule.

The methods of the invention for using immunomodulatory flagellin peptides to induce an immune response are also applicable to a flagellin polypeptide, or a modification thereof. Accordingly, the invention provides a method of inducing an immune response in an individual, including a human, having a pathological condition. The method involves administering to the individual an immunogenic amount of an immunomodulatory flagellin polypeptide, or modification thereof, when the flagellin polypeptide induces an immune response.

An immunomodulatory flagellin peptide of the invention binds to TLR5 and stimulates a TLR5 activity. The ability of an immunomodulatory flagellin peptide or modification thereof to bind to TLR5 or stimulate a TLR5 activity can be determined using methods known in the art. Methods of determining specific binding interactions of flagellin peptides and modifications thereof with TLR5 can be determined using well known methods in the art such as methods of trapping ligand-receptor complexes using chemical cross-linking, and competitive inhibition of reagents specific for TLR5 such as specific flagellin peptides or modifications, antibodies or other TLR-5 specific reagents.

Methods of determining TLR5 functional activities in response to an immunomodulatory flagellin peptide or modification thereof include methods described herein, in Examples I through IV, as well as methods known in the art. A variety of methods well known in the art can be used for

determining transcription factor activities. For example, fos, jun, and NF- κ B activation in response to TLR5 binding to a flagellin molecule can be detected by electrophoretic mobility shift assays well known in the art that detect NF- κ B binding to specific polynucleic acid sequences, and promoter-reporter nucleic acid constructs such that, for example, β -lactamase, luciferase, green fluorescent protein or β -galactosidase will be expressed in response to contacting a TLR5 with a flagellin polypeptide, peptide or equivalent thereof. For example, a luciferase reporter plasmid in which luciferase protein expression is driven by one or more NF- κ B binding sites can be transfected into a cell, as described in Examples I-IV. Activation of NF- κ B results in activation of luciferase reporter expression, resulting in production of luciferase enzyme able to catalyze the generation of a molecule that can be detected by colorimetric, fluorescence, chemiluminescence or radiometric assay.

An amount or activity of a polypeptide, including a cytokine such as TNF α , IL-1 or IL-6, can be a read-out for activation of a TLR5 in response to binding an immunomodulatory flagellin peptide or modification thereof. A variety of methods well known in the art can be used to measure cytokine amounts, such as, for example, flow cytometry methods, immunoassays such as ELISA and RIA, and cytokine RNA protection assays. Commercially available cytokine assay kits, such as ELISA assay formats, can be conveniently used to determine the amount of a variety of cytokines in a sample. Those skilled in the art will determine the particular cytokines to be measured when assessing an immune response in a cell or animal. For example, to determine whether a particular response is characterized as a TH1 or TH2 immune response, those skilled in the art will be able to select appropriate cytokines within the TH1 and TH2 categories, which are well known in the art.

A sample used for determining a TLR5-mediated response or immune response can include, for example, a fluid or tissue obtained from an animal, a cell obtained from an animal fluid or tissue, cultured cells including in vitro and ex vivo cultured cells, and lysates or fractions thereof and cultured cells that express TLR5.

An immune response in an animal is determined by the collective responses of the cells of the immune system. An immune response can be detected by observing various indicators of immune response in an animal. Such indicators include, for example, visible signs of inflammation of tissues, such as swelling, production of antibodies, such as levels of IgA, IgG and IgM in blood and levels of IgA in saliva, alterations in immune cell numbers, such as increased or decreased proliferation of particular immune cells, and in immune cell activities, such as production of immunomodulatory molecules and second messenger molecules. For example, an immune response to a particular antigen can be observed in a animal using methods well known in the art such as delayed hypersensitivity skin tests. An immune response can be determined by the presence of antibodies cross reactive with an antigen, such as by ELISA and Western blotting, lymphocyte activation tests employing mitogen or antigen stimulation, mixed lymphocyte culture tests, assays for human T and B lymphocytes, flow cytometry and cell sorting to characterize populations of immune system cells obtained from an individual, soluble antigen uptake by macrophages, and tests of neutrophil functions (Stites et al. *Basic and Clinical Immunology*, 4th edition, Lange Medical Publications, Los Altos, Calif. (1982)). An immune response can also be assessed by examining amounts or activities of immune system mediators, such as cytokines and chemokines, in cells collected from fluids or tissues of animals. A

variety of methods are well known in the art for qualitative and quantitative measurement of cytokine amount and bioassay of cytokine activity.

The methods of the invention for inducing an immune response can be used to treat any animal species having an immune response upon treatment with flagellin polypeptide, peptide, or modification thereof, and for which a stimulation of an immune response is desired. Such animals include avian species such as chicken, and mammalian species such as rodent, canine, feline, bovine, porcine and human subjects. Methods for using adjuvants with vaccines and vaccinating animals are well known in the art and are routinely used in laboratory animals. Those skilled in the art will be able to determine if a particular animal species has a flagellin-stimulated TLR5-mediated innate immune response.

A vaccine to be used in the methods of the invention for inducing an immune response can be administered as a solution or suspension together with a pharmaceutically acceptable medium. Such a pharmaceutically acceptable medium can be, for example, water, phosphate buffered saline, normal saline or other physiologically buffered saline, or other solvent or vehicle such as glycol, glycerol, and oil such as olive oil or an injectable organic ester. A pharmaceutically acceptable medium can also contain liposomes or micelles, and can contain immunostimulating complexes prepared by mixing polypeptide or peptide antigens with detergent and a glycoside, such as Quil A. Further methods for preparing and administering an immunomodulatory flagellin polypeptide or peptide, or modification in a pharmaceutically acceptable medium are presented below, in reference to compounds that induce a TLR-mediated response.

The immunomodulatory flagellin polypeptides, peptides and modifications thereof used in the methods of the invention can be administered by a variety of routes to stimulate an immune response. For example, these immunomodulatory molecules can be delivered intranasally, subcutaneously, intradermally, intralymphatically, intra-muscularly, intratumorally, orally, intravesically, intraperitoneally and intracerebrally. Oral administration is convenient and relatively safe. Oral vaccination protocols can be useful for inducing the state of immunological tolerance which normally occurs in response to most soluble antigens and the proteolytic degradation of antigen preparations in the digestive tract. Nasal delivery routes may be useful for inducing both mucosal and systemic immune responses. A variety of devices are under development for convenient and effective delivery of formulations to the nasal cavity and pulmonary tissues. Those skilled in the art will know how to select appropriate delivery routes for particular formulations of flagellin polypeptides, peptides and modifications thereof.

The invention provides a screening composition consisting of an immunomodulatory flagellin peptide comprising at least about 10 amino acids of substantially the amino acid sequence GAVQNRFN₅SAIT (SEQ ID NO:2), or a modification thereof, and having toll-like receptor 5 (TLR5) binding, and a TLR5. The composition is useful for identifying agonists, antagonists and ligands for TLR5. The characteristics of an immunomodulatory flagellin peptide comprising at least about 10 amino acids of substantially the amino acid sequence GAVQNRFN₅SAIT (SEQ ID NO:2), or a modification thereof, and having toll-like receptor 5 (TLR5) binding, and preparation of a flagellin peptide are described herein. Similarly, the characteristics of a TLR5 polypeptide and modifications thereof that have a TLR5 activity, and methods for preparing a TLR5 polypeptide to be used in the methods of the invention are described herein. Chimeric TLR5s, such as

the CD4-TLR5 described herein in Example I, are included in the screening compositions of the invention.

The screening composition of the invention includes, for example, cells, cell extracts and artificial signaling systems that contain a TLR5 polypeptide or modification thereof. The cell compositions of the invention include any cell in which TLR5 can couple to a signal transduction pathway to produce a detectable signal in response to an agonist, such as flagellin or a flagellin peptide. Such cells include insect cells such as *Drosophila* cells, yeast cells such as *S. cerevisiae*, prokaryotic cells such as *E. coli*, amphibian cells such as *Xenopus* oocytes, and vertebrate cells such as mammalian primary cells, such as macrophages. Primary cells such as macrophages and other lymphocytes can be conveniently isolated from blood using methods well known in the art. Cells obtained from transgenic animals, such as transgenic mice that have been engineered by known methods of express recombinant TLR5 or TLR5 signal transduction components are also included in the screening compositions of the invention. Cell lines prepared from any of these cell types, such as S2, CHO, NIH-3T3, 293 and HeLa cells are also included in a screening composition of the invention.

The screening compositions of the invention can include crude or partially purified lysates or extracts of the cell compositions of the invention, and reconstituted signaling systems. Artificial signaling systems include, for example, natural or artificial lipid bilayers, such as a liposome or micelle, which promote an active conformation of a TLR5. The compositions can further contain cellular fractions or isolated components necessary for producing and detecting the desired predetermined signal.

The invention provides a method of screening for a TLR5 ligand, agonist or antagonist. The method involves, (a) contacting a TLR5 with a candidate compound in the presence of a flagellin polypeptide or immunomodulatory flagellin peptide under conditions wherein binding of the flagellin polypeptide or immunomodulatory flagellin peptide to the TLR5 produces a predetermined signal; (b) determining the production of the predetermined signal in the presence of the candidate compound; and (c) comparing the predetermined signal in the presence of the candidate compound with a predetermined signal in the absence of the candidate compound, wherein a difference between the predetermined signals in the presence and absence of the candidate compound indicates that the compound is a TLR5 ligand, agonist or antagonist.

TLR5 can produce a variety of predetermined signals useful in the methods of the invention for identifying a TLR5 ligand, agonist or antagonist. TLR5 has an extracellular domain that participates in ligand recognition and intracellular domain that contain a conserved region called the Toll/IL-1R homology (TIR) domain that, upon activation, recruits an adaptor protein, MyD88. Through an amino terminal death domain, MyD88 recruits the serine kinase IRAK to propagate a pro-inflammatory signal through binding to TRAF6, which then binds to other molecules that participate in the TLR5 signaling cascade. Immunomodulatory flagellin peptides and modifications binding to TLR5 induces signal transduction events which result in, for example, stimulating NF- κ B activity and inducing production of gene products of NF- κ B-regulated genes, such as TNF α , IL-1 and IL-6, as well as stimulating AP-1 transcription factors fos and jun. Therefore, a predetermined signal can include a signal produced by an immunomodulatory flagellin polypeptide or peptide or modification binding to TLR5, a signal produced by a TLR5 intracellular signal transduction even, such as kinase or phosphatase activity or protein-protein interactions, by activation

of fos, jun or NF- κ B, and by an amount or activity of a fos-, jun- or NF- κ B-regulated gene or gene product, such as TNF α , IL-1 and IL-6.

A variety of low- and high-throughput assays suitable for detecting selective binding interactions between a receptor and a ligand are known in the art. Both direct and competitive assays can be performed, including, for example, fluorescence correlation spectroscopy (FCS) and scintillation proximity assays (SAP) reviewed in Major, *J. Receptor and Signal Transduction Res.* 15:595-607 (1995); and in Sterrer et al., *J. Receptor and Signal Transduction Res.* 17:511-520 (1997)). Other assays for detecting binding interactions include, for example, ELISA assays, FACS analysis, and affinity separation methods. Such assays can involve labeling a TLR5 ligand, such as flagellin or a flagellin peptide, with a detectable moiety such as a radiolabel, fluorochrome, ferromagnetic substance, or luminescent substance. A detectably labeled flagellin polypeptide or peptide can be prepared using methods well known in the art. Receptor binding assays, including high-throughput automated binding assays, and methods of determining binding affinity from such assays, are well known in the art, and any suitable direct or competitive binding assay can be used. Exemplary high-throughput receptor binding assays are described, for example, in Melentin-Micelotti et al., *Anal. Biochem.* 272:P 182-190 (1999); Zuck et al., *Proc. Natl. Acad. Sci. USA* 96:11122-11127 (1999); and Zhang et al., *Anal. Biochem.* 268: 134-142 (1999).

A variety of methods well known in the art can be used to detect activation of transcription factors, such as NF- κ B, in low- or high-throughput formats. The methods described herein and in the Examples can be adapted to formats suitable for candidate compound screening.

A variety of low- and high-throughput assays suitable for detecting amounts and activities of polypeptides such as cytokines are known in the art. Methods for detecting polypeptides, include, for example, flow cytometric measurements as described herein, immunodetection methods such as radioimmune assay (RIA), ELISA, immunoprecipitation and Western blotting. Assay of the activity of a cytokine include function bioassays and detection of amounts of polypeptides regulated by a particular cytokine. Those skilled in the art can determine an appropriate method for detecting an activity of a particular cytokine.

Suitable conditions under which TLR5 produces a predetermined signal in response to a flagellin polypeptide, peptide or modification can be determined by those skilled in the art, and will depend on the particular predetermined signal selected. Exemplary conditions for determining the production of a predetermined signal are provided herein in Examples I-IV. Any known or predicted TLR5-mediated cellular event, such as elicitation of second messengers, induction of gene expression or altered cellular proliferation, differentiation or viability can be a predetermined signal that is an indication of activation of signal transduction through TLR5.

Assays for detecting a predetermined signal produced by binding of flagellin or flagellin peptide to TLR5 can be performed, for example, with whole cells that express TLR5, membrane fractions, or artificial systems, as described herein, or with isolated TLR5 polypeptide, either in solution, in an artificial membrane, or bound to a solid support.

A method of identifying TLR5 agonists and antagonists can be performed either in the presence of a predetermined concentration of a known TLR5 agonist, such as flagellin, flagellin peptide, or modifications thereof, or in the absence of agonist. The agonist can be added either prior to, simulta-

neously with, or after, addition of the test compound. When present, the agonist concentration is preferably within 10-fold of its EC₅₀ under the assay conditions to allow the identification of a compound that competes with a known agonist for signaling through TLR5, or indirectly augments signaling through the receptor. Likewise, a compound that reduces binding between a known agonist and its receptor, or indirectly decreases signaling through the receptor, can also be identified.

The method of screening to identify a ligand, agonist or antagonist of TLR5 involve testing a candidate compound. A candidate compound can be any substance, molecule, compound, mixture of molecules or compounds, or any other composition. The candidate compounds can be small molecules or macromolecules, such as biological polymers, including proteins, polysaccharides and nucleic acids. Sources of candidate compounds which can be screened for a ligand, agonist or antagonist of TLR5 include, for example, libraries of small molecules, peptides and polypeptides.

Additionally, candidate compounds can be preselected based on a variety of criteria. For example, suitable candidate compounds can be selected as having known ligand, agonist or antagonist activity. Alternatively, candidate compounds can be selected randomly. Candidate compounds can be administered to the reaction system at a single concentration or, alternatively, at a range of concentrations to determine, for example, an EC₅₀ or IC₅₀ of a candidate compound.

The method of screening for TLR5 ligands, agonists or antagonists can involve groups or libraries of compounds. Methods for preparing large libraries of compounds, including simple or complex organic molecules, carbohydrates, peptides, peptidomimetics, polypeptides, nucleic acids, antibodies, and the like, are well known in the art. Libraries containing large numbers of natural and synthetic compounds can be obtained from commercial sources.

The number of different candidate compounds to examine using the methods of the invention will depend on the application of the method. It is generally understood that the larger the number of candidate compounds, the greater the likelihood of identifying a compound having the desired activity in a screening assay. Large numbers of compounds can be processed in a high-throughput automated format.

The TLR5 agonists, antagonists and ligands identified using the methods and compositions described herein, are potential therapeutic compounds that can be administered to an individual, such as a human or other mammal, in an effective amount to increase or decrease signaling through TLR5, for example, to alter an immune response or treat a TLR5-associated condition. Such compounds can be used analogously to immunomodulatory compounds useful for augmenting and altering an immune response, as described above. For example, a compound can be used to induce a general immune response and to induce a specific immune response in the presence of an antigen and to alter the level of a particular cytokine in an individual having a pathological condition.

The TLR5 agonists and antagonists, immunomodulatory flagellin peptides, polypeptides and modifications thereof, are useful for ameliorating, or reducing the severity of a pathological condition. Reduction in severity includes, for example, an arrest or decrease in clinical symptoms, physiological indicators, biochemical markers or metabolic indicators of disease. Those skilled in the art will know, or will be able to determine the appropriate clinical symptoms, physiological indicators, biochemical markers or metabolic indicators to observe for a particular pathological condition. To

prevent a disease means to preclude the occurrence of a disease or restoring a diseased individual to their state of health prior to disease.

In addition to applications described herein for agonists and antagonists, a TLR5 ligand can be used, for example, to specifically target a diagnostic moiety to cells and tissues that express TLR5, such as monocytes, immature dendritic cells, epithelial cells, and other cells involved in an immune response. Thus, a TLR5 ligand can be labeled with a detectable moiety, such as a radiolabel, fluorochrome, ferromagnetic substance, or luminescent substance, and used to detect normal or abnormal expression of TLR5 polypeptide in an isolated sample or in vivo diagnostic imaging procedures.

A heterologous amino acid sequence can be advantageously used to provide a tag for detection or purification or to impart an activity to a reference polypeptide or peptide, such as an enzyme activity, a biological activity, an immunological activity or stability. An immunomodulatory flagellin peptide, polypeptide or modification thereof, or TLR5 polypeptide can contain a heterologous amino acid sequence, or amino acid sequence not present in the native amino acid sequence of a reference polypeptide or peptide and not represented by a modification of a reference polypeptide or peptide. A heterologous amino acid sequence can be of any size in relation to the reference amino acid sequence. A TLR5 polypeptide containing the heterologous sequence of CD4 is a specific example of such a modification and is described further in Example I. The described CD4-TLR5 chimera is identified by the amino acid sequence of SEQ ID NO:10, encoded by the nucleic acid sequence of SEQ ID NO:9. A chimeric TLR5 can be prepared using cloning methods well known in the art. For example, a chimeric polypeptide can be produced by amplifying by PCR a nucleotide sequence encoding a portion of a selected polypeptide using sequence specific primers. Primers useful for amplifying a TLR5 include, for example, huTLR5-A6: TTAAAGTGGTAC-CAGTTCTCCCTTTTCATTGT ATGCACT (SEQ ID NO:35) and huTLR5DNS: CGGGATCCCGTTAGGAG ATGGTTGCTACAGTTTGC (SEQ ID NO:36). A portion of a TLR5 nucleotide sequence, such as a sequence amplified using such primers can be fused to a nucleotide sequence encoding a heterologous amino acid sequence. A variety of methods for generating nucleic acid sequences encoding chimeric polypeptides are well known to those skilled in the art.

The polypeptides and peptides described herein, including immunomodulatory flagellin peptides, flagellin polypeptide, TLR5 polypeptides and fragments thereof can be prepared using a variety of protein expression systems well known in the art, including prokaryotic and eukaryotic expression systems. Prokaryotic expression systems are advantageous due to their ease in manipulation, low complexity growth media, low cost of growth media, rapid growth rates and relatively high yields. Well known prokaryotic expression systems include, for example, *E. coli* bacterial expression systems based on bacteriophage T7 RNA polymerase, the trc promoter, the araB promoter and *bacillus* expression. Eukaryotic expression systems are advantageous because expressed polypeptides can contain eukaryotic post-translational modifications such as O-linked glycosylation, phosphorylation and acetylation and can have improved protein folding. Well known eukaryotic expression systems include, for example, expression in yeast, such as *Pichia pastoris* and *Pichia methanolic*, expression in insect systems such as the *Drosophila* S2 system and baculovirus expression systems and expression in mammalian cells using adenoviral vectors and cytomegalovirus promoter-containing vectors.

An immunomodulatory flagellin peptide, polypeptide, TLR5 or fragments thereof can be purified using a variety of methods of protein purification well known in the art. Biochemical purification can include, for example, steps such as solubilization of the polypeptide or peptide-expressing cell, isolation of the desired subcellular fractions, chromatography, such as ion exchange, size, or affinity-based chromatographies, electrophoresis, and immunoaffinity procedures. Other well-known methods are described in Deutscher et al., *Guide to Protein Purification: Methods in Enzymology* Vol. 182, (Academic Press, (1990)). An exemplary method for purifying a flagellin peptide is provided in Example III. The methods and conditions for biochemical purification of a polypeptide of the invention can be chosen by those skilled in the art, and the purification monitored, for example, by staining SDS-PAGE gels containing protein samples, by immunodetection methods such as Western blotting and ELISA, and by functional assay of immunogenic activity of flagellin or a TLR5 activity of TLR5.

An immunomodulatory flagellin peptide, polypeptide, TLR5 or fragments thereof can be modified, for example, to increase polypeptide stability, alter an activity, facilitate detection or purification, or render the enzyme better suited for a particular application, such as by altering substrate specificity. Computer programs known in the art can be used to determine which amino acid residues of an immunomodulatory flagellin peptide, flagellin polypeptide or TLR5 can be modified as described above without abolishing a corresponding activity (see, for example, Eroshkin et al., *Comput. Appl. Biosci.* 9:491-497 (1993)). In addition, structural and sequence information can be used to determine the amino acid residues important for activity. For example, a comparisons of flagellin amino acid sequences, such as that shown in FIG. 7 can provide guidance in determining amino acid residues that can be altered without abolishing flagellin or flagellin peptide activity by indicating amino acid residues that are conserved across species. Conserved regions of flagellin are well known in the art and have been described, for example, in Mimori-Kiyosue, et al., *J. Mol. Biol.* 270:222-237, (1997). A crystal structure of flagellin can also provide guidance for making flagellin modifications (Samatey et al. *Nature*, 410: 331-337 (2001)). Similarly, amino acid sequence comparisons between the disclosed murine TLR5, TLR5s of other species, and other toll-like receptor family members can provide guidance for determining amino acid residues important for activity.

An isolated TLR5 is a TLR5 removed from one or more components with which it is naturally associated. Therefore, an isolated TLR5 can be a cell lysate, cell fraction, such as a membrane fraction, or a purified TLR5 polypeptide. An isolated TLR5 can include a liposome or other compound or matrix that stabilizes or promotes an active conformation of the receptor.

For treating or reducing the severity of a pathological condition a TLR5 agonist or antagonist, immunomodulatory flagellin peptide, polypeptide or modification thereof, including a vaccine, can be formulated and administered in a manner and in an amount appropriate for the condition to be treated; the weight, gender, age and health of the individual; the biochemical nature, bioactivity, bioavailability and side effects of the particular compound; and in a manner compatible with concurrent treatment regimens. An appropriate amount and formulation for a particular therapeutic application in humans can be extrapolated based on the activity of the compound in recognized animal models of the particular disorder.

Animal models of aberrantly proliferative diseases can be used to assess a formulation of compound, including a vaccine or adjuvant containing an immunomodulatory flagellin peptide, polypeptide or modification thereof, for an amount sufficient to induce an immune response or ameliorate disease symptoms. Animal models of such pathological conditions well known in the art which are reliable predictors of treatments in human individuals for include, for example, animal models for tumor growth and metastasis, infectious diseases and autoimmune disease.

There are numerous animal tumor models predictive of therapeutic treatment which are well known in the art. These models generally include the inoculation or implantation of a laboratory animal with heterologous tumor cells followed by simultaneous or subsequent administration of a therapeutic treatment. The efficacy of the treatment is determined by measuring the extent of tumor growth or metastasis. Measurement of clinical or physiological indicators can alternatively or additionally be assessed as an indicator of treatment efficacy. Exemplary animal tumor models can be found described in, for example, Brugge et al., *Origins of Human Cancer*, Cold Spring Harbor Laboratory Press, Plain View, N.Y., (1991).

Similarly, animal models predictive for infectious disease also follow a similar approach. Briefly, laboratory animals are inoculated with an infectious agent and the progression of the infection is monitored by, for example, clinical symptoms, growth culture of the agent from an infected tissue sample or biopsy in the presence or absence of the therapeutic treatment. The reduction in severity of the diagnostic indicator is indicative of the efficacy of the treatment. A variety of animal models for infectious diseases are well known to those skilled in the art.

One animal model predictive for autoimmune diseases is Experimental allergic encephalomyelitis (EAE), also called experimental autoimmune encephalomyelitis. Although originally characterized as a model for neurological autoimmune disease such as human multiple sclerosis, the use of this model to predict treatments of other autoimmune diseases has been widely accepted. EAE is induced in susceptible animals by active immunization with myelin basic protein (MBP) or by passive transfer of MBP-specific T helper lymphocytes. Progression of the disease is characterized by chronic relapsing paralysis and central nervous system demyelination, which can be monitored by observation or by immunological determinants such as delayed-type hypersensitivity (DTH; a measure of cell mediated immunity) response to the immunogen. Efficacy of a therapeutic treatment is compared to progression of the disease in the absence of treatment. A reduction in severity of EAE symptoms or immunological determinants in treated animals is indicative of the efficacy of the therapeutic treatment. For a review of autoimmune disease models see, for example, Urban et al., *Cell*, 54:577-592 (1988); Brostoff et al., *Immunol. Ser.* 59:203-218 (1993) and U.S. Pat. Nos. 5,614,192 and 5,612,035.

A growing number of human diseases have been classified as autoimmune and include, for example, rheumatoid arthritis, myasthenia gravis, multiple sclerosis, psoriasis, systemic lupus erythematosis, autoimmune thyroiditis, Graves' disease, inflammatory bowel disease, autoimmune uveoretinitis, polymyositis and diabetes. Animal models for many of these have been developed and can be employed analogously as the EAE model described above predictive assessment of therapeutic treatments using the compounds, vaccines and adjuvants in the methods of the invention.

Other reliable and predictive animal models are well known in the art and similarly can be used to assess a com-

pound formulation, including vaccine and adjuvant formulations containing an immunomodulatory flagellin peptide, polypeptide or modification thereof.

The total amount of a compound including an immunomodulatory flagellin peptide, polypeptide or modification thereof, that modulates a TLR5-mediated immune response can be administered as a single dose or by infusion over a relatively short period of time, or can be administered in multiple doses administered over a more prolonged period of time. Additionally, a compound can be administered in a slow-release matrix, which can be implanted for systemic delivery at or near the site of the target tissue.

A compound that modulates a TLR5-mediated immune response can be administered to an individual using a variety of methods known in the art including, for example, intravenously, intramuscularly, subcutaneously, intraorbitally, intracapsularly, intraperitoneally, intracisternally, intra-articularly, intracerebrally, orally, intravaginally, rectally, topically, intranasally, or transdermally.

A compound that modulates a TLR5-mediated immune response can be administered to a subject as a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. The choice of pharmaceutically acceptable carrier depends on the route of administration of the compound and on its particular physical and chemical characteristics. Pharmaceutically acceptable carriers are well known in the art and include sterile aqueous solvents such as physiologically buffered saline, and other solvents or vehicles such as glycols, glycerol, oils such as olive oil and injectable organic esters. A pharmaceutically acceptable carrier can further contain physiologically acceptable compounds that stabilize the compound, increase its solubility, or increase its absorption. Such physiologically acceptable compounds include carbohydrates such as glucose, sucrose or dextrans; antioxidants, such as ascorbic acid or glutathione; chelating agents; and low molecular weight proteins. As described above in reference to vaccines, such routes of administration are also applicable to administration of an immunomodulatory flagellin peptide, polypeptide or modification thereof.

In addition, a formulation of a compound that modulates a TLR5-mediated immune response can be incorporated into biodegradable polymers allowing for sustained release of the compound, the polymers being implanted in the vicinity of where drug delivery is desired, for example, at the site of a tumor or implanted so that the compound is released systemically over time. Osmotic minipumps also can be used to provide controlled delivery of specific concentrations of a compound through cannulae to the site of interest, such as directly into a tumor growth or other site of a pathology involving a perturbation state. The biodegradable polymers and their use are described, for example, in detail in Brem et al., *J. Neurosurg.* 74:441-446 (1991). These methods, in addition to those described above in reference to vaccines, are applicable to administering an immunomodulatory flagellin peptide, polypeptide or modification thereof to induce an immune response.

The methods of treating a pathological condition additionally can be practiced in conjunction with other therapies. For example, for treating cancer, the methods of the invention can be practiced prior to, during, or subsequent to conventional cancer treatments such as surgery, chemotherapy, including administration of cytokines and growth factors, radiation or other methods known in the art. Similarly, for treating pathological conditions which include infectious disease, the methods of the invention can be practiced prior to, during, or subsequent to conventional treatments, such as antibiotic administration, against infectious agents or other methods

known in the art. Treatment of pathological conditions of autoimmune disorders also can be accomplished by combining the methods of the invention for inducing an immune response with conventional treatments for the particular autoimmune diseases. Conventional treatments include, for example, chemotherapy, steroid therapy, insulin and other growth factor and cytokine therapy, passive immunity and inhibitors of T cell receptor binding. The methods of the invention can be administered in conjunction with these or other methods known in the art and at various times prior, during or subsequent to initiation of conventional treatments. For a description of treatments for pathological conditions characterized by aberrant cell growth see, for example, *The Merck Manual*, Sixteenth Ed, (Berkow, R., Editor) Rahway, N.J., 1992.

As described above, administration of a compound, immunomodulatory flagellin peptide, flagellin polypeptide or modification thereof can be, for example, simultaneous with or delivered in alternative administrations with the conventional therapy, including multiple administrations. Simultaneous administration can be, for example, together in the same formulation or in different formulations delivered at about the same time or immediately in sequence. Alternating administrations can be, for example, delivering an immunomodulatory flagellin peptide or polypeptide formulation and a conventional therapeutic treatment in temporally separate administrations. As described previously, the temporally separate administrations of a compound, immunomodulatory flagellin peptide, polypeptide or modification thereof, and conventional therapy can similarly use different modes of delivery and routes.

The invention provides a method of using a signal produced in response to flagellin binding to TLR5 to detect bacterial contamination in a sample. The method can be used to detect picogram amounts of flagellin in a sample.

Food-borne diseases resulting from the presence of harmful bacteria account for 325,000 hospitalizations and 5,000 deaths each year in the United States (National Institutes of Health, Foodborne Diseases NIAID Fact Sheet). The U.S. Centers for Disease Control and Prevention (CDC) estimates that 1.4 million people in the United States are infected each year with *Salmonella*. Other bacterial pathogens that cause pathological conditions characterized by symptoms ranging from intestinal discomfort to severe dehydration, bloody diarrhea and even death, include enterohemorrhagic *E. coli*, such as strains designated O157:H7 and O26:H11, *Campylobacter* strains such as *C. jejuni*, and *Shigella* strains such as *S. flexneri*.

All of these bacterial strains are flagellated, and therefore express flagellin polypeptides. For example, the amino acid sequences of flagellins from *Salmonella*, *E. coli*, *Campylobacter*, *Shigella* strains are shown in FIG. 7. The methods of the invention for detecting flagellin polypeptides contained in samples suspected of bacterial contamination can be applied to quality assurance protocols for preparation of foods and numerous other applications.

The invention also provides a bioassay for detecting bacterial contamination in a sample. The method involves, (a) contacting the sample with a TLR5 under conditions wherein binding of a flagellin polypeptide or fragment thereof in the sample to the TLR5 produces a predetermined signal, (b) determining the production of the predetermined signal in the presence and absence of the sample, and (c) comparing the predetermined signal in the presence of the sample with a predetermined signal in the absence of the sample, wherein a

difference between the predetermined signals in the presence and absence of the sample indicates that the sample contains flagellin.

The methods of the invention for detecting bacterial contamination are based on the finding disclosed herein that flagellin is a ligand for TLR5. Therefore, a flagellin molecule in a sample can bind to a TLR5 and elicit the production of a predetermined signal. A predetermined signal produced by TLR5 in a particular assay system is compared in the presence and absence of a sample known or suspected of containing a bacterial contaminant. A sample known to be free of flagellin can be used as a negative control, while a sample containing a known concentration of flagellin, flagella or bacteria having flagella can be used as a positive control.

A sample to be tested for the presence of flagellin can be any material that is suspected of being contaminated with a gram-positive or gram-negative flagellated bacterium. For example, the method for determining the presence of flagellin can be performed using a sample of a biological fluid, cell, tissue, organ or portion thereof, such as a sample of a tissue to be used for preparing a product, a product for human or animal consumption, such as a food or pharmaceutical preparation, and a product for external application or administration by any route to an animal.

A variety of predetermined signals produced by a TLR5, as discussed above and in the Examples herein, can be used to detect the binding and activation of a TLR5 by a flagellin molecule present in a sample. A variety of methods known in the art, including those described herein can be used to detect a predetermined signal produced by a TLR5.

It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also included within the definition of the invention provided herein. Accordingly, the following examples are intended to illustrate but not limit the present invention.

EXAMPLE I

Constitutively Active TLR5 Activates NF- κ B and TNF α Production

This example shows activation of NF- κ B and TNF α production in CHO cells in response to constitutively active TLR5.

To determine if TLR5 activates NF- κ B and TNF α production, the activity of a constitutively active form of TLR5 was examined in CHO cells. Constitutively active forms of TLR4 and TLR5 were generated by fusing the extracellular domain of CD4 to the transmembrane and TIR domain of TLR4 or TLR5 (Medzhitov, R. et al. *Nature* 388, 394-7 (1997); Ozinsky, A. et al., *Proc. Natl. Acad. Sci.* 97, 13766-13881 (2000)). CD4-TLR5 was constructed by fusing the murine CD4 extracellular domain (amino acids 1-391) to the putative transmembrane and cytoplasmic domains of human TLR5 (amino acids 639-859) and cloning into pEF6-TOPO (pEF6-mCD4-hTLR5). These chimeras, referred to as CD4-TLR4 and CD4-TLR5 were expressed in CHO cells.

For determining NF- κ B activity in response to TLR5, CHO cells were transiently transfected with expression vectors for CD4-TLR4, CD4-TLR5, or empty expression vector (control) together with an NF- κ B luciferase reporter. NF- κ B-induced luciferase activity was measured. CHO cells (CHO-K1) were obtained from ATCC (no. CRL-9618) and grown in Ham's F-12 medium supplemented with 10% FBS, L-glutamine, penicillin, and streptomycin. CHO cells were transfected by electroporation as described previously (Underhill, D. M. et al., *Nature*, 401, 811-5 (1999)), with 1 μ g of

the indicated TLR expression vector, 1 µg of ELAM-firefly luciferase, 0.1 µg of TK-renilla luciferase (Promega). Cells were plated on 96-well plates at 100,000 cells/well, and incubated overnight at 37° C., 5% CO₂. Firefly and renilla luciferase activities were measured using the Dual Luciferase Assay System (Promega, Madison, Wis.). Luciferase activity is expressed as a ratio of NF-κB-dependent ELAM-firefly luciferase activity divided by control thymidine kinase-renilla luciferase activity (relative luciferase units).

For determining TNFα production in response to TLR5, RAW-TTIO Macrophage cells were transfected with a CD4-TLR5 expression vector, and the production of TNFα was measured by flow cytometry, as described previously (Ozinsky, A. et al. *Proc. Natl. Acad. Sci.* 97, 13766-13771 (2000)). Transfections were performed by electroporation using 10 µg of pEF6-mCD4-hTLR5, and 18 hours later the cells were incubated with 5 µg/ml of brefeldin A for 4 hours to accumulate intracellular pools of newly synthesized TNFα. Cells were fixed, permeabilized, stained for the expression of CD4 (anti-CD4-FITC, Pharmingen) and TNFα (anti-murine TNFα-PE, Pharmingen), and analyzed on a FACscan (Beckton-Dickenson). FACS data were analyzed with WinMDI (Joseph Trotter, Scripps Research Institute, La Jolla, Calif.). Cells were gated to exclude dead cells and for expression of CD4.

FIG. 1 shows that expression of CD4-TLR5 induced NF-κB activation-mediated luciferase production in CHO cells (FIG. 1a) and TNFα production in mouse macrophages (FIG. 1b). In FIG. 1b, the dotted line indicates TNFα produced in cells not expressing CD4-TLR5, and the solid line indicates TNFα produced in cells expressing CD4-TLR5.

Thus, homo-oligomerization of the TLR5 signaling domain induces a cellular signal characterized by the induction of NF-κB activity and production of TNFα.

EXAMPLE II

Bacterial Culture Supernatants Contain TLR5-Stimulating Activity

This Example shows that bacterial culture supernatants contain TLR5-stimulating activity.

CHO cells expressing human TLR5 and a luciferase-linked reporter were used to screen for PAMPs recognized by the receptor. PAMPs tested included LPS, lipopeptide, yeast, and extracts from *E. coli*, *Pseudomonas*, and *Listeria*. CHO cells were transiently transfected with TLR2, TLR5, or empty expression vectors together with a NF-κB luciferase reporter. The cells were treated with 100 ng/ml LPS, 100 ng/ml lipopeptide, 10⁷ yeast particles/ml, or untreated (control), and luciferase activity was measured. The cells were treated with 67 µg/ml of supernatant from the indicated saturated bacterial cultures, or LB alone (control), and the luciferase activity was measured. Data are representative of 3 independent experiments.

Human TLR5 and TLR2 were generated by PCR from cDNA derived from human peripheral blood mononuclear cells and cloned into pEF6-TOPO (Invitrogen) (pEF6-hTLR5 and pEF6-hTLR2). Murine TLR5 was generated by PCR using cDNA derived from RAW-TTIO cells and cloned into pEF6 (pEF6-mTLR5).

For luciferase assays, CHO cells were transfected by electroporation as described above, with 1 µg of the indicated TLR expression vector, 1 µg of ELAM-firefly luciferase, 0.1 µg of TK-renilla luciferase (Promega, Madison, Wis.). The medium was replaced with medium containing the stimuli at the indicated concentration/dilution. Bacterial lipopeptide

and PAM₃CSK₄, were obtained from Roche, LPS (*Salmonella minnesota* R595) was from List, and yeast particles (zymosan) were from Molecular Probes (Eugene, Oreg.). Cells were stimulated for 5 hours at 37° C., and firefly and renilla luciferase activities were measured using the Dual Luciferase Assay System (Promega).

For preparation of bacterial supernatants, bacteria were grown either in Luria broth (LB) (*Escherichia coli* TOP 10 (Invitrogen), *Salmonella minnesota* (ATCC#49284), mutant *Salmonella typhimurium* (TH4778 fliB⁻ fliC⁺), TH2795 (fliB⁻ fliC⁻), (Dr. Kelly Hughes, University of Washington), or grown in trypticase soy broth (TSB) (*Listeria monocytogenes* (10403, gift of Dr. Daniel Portnoy, UCSF), *Listeria innocua* (ATCC#33090), *Bacillus subtilis*, and *Pseudomonas aeruginosa* (Susan R. Swanzy, University of Washington)). Bacteria were grown to saturation (about 16 hours, 37° C. with vigorous aeration). The bacterial culture supernatants were centrifuged for 30 minutes at 2000×g, filtered. (0.2 µM), and stored at 4° C. prior to use. For flaA transfections, *E. coli* TOP10 containing pTrcHis2-flaA or pTrcHis2-flaArev were selected from bacterial plates and grown to OD₆₀₀ of 0.6 in LB with 100 µg/ml ampicillin and 1% w/v glucose. The bacteria were centrifuged for 30 minutes at 2000×g, and split into two LB cultures, one containing 100 µg/ml ampicillin and 1% w/v glucose (to repress flaA) and the other containing 100 µg/ml ampicillin and 1 mM IPTG (to induce flaA). Samples were taken at 4 hours after induction, centrifuged 5 min at 10,000×g, and the supernatants stored at 4° C. before use.

TLR5 did not respond to any of the PAMPs known to stimulate TLR pathways, such as LPS, lipopeptide, yeast cell wall, or peptidoglycan, while CHO cells transfected with TLR2 were stimulated by lipopeptide, yeast cell wall, and peptidoglycan (FIG. 2a). However, TLR5-stimulating activity was detected in culture supernatants of a variety of Gram-positive and Gram-negative bacteria (FIG. 2b). The TLR5-stimulating activity of Gram-positive bacteria was not enhanced by co-expression of CD14. Interestingly, the TOP10 strain of *E. coli* had very little TLR5 activity (FIG. 2b), and was used in subsequent reconstitution experiments (see below). Experiments using murine TLR5 yielded similar results.

Thus, the activity of TLR5 was stimulated by a component of bacterial culture supernatants, but not by PAMPs known to stimulate other toll like receptor family members.

EXAMPLE III

Purification of TLR5-Stimulating Activity from *L. monocytogenes* Culture Supernatant

This Example shows the purification of TLR5-stimulating activity from *L. monocytogenes* culture supernatant.

The biological activity recognized by TLR5 was determined to be TCA precipitable, phenol soluble, and sensitive to proteinase K and trypsin digestion. To identify the bacterial components that stimulate TLR5, the supernatant from a saturated *L. monocytogenes* culture was concentrated, fractionated by reverse-phase chromatography, and each fraction was assessed for TLR5-stimulating activity in CHO cells (FIG. 3a).

For assessing the TLR-stimulating activity of FPLC fractions, CHO cells were transfected as described in Example I with the addition of 0.1 µg of pNeo/Tak (Underhill et al., *Nature* 401, 811-5 (1999)), and stable populations of cells expressing the indicated TLR with the luciferase reporters

were selected in 100 µg/ml G418. These cells were plated on 96-well plates at 100,000 cells/well and incubated overnight.

For the purification of the TLR5-stimulating activity, saturated *L. monocytogenes* culture (200 ml of TSB) was centrifuged, and the supernatant was enriched for molecules larger than 30 kDa by ultrafiltration (Ultrafree-15 filter unit with Biomax-30 membrane, Millipore). The buffer was changed to 100 mM Tris pH 7.5, and the volume was adjusted to 5 ml. The sample was loaded onto a HR5/10 reverse-phase chromatography column (AP Biotech) and run at 0.3 ml/min. Reverse-phase chromatography was performed with the indicated elution profile using the following buffers: (A) initial buffer, 0.1% TFA in water, (B) final buffer, 0.1% TFA in acetonitrile. Fractions were collected at 3-minute intervals. FPLC fractions (50 µl) were separated on a 10% SDS-PAGE gel.

As shown in FIG. 3a, CHO cells expressing an NF-κB luciferase reporter and TLR5 were stimulated with reverse-phase FPLC fractions, and TLR5-mediated NF-κB luciferase activity was measured. The fraction numbers correspond to 3 minute fractions of reverse-phase FPLC eluted with a non-linear gradient of buffer B as shown. Fraction number "N" is control LB growth medium and "P" is the *L. monocytogenes* culture supernatant prior to chromatography. Fractions containing background activity (1), low activity (2) and high activity (3) as indicated in FIG. 3a were analyzed by SDS-PAGE and silver stain. Silver staining was performed according to established methods. Two bands with apparent molecular masses of 30-34 kDa were clearly enriched in the fraction containing the highest level of TLR5-stimulating activity (FIG. 3b, Lane 3). Proteins eluted from regions A, B, and C of the SDS-PAGE gel, as indicated in FIG. 3b were assayed for TLR5-mediated NF-κB activation in CHO cells. In FIG. 3c, "*Listeria*" indicates *L. monocytogenes* culture supernatant. One of these bands, (FIG. 3b, band A), was trypsin-treated, subject to microcapillary HPLC-tandem mass spectrometry, and identified by comparison of peptide tandem mass spectra to sequences in a non redundant protein database using the computer program, SEQUEST27 (FIG. 4a). TLR5-stimulating activity was not recovered from any other section of the gel.

Thus, a TLR5-stimulating activity was purified from culture supernatants from *L. monocytogenes*.

EXAMPLE IV

Flagellin is a TLR5 Stimulus

This example shows that flagellin is a TLR5 stimulus purified from culture supernatants from *L. monocytogenes*.

As described above, a TLR5-stimulating activity was purified from *L. monocytogenes* culture supernatants using HPLC. The isolated polypeptide of band A in FIG. 3b was trypsinized and identified by microcapillary HPLC-tandem mass spectrometry. Peaks corresponding to *L. monocytogenes* flagellin peptides are indicated in FIG. 4a. Five sequences were identified (FIG. 4a) that correspond to flagellin, the product of the flaA gene of *L. monocytogenes* (Genbank Q02551). The location of these sequences within the protein is indicated in FIG. 4b. Band B of FIG. 3b also is flagellin, which migrates as a doublet of approximately 30 kDa on SDS-PAGE (FIG. 3b).

For analysis, bands A and B were excised from SDS-PAGE gels, dehydrated with acetonitrile, dried under reduced vacuum, and trypsin (12.5 ng/µL) was infused into the gel. The gel slice was allowed to incubate on ice for 45 min in the presence of trypsin and then excess trypsin removed and

replaced with 50 mM ammonium bicarbonate and the gel slice incubated overnight at 37° C. Peptides were extracted by 3 washes with 5% acetic acid in 50% aqueous acetonitrile. The extractions were pooled and concentrated by vacuum centrifugation. The peptides were injected onto a C18 peptide trap cartridge (Michrom BioResources, Inc. Auburn, Calif.), desalted, and then injected onto a 75 µm (internal diameter) × 10 cm micro-capillary HPLC column (Magic C18; 5-µm packing; 100 Å pore size; Michrom BioResources, Inc. Auburn, Calif.). The sample injection was made using a FAMOS autosampler (LCPackings, San Francisco, Calif.) coupled with an Agilent HP1100 Pump. Peptides were separated by a linear gradient of acetonitrile, and subjected to collision induced dissociation using an electrospray ionization-ion trap mass spectrometer (ESI-ITMS; ThermoQuest, San Jose, Calif.) in data-dependent mode with dynamic exclusion (Goodlett, et al. *Anal. Chem.* 72, 1112-1118 (2000)). Protein identification was accomplished by use of the SEQUEST computer program (Eng et al. *J. Am. Soc. Mass. Spectrom.* 5, 976-989 (1994)).

CHO cells expressing an NF-κB luciferase reporter and TLR5 or TLR2 were stimulated with 100 µl/ml *Listeria* supernatant or 33 µg/ml purified *Salmonella* flagellin. Flagellin was purified from *Salmonella typhimurium* (TH4778 fliB- fliC+) by the procedure of Ibrahim et al., *J. Clin. Microbiol.* 22, 1040-1044 (1985). As shown in FIG. 4c, flagellin stimulated TLR5-expressing CHO cells, but not TLR2-expressing CHO cells. The mean and standard deviation of quadruplicate samples are indicated. CHO cells were transfected as described in above Examples with the addition of 0.1 µg of pNeo/Tak, and stable populations of cells expressing the indicated TLR with the luciferase reporters were selected in 100 µg/ml G418. These cells were plated on 96-well plates at 100,000 cells/well, incubated overnight, and processed in luciferase assays as described above.

The observation that flagellin is the TLR5 ligand also is supported by the finding that the flagellated bacteria, *L. monocytogenes* and *P. aeruginosa*, stimulate TLR5, while the TOP10 strain of *E. coli*, that has lost its flagella, does not (FIG. 2b).

Similarly, TLR5-stimulating activity was found in *B. subtilis*, *L. innocua*, *S. typhimurium* and *S. minnesota*, all flagellated bacteria, while non-flagellated bacteria such as *H. influenza*, did not activate TLR5.

Thus, the TLR5-stimulating activity purified from *L. monocytogenes* culture supernatants was identified as flagellin by tandem mass spectrometry.

EXAMPLE V

Flagellin Expression in Bacteria Reconstitutes TLR5-Stimulating Activity

This Example shows that flagellin expression in bacteria reconstitutes TLR-stimulating activity, and deletion of flagellin genes abrogates TLR5-stimulating activity.

To confirm that flagellin is the sole TLR5 ligand in bacteria, *E. coli* (TOP10) that secrete little TLR5 activity (FIG. 2b) were transformed with the cDNA of *L. monocytogenes* flagellin (flaA) under the control of an inducible promoter. TLR-expressing CHO cells were stimulated for 5 hours with *E. coli* culture supernatants (67 µl/ml) in which expression of *L. monocytogenes* flagellin was induced or repressed. In the control sample, CHO cells were stimulated with supernatants from induced *E. coli* containing the *L. monocytogenes* flagellin gene cloned in the reverse orientation. Supernatants of *E. coli* that were induced to express *L. monocytogenes* flaA

35

contained substantial TLR5-stimulating activity (FIG. 5a), whereas supernatants from *E. coli* in which expression was repressed, or from *E. coli* expressing flaA in the reverse orientation, contained little TLR5 activity in CHO cells expressing an NF- κ B luciferase reporter and TLR5 (FIG. 5a) or TLR2 (FIG. 5b). CHO cells expressing an NF- κ B luciferase reporter and TLR5 (c) or TLR2 (d) were stimulated for 5 hours with culture supernatants (100 μ l/ml) from *S. typhimurium* lacking one copy of flagellin (FliB⁻ fliC⁺) or both copies of flagellin (FliB⁻ fliC⁻). Control is stimulation with LB medium. The mean and standard deviation of quadruplicate samples are indicated.

CHO cells were transfected with TLR2 and TLR5 expression plasmids as described above with the addition of 0.1 μ g of pNeo/Tak, and stable populations of cells expressing the indicated TLR with the luciferase reporters were selected in 100 μ g/ml G418. These cells were plated on 96-well plates at 100,000 cells/well, incubated overnight, and processed in luciferase assays as described above.

L. monocytogenes flagellin is not recognized by TLR2, since supernatants from *E. coli* expressing flaA did not show enhanced TLR2-dependent stimulation of CHO cells relative to supernatants from *E. coli* with repressed flaA expression (FIG. 5b). In addition to the experiments that demonstrate reconstitution of TLR5-stimulating activity by the expression of flagellin, a bacterium from which flagellin had been deleted was tested. It was observed that TLR5-stimulating activity was abrogated in the flagellin deleted strain. *S. typhimurium* possess two genes for flagellin, fliB and fliC (Fujita, J., *J. Gen Microbiol.* 76, 127-34 (1973)). Culture supernatants of fliB⁻ fliC⁺ *S. typhimurium* contained TLR5-stimulating activity, while culture supernatants from *S. typhimurium* lacking both flagellins (fliB⁻ fliC⁻) expressed no TLR5-stimulating activity (FIG. 5c). The lack of both flagellin genes had no effect on TLR2-stimulating activity (FIG. 5d). The observed TLR2-stimulating activity found in *S. typhimurium* supernatants most likely was due to bacterial lipoproteins (Underhill, et al. *Nature* 401, 811-5 (1999); Brightbill et al., *Science* 285, 732-6 (1999)). These results indicate that flagellin is the sole TLR5-stimulating activity present in *S. typhimurium* culture supernatant.

36

Thus, TLR5-stimulating activity was elicited by introducing the flagellin gene into a non-flagellated bacterium, and abrogated by deleting the flagellin genes from a flagellated bacterium.

EXAMPLE VI

Flagellin-Induced System IL-6 Production in Mice

This example shows that TLR signaling is required for the in vivo immune response to flagellin.

To determine if TLR signaling is required for the in vivo immune response to flagellin, wild type mice and mice lacking a component of the TLR5 signal transduction pathway, MyD88, were injected with flagellin and systemic IL-6 production was monitored. MyD88 is an adaptor protein required for TLR5-mediated signal transduction (Aderem A. and Ulevitch, R. J., *Nature* 406:782-787, (2000); Brightbill, H. D. and Modlin, R. L., *Immunology* 101:1-10, (2000)).

MyD88^{-/-} mice (129/SvJxC57B1/6 background) were backcrossed for three generations with C57B1/6 mice (Adachi, O. et al. *Immunity*, 9:143-150 (1998)). Mice from the F₃ generation (MyD88^{-/-}, n=5) and littermate controls (MyD88^{+/+}, n=5) were injected i.p. with 30 μ g purified flagellin in 0.5 cc of saline. Blood was sampled at 0, 1, 2, 4 and 8 hours after injection, and IL-6 levels were determined by ELISA (Duoset, R&D Systems, Minneapolis, Minn.).

FIG. 6 shows that flagellin induced systemic IL-6 within 2 h in wild type mice. By contrast, mice deficient in MyD88 were completely unresponsive to flagellin.

Therefore, flagellin stimulates TLR5-mediated responses in vivo.

Throughout this application various publications have been referenced. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.

Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 43

<210> SEQ ID NO 1

<211> LENGTH: 36

<212> TYPE: DNA

<213> ORGANISM: Salmonella typhimurium flagellin

<400> SEQUENCE: 1

ggtgcggtac agaaccgttt caactccgct attacc

36

<210> SEQ ID NO 2

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Salmonella typhimurium flagellin

<400> SEQUENCE: 2

Gly Ala Val Gln Asn Arg Phe Asn Ser Ala Ile Thr
1 5 10

<210> SEQ ID NO 3

<211> LENGTH: 12

-continued

<212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic construct

<400> SEQUENCE: 3

Gly Ala Val Ala Asn Arg Phe Asn Ser Ala Ile Thr
 1 5 10

<210> SEQ ID NO 4
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic construct

<400> SEQUENCE: 4

Gly Ala Val Gln Asn Ala Phe Asn Ser Ala Ile Thr
 1 5 10

<210> SEQ ID NO 5
 <211> LENGTH: 4286
 <212> TYPE: DNA
 <213> ORGANISM: Mus musculus
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (999)...(3575)

<400> SEQUENCE: 5

ttgaaatctc acagcccggt tggttgcagt gacccacttc gttgaacata ttcttcctaa	60
tcctagtact ttcaatttgc tctattccct ggtgtctatg catttaaadc gactatgggg	120
ccattcttcc ttgaaccacc acagaagaca ttagctctct gggatccttg ttaatttttt	180
ctcctcttac atagcaccta cgttgggaac atatgccaga cacatctgtg agacaccct	240
tgccgctgca gctcatggat ggatgctgag ttccccacg caccacactt cagcaggtgg	300
gtgtatttct gcttcacatt atactccac acggccatgc atgtcaggca tggagcaggc	360
tcataaccca cttaattaag gtgatcatat cagatccttt atcaagatgc atagagtgt	420
cagtgcctgt actatgatct cggatccttg ggagatgggc tagatagagt ctgggacaga	480
atacagcaga gaaaccgata tgtttattgt ccgatcatca gctaagcttc tgggagctag	540
gaatggggct ccttggatga acagaagtaa aaatgcctcg tctttatgac ttccaacttc	600
cctcagcagg tctggaatgg gtgaacaaac actgcctgcg tgggtgataa atagcctctt	660
tttgctgctt gtttgcgtct tttatgggtc tgggaggga cctagaacct agcacatgct	720
agacaagtcc tctagcactg agctatctcc ccagcttgga tgaaatatct gtaaagtact	780
ggtgcccgtg tgtaaaatat gcaccattaa gtgttcaaga agaaaagact gggcatttct	840
gttccaccaa gacaagaaga atctgccagc agaattgttg cgcagtcatt tgagcaaagg	900
ggtccaaggg acagtacct ccagtgtctg ggacccatgt gccgagcctc aggtgtgtat	960
gtggtgttgt ttttaattct ctcttttccc ataggatc atg gca tgt caa ctt gac	1016
Met Ala Cys Gln Leu Asp	
1 5	
ttg ctc ata ggt gtg atc ttc atg gcc agc ccc gtg ttg gta ata tct	1064
Leu Leu Ile Gly Val Ile Phe Met Ala Ser Pro Val Leu Val Ile Ser	
10 15 20	
ccc tgt tct tca gac ggc agg ata gcc ttt ttc cga ggc tgt aac ctc	1112
Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe Phe Arg Gly Cys Asn Leu	
25 30 35	
acc cag att ccc tgg atc ctc aat act acc act gag agg ctc ctg ctc	1160

-continued

Thr	Gln	Ile	Pro	Trp	Ile	Leu	Asn	Thr	Thr	Thr	Glu	Arg	Leu	Leu	Leu	
40						45					50					
agc	ttc	aac	tat	atc	agt	atg	gtg	gtt	gcc	aca	tca	ttt	cca	ctc	ctg	1208
Ser	Phe	Asn	Tyr	Ile	Ser	Met	Val	Val	Ala	Thr	Ser	Phe	Pro	Leu	Leu	
55					60				65					70		
gag	egg	ctc	cag	ttg	ctg	gag	ctg	ggg	acc	cag	tat	gct	aac	ttg	acc	1256
Glu	Arg	Leu	Gln	Leu	Leu	Glu	Leu	Gly	Thr	Gln	Tyr	Ala	Asn	Leu	Thr	
				75				80						85		
att	ggt	cca	ggg	gct	ttc	aga	aac	ctg	ccc	aat	ctt	agg	atc	ttg	gac	1304
Ile	Gly	Pro	Gly	Ala	Phe	Arg	Asn	Leu	Pro	Asn	Leu	Arg	Ile	Leu	Asp	
			90				95						100			
ttg	ggc	caa	agc	cag	atc	gaa	gtc	ttg	aat	cga	gat	gcc	ttt	caa	ggt	1352
Leu	Gly	Gln	Ser	Gln	Ile	Glu	Val	Leu	Asn	Arg	Asp	Ala	Phe	Gln	Gly	
		105					110					115				
ctg	ccc	cat	ctc	ttg	gaa	ctt	cgg	ctg	ttt	tcc	tgt	gga	ctc	tcc	agt	1400
Leu	Pro	His	Leu	Leu	Glu	Leu	Arg	Leu	Phe	Ser	Cys	Gly	Leu	Ser	Ser	
	120					125					130					
gct	gtg	tta	agt	gac	ggt	tac	ttc	aga	aat	cta	tat	tca	tta	gct	cgc	1448
Ala	Val	Leu	Ser	Asp	Gly	Tyr	Phe	Arg	Asn	Leu	Tyr	Ser	Leu	Ala	Arg	
135					140					145				150		
tta	gac	cta	tct	ggc	aac	cag	att	cac	agc	ctc	cgc	ctc	cat	tct	tca	1496
Leu	Asp	Leu	Ser	Gly	Asn	Gln	Ile	His	Ser	Leu	Arg	Leu	His	Ser	Ser	
				155				160						165		
ttc	egg	gaa	ctg	aat	tcc	tta	agc	gac	gta	aat	ttt	gct	ttc	aac	caa	1544
Phe	Arg	Glu	Leu	Asn	Ser	Leu	Ser	Asp	Val	Asn	Phe	Ala	Phe	Asn	Gln	
			170					175					180			
ata	ttc	act	ata	tgt	gaa	gat	gaa	ctc	gag	cct	ctg	cag	ggc	aaa	aca	1592
Ile	Phe	Thr	Ile	Cys	Glu	Asp	Glu	Leu	Glu	Pro	Leu	Gln	Gly	Lys	Thr	
		185					190					195				
ctg	tct	ttc	ttt	ggc	ctc	aaa	tta	act	aag	ctg	ttc	agc	aga	gtc	tct	1640
Leu	Ser	Phe	Phe	Gly	Leu	Lys	Leu	Thr	Lys	Leu	Phe	Ser	Arg	Val	Ser	
	200					205						210				
gtg	ggc	tgg	gag	aca	tgc	agg	aac	ccc	ttc	aga	ggc	gtg	agg	cta	gaa	1688
Val	Gly	Trp	Glu	Thr	Cys	Arg	Asn	Pro	Phe	Arg	Gly	Val	Arg	Leu	Glu	
215					220					225				230		
act	cta	gat	ctt	tct	gaa	aat	ggc	tgg	acg	gtg	gac	atc	aca	agg	aac	1736
Thr	Leu	Asp	Leu	Ser	Glu	Asn	Gly	Trp	Thr	Val	Asp	Ile	Thr	Arg	Asn	
				235				240						245		
ttc	agc	aac	atc	atc	cag	gga	agc	cag	att	tcc	tct	ttg	att	ctt	aaa	1784
Phe	Ser	Asn	Ile	Ile	Gln	Gly	Ser	Gln	Ile	Ser	Ser	Leu	Ile	Leu	Lys	
			250					255					260			
cac	cac	atc	atg	ggt	cct	ggc	ttt	ggc	ttc	cag	aac	atc	aga	gat	cct	1832
His	His	Ile	Met	Gly	Pro	Gly	Phe	Gly	Phe	Gln	Asn	Ile	Arg	Asp	Pro	
		265				270						275				
gac	cag	agc	aca	ttt	gcc	agc	ctg	gcc	aga	agt	tcg	gtg	ctg	caa	ctg	1880
Asp	Gln	Ser	Thr	Phe	Ala	Ser	Leu	Ala	Arg	Ser	Ser	Val	Leu	Gln	Leu	
		280				285					290					
gac	ctt	tcg	cac	ggc	ttt	atc	ttc	tcc	ttg	aat	cct	cga	ctg	ttt	ggg	1928
Asp	Leu	Ser	His	Gly	Phe	Ile	Phe	Ser	Leu	Asn	Pro	Arg	Leu	Phe	Gly	
	295				300					305				310		
aca	ctg	aag	gat	ttg	aag	atg	ctg	aac	ctt	gcc	ttc	aac	aag	ata	aac	1976
Thr	Leu	Lys	Asp	Leu	Lys	Met	Leu	Asn	Leu	Ala	Phe	Asn	Lys	Ile	Asn	
			315					320						325		
aag	att	gga	gag	aat	gcc	ttt	tat	ggg	ctt	gac	agc	ctc	cag	gtt	ctc	2024
Lys	Ile	Gly	Glu	Asn	Ala	Phe	Tyr	Gly	Leu	Asp	Ser	Leu	Gln	Val	Leu	
		330					335						340			
aat	cta	tcc	tat	aat	ctt	ttg	ggg	gaa	ctc	tat	aat	tcc	aac	ttc	tat	2072
Asn	Leu	Ser	Tyr	Asn	Leu	Leu	Gly	Glu	Leu	Tyr	Asn	Ser	Asn	Phe	Tyr	
		345				350						355				

-continued

ggg ctt cct aga gta gcc tac gtt gac ctt caa agg aac cac att ggg	2120
Gly Leu Pro Arg Val Ala Tyr Val Asp Leu Gln Arg Asn His Ile Gly	
360 365 370	
atc att caa gac caa aca ttc aga tta tta aaa acg tta caa acc tta	2168
Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu Lys Thr Leu Gln Thr Leu	
375 380 385 390	
gat ctc cgt gac aat gct ctt aag gcc att ggt ttt att cca agc ata	2216
Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile Gly Phe Ile Pro Ser Ile	
395 400 405	
cag atg gtc ctc ctg gga ggc aat aag ctg gtc cat ttg cca cac atc	2264
Gln Met Val Leu Leu Gly Gly Asn Lys Leu Val His Leu Pro His Ile	
410 415 420	
cac ttt act gcc aac ttc cta gag tta tct gaa aac agg cta gaa aac	2312
His Phe Thr Ala Asn Phe Leu Glu Leu Ser Glu Asn Arg Leu Glu Asn	
425 430 435	
ctg tcc gac ctc tac ttc ctc ctg cga gtc ccc cag ctc cag ttt ctc	2360
Leu Ser Asp Leu Tyr Phe Leu Leu Arg Val Pro Gln Leu Gln Phe Leu	
440 445 450	
atc ttg aat cag aat cgc ctt tcg tca tgc aag gca gcc cac act ccc	2408
Ile Leu Asn Gln Asn Arg Leu Ser Ser Cys Lys Ala Ala His Thr Pro	
455 460 465 470	
tcg gag aac cca agc tta gaa cag ctt ttc ctt aca gag aat atg ctg	2456
Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu Thr Glu Asn Met Leu	
475 480 485	
cag ctg gcc tgg gag acc ggc ctc tgt tgg gat gtt ttt caa ggc ctt	2504
Gln Leu Ala Trp Glu Thr Gly Leu Cys Trp Asp Val Phe Gln Gly Leu	
490 495 500	
tcc cgc ctc cag att ctt tac ctg agt aat aac tac ctt aat ttc ctt	2552
Ser Arg Leu Gln Ile Leu Tyr Leu Ser Asn Asn Tyr Leu Asn Phe Leu	
505 510 515	
cca cct ggg ata ttt aac gac ctg gtt gca tta cgg atg ctt agt ctt	2600
Pro Pro Gly Ile Phe Asn Asp Leu Val Ala Leu Arg Met Leu Ser Leu	
520 525 530	
agt gct aac aag ctg acc gtg ctc tct ccg ggc agt tta cct gct aat	2648
Ser Ala Asn Lys Leu Thr Val Leu Ser Pro Gly Ser Leu Pro Ala Asn	
535 540 545 550	
tta gag att ctc gac ata tct aga aat cag ctt ttg tgt cct gac cct	2696
Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu Leu Cys Pro Asp Pro	
555 560 565	
gct ttg ttt tct tcg ctt cgt gtt ttg gac ata act cat aac gag ttc	2744
Ala Leu Phe Ser Ser Leu Arg Val Leu Asp Ile Thr His Asn Glu Phe	
570 575 580	
gtc tgc aac tgt gaa ctt agc act ttt atc tcc tgg ctc aac caa acc	2792
Val Cys Asn Cys Glu Leu Ser Thr Phe Ile Ser Trp Leu Asn Gln Thr	
585 590 595	
aac gtc acc ctg ttc ggc tct cct gca gac gtg tat tgc atg tac cct	2840
Asn Val Thr Leu Phe Gly Ser Pro Ala Asp Val Tyr Cys Met Tyr Pro	
600 605 610	
aac tca ctg cta ggg ggc tcc ctc tac aac ata tcc acc gaa gac tgc	2888
Asn Ser Leu Leu Gly Gly Ser Leu Tyr Asn Ile Ser Thr Glu Asp Cys	
615 620 625 630	
gat gaa gag gaa gcc atg cgg tcc cta aag ttt tcc ctt ttc atc ctg	2936
Asp Glu Glu Glu Ala Met Arg Ser Leu Lys Phe Ser Leu Phe Ile Leu	
635 640 645	
tgc acg gtc act ttg act cta ttc ctc gtc atc acc ctt gta gtc ata	2984
Cys Thr Val Thr Leu Thr Leu Phe Leu Val Ile Thr Leu Val Val Ile	
650 655 660	
aag ttc cgg gga atc tgt ttc ctg tgc tat aag acc atc cag aag ctg	3032
Lys Phe Arg Gly Ile Cys Phe Leu Cys Tyr Lys Thr Ile Gln Lys Leu	
665 670 675	

-continued

gtg ttc aag gac aag gtc tgg agt ttg gaa cct ggt gca tat aga tat	3080
Val Phe Lys Asp Lys Val Trp Ser Leu Glu Pro Gly Ala Tyr Arg Tyr	
680 685 690	
gat gcc tac ttc tgc ttc agc agc aaa gac ttt gaa tgg gca cag aat	3128
Asp Ala Tyr Phe Cys Phe Ser Ser Lys Asp Phe Glu Trp Ala Gln Asn	
695 700 705 710	
gct ttg ctc aaa cac ctg gat gct cac tac agt tcc cga aac agg ctc	3176
Ala Leu Leu Lys His Leu Asp Ala His Tyr Ser Ser Arg Asn Arg Leu	
715 720 725	
agg cta tgc ttt gaa gaa aga gac ttc att ccg ggg gaa aac cat atc	3224
Arg Leu Cys Phe Glu Glu Arg Asp Phe Ile Pro Gly Glu Asn His Ile	
730 735 740	
tcc aac atc cag gcg gct gtc tgg ggc agc agg aag acg gtg tgt cta	3272
Ser Asn Ile Gln Ala Ala Val Trp Gly Ser Arg Lys Thr Val Cys Leu	
745 750 755	
gtg agc aga cac ttc ctg aag gat ggt tgg tgc ctg gag gcc ttc agg	3320
Val Ser Arg His Phe Leu Lys Asp Gly Trp Cys Leu Glu Ala Phe Arg	
760 765 770	
tat gcc cag agc cgg agt ctg tct gac ctc aag agc att ctc atc gtg	3368
Tyr Ala Gln Ser Arg Ser Leu Ser Asp Leu Lys Ser Ile Leu Ile Val	
775 780 785 790	
gtg gtg gtg gga tgc ctg tcc cag tat cag ctg atg aga cat gag acc	3416
Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu Met Arg His Glu Thr	
795 800 805	
atc aga ggg ttt ctg caa aag caa cag tac ttg agg tgg cct gaa gac	3464
Ile Arg Gly Phe Leu Gln Lys Gln Gln Tyr Leu Arg Trp Pro Glu Asp	
810 815 820	
ctc cag gat gtt ggc tgg ttt ctc gat aaa ctc tcc gga tgc att cta	3512
Leu Gln Asp Val Gly Trp Phe Leu Asp Lys Leu Ser Gly Cys Ile Leu	
825 830 835	
aag gaa gaa aaa gga aag aaa aga agc agt tcc atc cag ttg cga acc	3560
Lys Glu Glu Lys Gly Lys Lys Arg Ser Ser Ser Ile Gln Leu Arg Thr	
840 845 850	
ata gca acc att tcc tagcaggagc gcctcctagc agaagtgcaa gcacgtaga	3615
Ile Ala Thr Ile Ser	
855	
taactctcca cgctttatcc gcacagccgc tgggggtctc tccctggagt catttttctg	3675
acaatgaaaa caacaccaat ctcttgattt ttcattgtcaa caggagcctt tgtcttcact	3735
gtttttccaaa tggaaagtaa gaggtccaga aagctgcctc taagggtctc cacctgccat	3795
tgatgtcctt tcaggcccaa tgacatgggt tccctccatc ctattgcgta ctgtctgcta	3855
cccaggtggc aagagcacct tgggagaagt tacaggcagc ttcattgcttt ctgtgctgtt	3915
cagttcaaaa gcagggtgct tgagaatcct gaattcaagc actctgtaga acatggacag	3975
acaagatggg tcctttctctg gccataggca tgagggccag ttgctgagga ctgctctcac	4035
tacacctaag tgcacaagtg ataagaagtt ggacagatag acagatagca gcagtcccat	4095
tgctgtagcc agaatgcact tatttcctgt tctgacctg caggcccagc ttttggggac	4155
cacagccatg ttctgcacgg gacctctcaa cctggcattc atgccctttc acgacttagc	4215
accggcctgc ccttctttct tccccacaac tatacaagag ctgttgcaac cactgaaaaa	4275
aaaaaaaaa a	4286

<210> SEQ ID NO 6

<211> LENGTH: 859

<212> TYPE: PRT

<213> ORGANISM: Mus musculus

-continued

<400> SEQUENCE: 6

```

Met Ala Cys Gln Leu Asp Leu Leu Ile Gly Val Ile Phe Met Ala Ser
 1           5           10           15

Pro Val Leu Val Ile Ser Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe
      20           25           30

Phe Arg Gly Cys Asn Leu Thr Gln Ile Pro Trp Ile Leu Asn Thr Thr
 35           40           45

Thr Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Ser Met Val Val Ala
 50           55           60

Thr Ser Phe Pro Leu Leu Glu Arg Leu Gln Leu Leu Glu Leu Gly Thr
 65           70           75           80

Gln Tyr Ala Asn Leu Thr Ile Gly Pro Gly Ala Phe Arg Asn Leu Pro
      85           90           95

Asn Leu Arg Ile Leu Asp Leu Gly Gln Ser Gln Ile Glu Val Leu Asn
 100          105          110

Arg Asp Ala Phe Gln Gly Leu Pro His Leu Leu Glu Leu Arg Leu Phe
 115          120          125

Ser Cys Gly Leu Ser Ser Ala Val Leu Ser Asp Gly Tyr Phe Arg Asn
 130          135          140

Leu Tyr Ser Leu Ala Arg Leu Asp Leu Ser Gly Asn Gln Ile His Ser
 145          150          155          160

Leu Arg Leu His Ser Ser Phe Arg Glu Leu Asn Ser Leu Ser Asp Val
 165          170          175

Asn Phe Ala Phe Asn Gln Ile Phe Thr Ile Cys Glu Asp Glu Leu Glu
 180          185          190

Pro Leu Gln Gly Lys Thr Leu Ser Phe Phe Gly Leu Lys Leu Thr Lys
 195          200          205

Leu Phe Ser Arg Val Ser Val Gly Trp Glu Thr Cys Arg Asn Pro Phe
 210          215          220

Arg Gly Val Arg Leu Glu Thr Leu Asp Leu Ser Glu Asn Gly Trp Thr
 225          230          235          240

Val Asp Ile Thr Arg Asn Phe Ser Asn Ile Ile Gln Gly Ser Gln Ile
 245          250          255

Ser Ser Leu Ile Leu Lys His His Ile Met Gly Pro Gly Phe Gly Phe
 260          265          270

Gln Asn Ile Arg Asp Pro Asp Gln Ser Thr Phe Ala Ser Leu Ala Arg
 275          280          285

Ser Ser Val Leu Gln Leu Asp Leu Ser His Gly Phe Ile Phe Ser Leu
 290          295          300

Asn Pro Arg Leu Phe Gly Thr Leu Lys Asp Leu Lys Met Leu Asn Leu
 305          310          315          320

Ala Phe Asn Lys Ile Asn Lys Ile Gly Glu Asn Ala Phe Tyr Gly Leu
 325          330          335

Asp Ser Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu
 340          345          350

Tyr Asn Ser Asn Phe Tyr Gly Leu Pro Arg Val Ala Tyr Val Asp Leu
 355          360          365

Gln Arg Asn His Ile Gly Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu
 370          375          380

Lys Thr Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile
 385          390          395          400

Gly Phe Ile Pro Ser Ile Gln Met Val Leu Leu Gly Gly Asn Lys Leu
 405          410          415

```

Val	His	Leu	Pro	His	Ile	His	Phe	Thr	Ala	Asn	Phe	Leu	Glu	Leu	Ser
			420				425						430		
Glu	Asn	Arg	Leu	Glu	Asn	Leu	Ser	Asp	Leu	Tyr	Phe	Leu	Leu	Arg	Val
			435				440						445		
Pro	Gln	Leu	Gln	Phe	Leu	Ile	Leu	Asn	Gln	Asn	Arg	Leu	Ser	Ser	Cys
			450				455						460		
Lys	Ala	Ala	His	Thr	Pro	Ser	Glu	Asn	Pro	Ser	Leu	Glu	Gln	Leu	Phe
			465				470						480		
Leu	Thr	Glu	Asn	Met	Leu	Gln	Leu	Ala	Trp	Glu	Thr	Gly	Leu	Cys	Trp
			485				490						495		
Asp	Val	Phe	Gln	Gly	Leu	Ser	Arg	Leu	Gln	Ile	Leu	Tyr	Leu	Ser	Asn
			500				505						510		
Asn	Tyr	Leu	Asn	Phe	Leu	Pro	Pro	Gly	Ile	Phe	Asn	Asp	Leu	Val	Ala
			515				520						525		
Leu	Arg	Met	Leu	Ser	Leu	Ser	Ala	Asn	Lys	Leu	Thr	Val	Leu	Ser	Pro
			530				535						540		
Gly	Ser	Leu	Pro	Ala	Asn	Leu	Glu	Ile	Leu	Asp	Ile	Ser	Arg	Asn	Gln
			545				550						560		
Leu	Leu	Cys	Pro	Asp	Pro	Ala	Leu	Phe	Ser	Ser	Leu	Arg	Val	Leu	Asp
			565				570						575		
Ile	Thr	His	Asn	Glu	Phe	Val	Cys	Asn	Cys	Glu	Leu	Ser	Thr	Phe	Ile
			580				585						590		
Ser	Trp	Leu	Asn	Gln	Thr	Asn	Val	Thr	Leu	Phe	Gly	Ser	Pro	Ala	Asp
			595				600						605		
Val	Tyr	Cys	Met	Tyr	Pro	Asn	Ser	Leu	Leu	Gly	Gly	Ser	Leu	Tyr	Asn
			610				615						620		
Ile	Ser	Thr	Glu	Asp	Cys	Asp	Glu	Glu	Glu	Ala	Met	Arg	Ser	Leu	Lys
			625				630						640		
Phe	Ser	Leu	Phe	Ile	Leu	Cys	Thr	Val	Thr	Leu	Thr	Leu	Phe	Leu	Val
			645				650						655		
Ile	Thr	Leu	Val	Val	Ile	Lys	Phe	Arg	Gly	Ile	Cys	Phe	Leu	Cys	Tyr
			660				665						670		
Lys	Thr	Ile	Gln	Lys	Leu	Val	Phe	Lys	Asp	Lys	Val	Trp	Ser	Leu	Glu
			675				680						685		
Pro	Gly	Ala	Tyr	Arg	Tyr	Asp	Ala	Tyr	Phe	Cys	Phe	Ser	Ser	Lys	Asp
			690				695						700		
Phe	Glu	Trp	Ala	Gln	Asn	Ala	Leu	Leu	Lys	His	Leu	Asp	Ala	His	Tyr
			705				710						720		
Ser	Ser	Arg	Asn	Arg	Leu	Arg	Leu	Cys	Phe	Glu	Glu	Arg	Asp	Phe	Ile
			725				730						735		
Pro	Gly	Glu	Asn	His	Ile	Ser	Asn	Ile	Gln	Ala	Ala	Val	Trp	Gly	Ser
			740				745						750		
Arg	Lys	Thr	Val	Cys	Leu	Val	Ser	Arg	His	Phe	Leu	Lys	Asp	Gly	Trp
			755				760						765		
Cys	Leu	Glu	Ala	Phe	Arg	Tyr	Ala	Gln	Ser	Arg	Ser	Leu	Ser	Asp	Leu
			770				775						780		
Lys	Ser	Ile	Leu	Ile	Val	Val	Val	Val	Gly	Ser	Leu	Ser	Gln	Tyr	Gln
			785				790						800		
Leu	Met	Arg	His	Glu	Thr	Ile	Arg	Gly	Phe	Leu	Gln	Lys	Gln	Gln	Tyr
			805				810						815		
Leu	Arg	Trp	Pro	Glu	Asp	Leu	Gln	Asp	Val	Gly	Trp	Phe			

-continued

Leu Ser Gly Cys Ile Leu Lys Glu Glu Lys Gly Lys Lys Arg Ser Ser
 835 840 845

Ser Ile Gln Leu Arg Thr Ile Ala Thr Ile Ser
 850 855

<210> SEQ ID NO 7
 <211> LENGTH: 3431
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (704)...(3277)

<400> SEQUENCE: 7

```

ggcttatagg gctcgagcgg ccgcccgggc aggtatagaa ttcagcggcc gctgaattct      60
aggggttttca ggagcccagag cgagggcgcc gcttttgctg ccgggaggag ccaaccgtgg      120
cgcaggcggc gcggggaggc gtcccagagt ctactctgc cgcccaggct ggactgcagt      180
gacacaatct cggctgactg caaccactgc ctccagggtt caagcgattc tcttgccctca      240
gcctcccaag tagctgggat tacagattga tgttcattgt cctggcacta ctacaagatt      300
catactcctg atgctactga caacgtggct tctccacagt caccaaacca gggatgctat      360
actggacttc cctactctca tctgctccag cccctgacc ttatagtgc ccagctttcc      420
tggcaattga ctttgcccat caatacacag gatttagcat ccaggaaga tgcggagcc      480
tcagatgtta attttctaata tgagaatgtt ggcgctgtcc gaacctggag acagaaaaac      540
aaaaagtctt ttctcctgat tcacaaaaaa ataaaatact gactaccatc actgtgatga      600
gattcctata gtctcaggaa ctgaagtctt taaacaacca gggaccctct gccctagaa      660
taagaacata ctagaagtcc cttctgctag gacaacgagg atc atg gga gac cac      715
                                   Met Gly Asp His
                                   1

ctg gac ctt ctc cta gga gtg gtg ctc atg gcc ggt cct gtg ttt gga      763
Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly Pro Val Phe Gly
  5          10          15          20

att cct tcc tgc tcc ttt gat ggc cga ata gcc ttt tat cgt ttc tgc      811
Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe Tyr Arg Phe Cys
          25          30          35

aac ctc acc cag gtc ccc cag gtc ctc aac acc act gag agg ctc ctg      859
Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr Glu Arg Leu Leu
          40          45          50

ctg agc ttc aac tat atc agg aca gtc act gct tca tcc ttc ccc ttt      907
Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser Ser Phe Pro Phe
          55          60          65

ctg gaa cag ctg cag ctg ctg gag ctc ggg agc cag tat acc ccc ttg      955
Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln Tyr Thr Pro Leu
          70          75          80

act att gac aag gag gcc ttc aga aac ctg ccc aac ctt aga atc ttg      1003
Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn Leu Arg Ile Leu
          85          90          95          100

gac ctg gga agt agt aag ata tac ttc ttg cat cca gat gct ttt cag      1051
Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro Asp Ala Phe Gln
          105          110          115

gga ctg ttc cat ctg ttt gaa ctt aga ctg tat ttc tgt ggt ctc tct      1099
Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe Cys Gly Leu Ser
          120          125          130

gat gct gta ttg aaa gat ggt tat ttc aga aat tta aag gct tta act      1147
Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu Lys Ala Leu Thr
          135          140          145
  
```

-continued

cgc ttg gat cta tcc aaa aat cag att cgt agc ctt tac ctt cat cct	1195
Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu Tyr Leu His Pro	
150 155 160	
tca ttt ggg aag ttg aat tcc tta aag tcc ata gat ttt tcc tcc aac	1243
Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp Phe Ser Ser Asn	
165 170 175 180	
caa ata ttc ctt gta tgt gaa cat gag ctc gag ccc cta caa ggg aaa	1291
Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro Leu Gln Gly Lys	
185 190 195	
acg ctc tcc ttt ttt agc ctc gca gct aat agc ttg tat agc aga gtc	1339
Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu Tyr Ser Arg Val	
200 205 210	
tca gtg gac tgg gga aaa tgt atg aac cca ttc aga aac atg gtg ctg	1387
Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg Asn Met Val Leu	
215 220 225	
gag ata gta gat gtt tct gga aat ggc tgg aca gtg gac atc aca gga	1435
Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val Asp Ile Thr Gly	
230 235 240	
aac ttt agc aat gcc atc agc aaa agc cag gcc ttc tct ttg att ctt	1483
Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe Ser Leu Ile Leu	
245 250 255 260	
gcc cac cac atc atg ggt gcc ggg ttt ggc ttc cat aac atc aaa gat	1531
Ala His His Ile Met Gly Ala Gly Phe Gly Phe His Asn Ile Lys Asp	
265 270 275	
cct gac cag aac aca ttt gct ggc ctg gcc aga agt tca gtg aga cac	1579
Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser Ser Val Arg His	
280 285 290	
ctg gac ctt tca cat ggg ttt gtc ttc tcc ctg aac tca cga gtc ttt	1627
Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn Ser Arg Val Phe	
295 300 305	
gag aca ctc aag gat ttg aag gtt ctg aac ctt gcc tac aac aag ata	1675
Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala Tyr Asn Lys Ile	
310 315 320	
aat aag att gca gat gaa gca ttt tac gga ctt gac aac ctc caa gtt	1723
Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp Asn Leu Gln Val	
325 330 335 340	
ctc aat ttg tca tat aac ctt ctg ggg gaa ctt tgc agt tcg aat ttc	1771
Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys Ser Ser Asn Phe	
345 350 355	
tat gga cta cct aag gta gcc tac att gat ttg caa aag aat cac att	1819
Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln Lys Asn His Ile	
360 365 370	
gca ata att caa gac caa aca ttc aaa ttc ctg gaa aaa tta cag acc	1867
Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu Lys Leu Gln Thr	
375 380 385	
ttg gat ctc cga gac aat gct ctt aca acc att cat ttt att cca agc	1915
Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His Phe Ile Pro Ser	
390 395 400	
ata ccc gat atc ttc ttg agt ggc aat aaa cta gtg act ttg cca aag	1963
Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val Thr Leu Pro Lys	
405 410 415 420	
atc aac ctt aca gcg aac ctc atc cac tta tca gaa aac agg cta gaa	2011
Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu Asn Arg Leu Glu	
425 430 435	
aat cta gat att ctc tac ttt ctc cta cgg gta cct cat ctc cag att	2059
Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro His Leu Gln Ile	
440 445 450	
ctc att tta aat caa aat cgc ttc tcc tcc tgt agt gga gat caa acc	2107
Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser Gly Asp Gln Thr	
455 460 465	

-continued

cct tca gag aat ccc agc tta gaa cag ctt ttc ctt gga gaa aat atg Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu Gly Glu Asn Met 470 475 480	2155
ttg caa ctt gcc tgg gaa act gag ctc tgt tgg gat gtt ttt gag gga Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp Val Phe Glu Gly 485 490 495 500	2203
ctt tct cat ctt caa gtt ctg tat ttg aat cat aac tat ctt aat tcc Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn Tyr Leu Asn Ser 505 510 515	2251
ctt cca cca gga gta ttt agc cat ctg act gca tta agg gga cta agc Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu Arg Gly Leu Ser 520 525 530	2299
ctc aac tcc aac agg ctg aca gtt ctt tct cac aat gat tta cct gct Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn Asp Leu Pro Ala 535 540 545	2347
aat tta gag atc ctg gac ata tcc agg aac cag ctc cta gct cct aat Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu Leu Ala Pro Asn 550 555 560	2395
cct gat gta ttt gta tca ctt agt gtc ttg gat ata act cat aac aag Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile Thr His Asn Lys 565 570 575 580	2443
ttc att tgt gaa tgt gaa ctt agc act ttt atc aat tgg ctt aat cac Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn Trp Leu Asn His 585 590 595	2491
acc aat gtc act ata gct ggg cct cct gca gac ata tat tgt gtg tac Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile Tyr Cys Val Tyr 600 605 610	2539
cct gac tgc ctc tct ggg gtt tcc ctc ttc tct ctt tcc acg gaa ggt Pro Asp Ser Leu Ser Gly Val Ser Leu Phe Ser Leu Ser Thr Glu Gly 615 620 625	2587
tgt gat gaa gag gaa gtc tta aag tcc cta aag ttc tcc ctt ttc att Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe Ser Leu Phe Ile 630 635 640	2635
gta tgc act gtc act ctg act ctg ttc ctc atg acc atc ctc aca gtc Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr Ile Leu Thr Val 645 650 655 660	2683
aca aag ttc cgg ggc ttc tgt ttt atc tgt tat aag aca gcc cag aga Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys Thr Ala Gln Arg 665 670 675	2731
ctg gtg ttc aag gac cat ccc cag ggc aca gaa cct gat atg tac aaa Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro Asp Met Tyr Lys 680 685 690	2779
tat gat gcc tat ttg tgc ttc agc agc aaa gac ttc aca tgg gtg cag Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe Thr Trp Val Gln 695 700 705	2827
aat gct ttg ctc aaa cac ctg gac act caa tac agt gac caa aac aga Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser Asp Gln Asn Arg 710 715 720	2875
ttc aac ctg tgc ttt gaa gaa aga gac ttt gtc cca gga gaa aac cgc Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro Gly Glu Asn Arg 725 730 735 740	2923
att gcc aat atc cag gat gcc atc tgg aac agt aga aag atc gtt tgt Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg Lys Ile Val Cys 745 750 755	2971
ctt gtg agc aga cac ttc ctt aga gat ggc tgg tgc ctt gaa gcc ttc Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys Leu Glu Ala Phe 760 765 770	3019
agt tat gcc cag ggc agg tgc tta tct gac ctt aac agt gct ctc atc Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn Ser Ala Leu Ile	3067

-continued

775	780	785	
atg gtg gtg gtt ggg tcc ttg tcc cag tac cag ttg atg aaa cat caa			3115
Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu Met Lys His Gln			
790	795	800	
tcc atc aga ggc ttt gta cag aaa cag cag tat ttg agg tgg cct gag			3163
Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu Arg Trp Pro Glu			
805	810	815	820
gat ctc cag gat gtt ggc tgg ttt ctt cat aaa ctc tct caa cag ata			3211
Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu Ser Gln Gln Ile			
825	830	835	
cta aag aaa gaa aaa gaa aag aag aaa gac aat aac att ccg ttg caa			3259
Leu Lys Lys Glu Lys Glu Lys Lys Asp Asn Asn Ile Pro Leu Gln			
840	845	850	
act gta gca acc atc tcc taatcaaagg agcaatttcc aacttatctc			3307
Thr Val Ala Thr Ile Ser			
855			
aagccacaaa taactcttca ctttgtatgt gcaccaagtt atcattttgg ggctctctct			3367
ggagggttttt tttttctttt tgctactatg aaaacaacat aaatctctca attttcgtat			3427
caaaa			3431
<210> SEQ ID NO 8			
<211> LENGTH: 858			
<212> TYPE: PRT			
<213> ORGANISM: Homo sapiens			
<400> SEQUENCE: 8			
Met Gly Asp His Leu Asp Leu Leu Leu Gly Val Val Leu Met Ala Gly			
1	5	10	15
Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe			
20	25	30	
Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr			
35	40	45	
Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser			
50	55	60	
Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln			
65	70	75	80
Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn			
85	90	95	
Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro			
100	105	110	
Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe			
115	120	125	
Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu			
130	135	140	
Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu			
145	150	155	160
Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp			
165	170	175	
Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro			
180	185	190	
Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu			
195	200	205	
Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg			
210	215	220	
Asn Met Val Leu Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val			

-continued

225	230	235	240
Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe	245	250	255
Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His	260	265	270
Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser	275	280	285
Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn	290	295	300
Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala	305	310	315
Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp	325	330	335
Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys	340	345	350
Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln	355	360	365
Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu	370	375	380
Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His	385	390	395
Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val	405	410	415
Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu	420	425	430
Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro	435	440	445
His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser	450	455	460
Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu	465	470	475
Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp	485	490	495
Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn	500	505	510
Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu	515	520	525
Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn	530	535	540
Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu	545	550	555
Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile	565	570	575
Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn	580	585	590
Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile	595	600	605
Tyr Cys Val Tyr Pro Asp Ser Leu Ser Gly Val Ser Leu Phe Ser Leu	610	615	620
Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe	625	630	635
Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr	645	650	655

-continued

```

Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys
      660                      665                      670
Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro
      675                      680                      685
Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe
      690                      695                      700
Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser
      705                      710                      715                      720
Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro
      725                      730                      735
Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg
      740                      745                      750
Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys
      755                      760                      765
Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn
      770                      775                      780
Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu
      785                      790                      795                      800
Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu
      805                      810                      815
Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu
      820                      825                      830
Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn
      835                      840                      845
Ile Pro Leu Gln Thr Val Ala Thr Ile Ser
      850                      855

```

```

<210> SEQ ID NO 9
<211> LENGTH: 1839
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)...(1839)

```

```

<400> SEQUENCE: 9

```

```

atg tgc cga gcc atc tct ctt agg cgc ttg ctg ctg ctg ctg cag      48
Met Cys Arg Ala Ile Ser Leu Arg Arg Leu Leu Leu Leu Leu Gln
  1                      5                      10                      15

ctg tca caa ctc cta gct gtc act caa ggg aag acg ctg gtg ctg ggg      96
Leu Ser Gln Leu Leu Ala Val Thr Gln Gly Lys Thr Leu Val Leu Gly
  20                      25                      30

aag gaa ggg gaa tca gca gaa ctg ccc tgc gag agt tcc cag aag aag     144
Lys Glu Gly Glu Ser Ala Glu Leu Pro Cys Glu Ser Ser Gln Lys Lys
  35                      40                      45

atc aca gtc ttc acc tgg aag ttc tct gac cag agg aag att ctg ggg     192
Ile Thr Val Phe Thr Trp Lys Phe Ser Asp Gln Arg Lys Ile Leu Gly
  50                      55                      60

cag cat ggc aaa ggt gta tta att aga gga ggt tcg cct tcg cag ttt     240
Gln His Gly Lys Gly Val Leu Ile Arg Gly Gly Ser Pro Ser Gln Phe
  65                      70                      75                      80

gat cgt ttt gat tcc aaa aaa ggg gca tgg gag aaa gga tcg ttt cct     288
Asp Arg Phe Asp Ser Lys Lys Gly Ala Trp Glu Lys Gly Ser Phe Pro
  85                      90                      95

ctc atc atc aat aaa ctt aag atg gaa gac tct cag act tat atc tgt     336
Leu Ile Ile Asn Lys Leu Lys Met Glu Asp Ser Gln Thr Tyr Ile Cys
  100                      105                      110

```

-continued

gag ctg gag aac agg aaa gag gag gtg gag ttg tgg gtg ttc aaa gtg Glu Leu Glu Asn Arg Lys Glu Glu Val Glu Leu Trp Val Phe Lys Val 115 120 125	384
acc ttc agt ccg ggt acc agc ctg ttg caa ggg cag agc ctg acc ctg Thr Phe Ser Pro Gly Thr Ser Leu Leu Gln Gly Gln Ser Leu Thr Leu 130 135 140	432
acc ttg gat agc aac tct aag gtc tct aac ccc ttg aca gag tgc aaa Thr Leu Asp Ser Asn Ser Lys Val Ser Asn Pro Leu Thr Glu Cys Lys 145 150 155 160	480
cac aaa aag ggt aaa gtt gtc agt ggt tcc aaa gtt ctc tcc atg tcc His Lys Lys Gly Lys Val Val Ser Gly Ser Lys Val Leu Ser Met Ser 165 170 175	528
aac cta agg gtt cag gac agc gac ttc tgg aac tgc acc gtg acc ctg Asn Leu Arg Val Gln Asp Ser Asp Phe Trp Asn Cys Thr Val Thr Leu 180 185 190	576
gac cag aaa aag aac tgg ttc ggc atg aca ctc tca gtg ctg ggt ttt Asp Gln Lys Lys Asn Trp Phe Gly Met Thr Leu Ser Val Leu Gly Phe 195 200 205	624
cag agc aca gct atc acg gcc tat aag agt gag gga gag tca gcg gag Gln Ser Thr Ala Ile Thr Ala Tyr Lys Ser Glu Gly Glu Ser Ala Glu 210 215 220	672
ttc tcc ttc cca ctc aac ttt gca gag gaa aac ggg tgg gga gag ctg Phe Ser Phe Pro Leu Asn Phe Ala Glu Glu Asn Gly Trp Gly Glu Leu 225 230 235 240	720
atg tgg aag gca gag aag gat tct ttc ttc cag ccc tgg atc tcc ttc Met Trp Lys Ala Glu Lys Asp Ser Phe Phe Gln Pro Trp Ile Ser Phe 245 250 255	768
tcc ata aag aac aaa gag gtg tcc gta caa aag tcc acc aaa gac ctc Ser Ile Lys Asn Lys Glu Val Ser Val Gln Lys Ser Thr Lys Asp Leu 260 265 270	816
aag ctc cag ctg aag gaa acg ctc cca ctc acc ctc aag ata ccc cag Lys Leu Gln Leu Lys Glu Thr Leu Pro Leu Thr Leu Lys Ile Pro Gln 275 280 285	864
gtc tcg ctt cag ttt gct ggt tct ggc aac ctg act ctg act ctg gac Val Ser Leu Gln Phe Ala Gly Ser Gly Asn Leu Thr Leu Thr Leu Asp 290 295 300	912
aaa ggg aca ctg cat cag gaa gtg aac ctg gtg gtg atg aaa gtg gct Lys Gly Thr Leu His Gln Glu Val Asn Leu Val Val Met Lys Val Ala 305 310 315 320	960
cag ctc aac aat act ttg acc tgt gag gtg atg gga cct acc tct ccc Gln Leu Asn Asn Thr Leu Thr Cys Glu Val Met Gly Pro Thr Ser Pro 325 330 335	1008
aag atg aga ctg acc ctg aag cag gag aac cag gag gcc agg gtc tct Lys Met Arg Leu Thr Leu Lys Gln Glu Asn Gln Glu Ala Arg Val Ser 340 345 350	1056
gag gag cag aaa gta gtt caa gtg gtg gcc cct gag aca ggg ctg tgg Glu Glu Gln Lys Val Val Gln Val Val Ala Pro Glu Thr Gly Leu Trp 355 360 365	1104
cag tgt cta ctg agt gaa ggt gat aag gtc aag atg gac tcc agg atc Gln Cys Leu Leu Ser Glu Gly Asp Lys Val Lys Met Asp Ser Arg Ile 370 375 380	1152
cag gtt tta tcc aga ggg gtg tac cag ttc tcc ctt ttc att gta tgc Gln Val Leu Ser Arg Gly Val Tyr Gln Phe Ser Leu Phe Ile Val Cys 385 390 395 400	1200
act gtc act ctg act ctg ttc ctc atg acc atc ctc aca gtc aca aag Thr Val Thr Leu Thr Leu Phe Leu Met Thr Ile Leu Thr Val Thr Lys 405 410 415	1248
ttc cgg ggc ttc tgt ttt atc tgt tat aag aca gcc cag aga ctg gtg Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys Thr Ala Gln Arg Leu Val 420 425 430	1296

-continued

```

ttc aag gac cat ccc cag ggc aca gaa cct gat atg tac aaa tat gat      1344
Phe Lys Asp His Pro Gln Gly Thr Glu Pro Asp Met Tyr Lys Tyr Asp
    435                      440                      445

gcc tat ttg tgc ttc agc agc aaa gac ttc aca tgg gtg cag aat gct      1392
Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe Thr Trp Val Gln Asn Ala
    450                      455                      460

ttg ctc aaa cac ctg gac act caa tac agt gac caa aac aga ttc aac      1440
Leu Leu Lys His Leu Asp Thr Gln Tyr Ser Asp Gln Asn Arg Phe Asn
    465                      470                      475                      480

ctg tgc ttt gaa gaa aga gac ttt gtc cca gga gaa aac cgc att gcc      1488
Leu Cys Phe Glu Glu Arg Asp Phe Val Pro Gly Glu Asn Arg Ile Ala
    485                      490                      495

aat atc cag gat gcc atc tgg aac agt aga aag atc gtt tgt ctt gtg      1536
Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg Lys Ile Val Cys Leu Val
    500                      505                      510

agc aga cac ttc ctt aga gat ggc tgg tgc ctt gaa gcc ttc agt tat      1584
Ser Arg His Phe Leu Arg Asp Gly Trp Cys Leu Glu Ala Phe Ser Tyr
    515                      520                      525

gcc cag ggc agg tgc tta tct gac ctt aac agt gct ctc atc atg gtg      1632
Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn Ser Ala Leu Ile Met Val
    530                      535                      540

gtg gtt ggg tcc ttg tcc cag tac cag ttg atg aaa cat caa tcc atc      1680
Val Val Gly Ser Leu Ser Gln Tyr Gln Leu Met Lys His Gln Ser Ile
    545                      550                      555                      560

aga ggc ttt gta cag aaa cag cag tat ttg agg tgg cct gag gat ctc      1728
Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu Arg Trp Pro Glu Asp Leu
    565                      570                      575

cag gat gtt ggc tgg ttt ctt cat aaa ctc tct caa cag ata cta aag      1776
Gln Asp Val Gly Trp Phe Leu His Lys Leu Ser Gln Gln Ile Leu Lys
    580                      585                      590

aaa gaa aaa gaa aag aag aaa gac aat aac att ccg ttg caa act gta      1824
Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn Ile Pro Leu Gln Thr Val
    595                      600                      605

gca acc atc tcc taa
Ala Thr Ile Ser *
    610

```

```

<210> SEQ ID NO 10
<211> LENGTH: 612
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

```

```

<400> SEQUENCE: 10

```

```

Met Cys Arg Ala Ile Ser Leu Arg Arg Leu Leu Leu Leu Leu Gln
 1                      5                      10                      15

Leu Ser Gln Leu Leu Ala Val Thr Gln Gly Lys Thr Leu Val Leu Gly
20                      25                      30

Lys Glu Gly Glu Ser Ala Glu Leu Pro Cys Glu Ser Ser Gln Lys Lys
35                      40                      45

Ile Thr Val Phe Thr Trp Lys Phe Ser Asp Gln Arg Lys Ile Leu Gly
50                      55                      60

Gln His Gly Lys Gly Val Leu Ile Arg Gly Gly Ser Pro Ser Gln Phe
65                      70                      75                      80

Asp Arg Phe Asp Ser Lys Lys Gly Ala Trp Glu Lys Gly Ser Phe Pro
85                      90                      95

Leu Ile Ile Asn Lys Leu Lys Met Glu Asp Ser Gln Thr Tyr Ile Cys
100                      105                      110

Glu Leu Glu Asn Arg Lys Glu Glu Val Glu Leu Trp Val Phe Lys Val

```

-continued

115					120					125					
Thr	Phe	Ser	Pro	Gly	Thr	Ser	Leu	Leu	Gln	Gly	Gln	Ser	Leu	Thr	Leu
130						135					140				
Thr	Leu	Asp	Ser	Asn	Ser	Lys	Val	Ser	Asn	Pro	Leu	Thr	Glu	Cys	Lys
145					150					155					160
His	Lys	Lys	Gly	Lys	Val	Val	Ser	Gly	Ser	Lys	Val	Leu	Ser	Met	Ser
				165					170					175	
Asn	Leu	Arg	Val	Gln	Asp	Ser	Asp	Phe	Trp	Asn	Cys	Thr	Val	Thr	Leu
			180					185					190		
Asp	Gln	Lys	Lys	Asn	Trp	Phe	Gly	Met	Thr	Leu	Ser	Val	Leu	Gly	Phe
	195						200					205			
Gln	Ser	Thr	Ala	Ile	Thr	Ala	Tyr	Lys	Ser	Glu	Gly	Glu	Ser	Ala	Glu
210						215					220				
Phe	Ser	Phe	Pro	Leu	Asn	Phe	Ala	Glu	Glu	Asn	Gly	Trp	Gly	Glu	Leu
225					230					235					240
Met	Trp	Lys	Ala	Glu	Lys	Asp	Ser	Phe	Phe	Gln	Pro	Trp	Ile	Ser	Phe
				245					250					255	
Ser	Ile	Lys	Asn	Lys	Glu	Val	Ser	Val	Gln	Lys	Ser	Thr	Lys	Asp	Leu
		260						265					270		
Lys	Leu	Gln	Leu	Lys	Glu	Thr	Leu	Pro	Leu	Thr	Leu	Lys	Ile	Pro	Gln
	275						280					285			
Val	Ser	Leu	Gln	Phe	Ala	Gly	Ser	Gly	Asn	Leu	Thr	Leu	Thr	Leu	Asp
290						295					300				
Lys	Gly	Thr	Leu	His	Gln	Glu	Val	Asn	Leu	Val	Val	Met	Lys	Val	Ala
305					310					315					320
Gln	Leu	Asn	Asn	Thr	Leu	Thr	Cys	Glu	Val	Met	Gly	Pro	Thr	Ser	Pro
				325					330					335	
Lys	Met	Arg	Leu	Thr	Leu	Lys	Gln	Glu	Asn	Gln	Glu	Ala	Arg	Val	Ser
		340						345					350		
Glu	Glu	Gln	Lys	Val	Val	Gln	Val	Val	Ala	Pro	Glu	Thr	Gly	Leu	Trp
	355						360					365			
Gln	Cys	Leu	Leu	Ser	Glu	Gly	Asp	Lys	Val	Lys	Met	Asp	Ser	Arg	Ile
370						375					380				
Gln	Val	Leu	Ser	Arg	Gly	Val	Tyr	Gln	Phe	Ser	Leu	Phe	Ile	Val	Cys
385					390					395					400
Thr	Val	Thr	Leu	Thr	Leu	Phe	Leu	Met	Thr	Ile	Leu	Thr	Val	Thr	Lys
				405					410					415	
Phe	Arg	Gly	Phe	Cys	Phe	Ile	Cys	Tyr	Lys	Thr	Ala	Gln	Arg	Leu	Val
			420					425					430		
Phe	Lys	Asp	His	Pro	Gln	Gly	Thr	Glu	Pro	Asp	Met	Tyr	Lys	Tyr	Asp
	435						440					445			
Ala	Tyr	Leu	Cys	Phe	Ser	Ser	Lys	Asp	Phe	Thr	Trp	Val	Gln	Asn	Ala
450						455					460				
Leu	Leu	Lys	His	Leu	Asp	Thr	Gln	Tyr	Ser	Asp	Gln	Asn	Arg	Phe	Asn
465					470					475					480
Leu	Cys	Phe	Glu	Glu	Arg	Asp	Phe	Val	Pro	Gly	Glu	Asn	Arg	Ile	Ala
				485					490					495	
Asn	Ile	Gln	Asp	Ala	Ile	Trp	Asn	Ser	Arg	Lys	Ile	Val	Cys	Leu	Val
		500						505					510		
Ser	Arg	His	Phe	Leu	Arg	Asp	Gly	Trp	Cys	Leu	Glu	Ala	Phe	Ser	Tyr
		515						520				525			
Ala	Gln	Gly	Arg	Cys	Leu	Ser	Asp	Leu	Asn	Ser	Ala	Leu	Ile	Met	Val
530						535					540				

-continued

Val Val Gly Ser Leu Ser Gln Tyr Gln Leu Met Lys His Gln Ser Ile
 545 550 555 560

Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu Arg Trp Pro Glu Asp Leu
 565 570 575

Gln Asp Val Gly Trp Phe Leu His Lys Leu Ser Gln Gln Ile Leu Lys
 580 585 590

Lys Glu Lys Glu Lys Lys Lys Asp Asn Asn Ile Pro Leu Gln Thr Val
 595 600 605

Ala Thr Ile Ser
 610

<210> SEQ ID NO 11
 <211> LENGTH: 572
 <212> TYPE: PRT
 <213> ORGANISM: C. jejuni

<400> SEQUENCE: 11

Met Gly Phe Arg Ile Asn Thr Asn Val Ala Ala Leu Asn Ala Lys Ala
 1 5 10 15

Asn Ala Asp Leu Asn Ser Lys Ser Leu Asp Ala Ser Leu Ser Arg Leu
 20 25 30

Ser Ser Gly Leu Arg Ile Asn Ser Ala Ala Asp Asp Ala Ser Gly Met
 35 40 45

Ala Ile Ala Asp Thr Leu Arg Ser Gln Ala Asn Thr Leu Gly Gln Ala
 50 55 60

Ile Ser Asn Gly Asn Asp Ala Ile Gly Ile Leu Gln Thr Ala Asp Lys
 65 70 75 80

Ala Met Asp Glu Gln Leu Lys Ile Leu Asp Thr Ile Lys Thr Lys Ala
 85 90 95

Thr Gln Ala Ala Gln Asp Gly Gln Ser Leu Lys Thr Arg Thr Met Leu
 100 105 110

Gln Ala Asp Ile Asn Arg Leu Met Glu Glu Leu Asp Asn Ile Ala Asn
 115 120 125

Thr Thr Ser Phe Asn Gly Lys Gln Leu Leu Ser Gly Asn Phe Ile Asn
 130 135 140

Gln Glu Phe Gln Ile Gly Ala Ser Ser Asn Gln Thr Val Lys Ala Thr
 145 150 155 160

Ile Gly Ala Thr Gln Ser Ser Lys Ile Gly Leu Thr Arg Phe Glu Thr
 165 170 175

Gly Gly Arg Ile Ser Thr Ser Gly Glu Val Gln Phe Thr Leu Lys Asn
 180 185 190

Tyr Asn Gly Ile Asp Asp Phe Gln Phe Gln Lys Val Val Ile Ser Thr
 195 200 205

Ser Val Gly Thr Gly Leu Gly Ala Leu Ala Asp Glu Ile Asn Lys Asn
 210 215 220

Ala Asp Lys Thr Gly Val Arg Ala Thr Phe Thr Val Glu Thr Arg Gly
 225 230 235 240

Ile Ala Ala Val Arg Ala Gly Ala Thr Ser Asp Thr Phe Ala Ile Asn
 245 250 255

Gly Val Lys Ile Gly Lys Val Asp Tyr Lys Asp Gly Asp Ala Asn Gly
 260 265 270

Ala Leu Val Ala Ala Ile Asn Ser Val Lys Asp Thr Thr Gly Val Glu
 275 280 285

Ala Ser Ile Asp Ala Asn Gly Gln Leu Leu Leu Thr Ser Arg Glu Gly

-continued

290	295	300
Arg Gly Ile Lys Ile Asp	Gly Asn Ile Gly Gly	Gly Ala Phe Ile Asn
305	310	315 320
Ala Asp Met Lys Glu Asn Tyr	Gly Arg Leu Ser	Leu Val Lys Asn Asp
	325	330 335
Gly Lys Asp Ile Leu Ile Ser	Gly Ser Asn Leu Ser	Ser Ala Gly Phe
	340	345 350
Gly Ala Thr Gln Phe Ile Ser	Gln Ala Ser Val Ser	Leu Arg Glu Ser
	355	360 365
Lys Gly Gln Ile Asp Ala Asn	Ile Ala Asp Ala Met	Gly Phe Gly Ser
	370 375	380
Ala Asn Lys Gly Val Val Leu	Gly Gly Tyr Ser	Ser Val Ser Ala Tyr
	385 390	395 400
Met Ser Ser Ala Gly Ser	Gly Phe Ser Ser	Gly Tyr Ser Val
	405	410 415
Gly Ser Gly Lys Asn Tyr Ser	Thr Gly Phe Ala Asn	Ala Ile Ala Ile
	420	425 430
Ser Ala Ala Ser Gln Leu Ser	Thr Val Tyr Asn Val	Ser Ala Gly Ser
	435	440 445
Gly Phe Ser Ser Gly Ser	Thr Leu Ser Gln Phe	Ala Thr Met Lys Thr
	450 455	460
Thr Ala Phe Gly Val Lys Asp	Glu Thr Ala Gly	Val Thr Thr Leu Lys
	465 470	475 480
Gly Ala Met Ala Val Met Asp	Ile Ala Glu Thr	Ala Thr Thr Asn Leu
	485	490 495
Asp Gln Ile Arg Ala Asp	Ile Gly Ser Val	Gln Asn Gln Val Thr Ser
	500	505 510
Thr Ile Asn Asn Ile Thr Val	Thr Gln Val Asn Val	Lys Ala Ala Glu
	515	520 525
Ser Gln Ile Arg Asp Val Asp	Phe Ala Ala Glu	Ser Ala Asn Tyr Ser
	530 535	540
Lys Ala Asn Ile Leu Ala Gln	Ser Gly Ser Tyr	Ala Met Ala Gln Ala
	545 550	555 560
Asn Ser Val His Gln Asn Val	Leu Arg Leu Leu Gln	
	565	570

<210> SEQ ID NO 12

<211> LENGTH: 510

<212> TYPE: PRT

<213> ORGANISM: H. pylori

<400> SEQUENCE: 12

Met Ala Phe Gln Val Asn Thr	Asn Ile Asn Ala Met	Asn Ala His Val
1	5	10 15
Gln Ser Ala Leu Thr Gln	Asn Ala Leu Lys Thr	Ser Leu Glu Arg Leu
	20	25 30
Ser Ser Gly Leu Arg Ile	Asn Lys Ala Ala Asp	Asp Ala Ser Gly Met
	35	40 45
Thr Val Ala Asp Ser Leu	Arg Ser Gln Ala Ser	Ser Leu Gly Gln Ala
	50	55 60
Ile Ala Asn Thr Asn Asp	Gly Met Gly Ile Ile	Gln Val Ala Asp Lys
	65 70	75 80
Ala Met Asp Glu Gln Leu	Lys Ile Leu Asp Thr	Val Lys Val Lys Ala
	85	90 95

-continued

Thr	Gln	Ala	Ala	Gln	Asp	Gly	Gln	Thr	Thr	Glu	Ser	Arg	Lys	Ala	Ile
			100					105					110		
Gln	Ser	Asp	Ile	Val	Arg	Leu	Ile	Gln	Gly	Leu	Asp	Asn	Ile	Gly	Asn
		115					120					125			
Thr	Thr	Thr	Tyr	Asn	Gly	Gln	Ala	Leu	Leu	Ser	Gly	Gln	Phe	Thr	Asn
	130					135					140				
Lys	Glu	Phe	Gln	Val	Gly	Ala	Tyr	Ser	Asn	Gln	Ser	Ile	Lys	Ala	Ser
145					150					155					160
Ile	Gly	Ser	Thr	Thr	Ser	Asp	Lys	Ile	Gly	Gln	Val	Arg	Ile	Ala	Thr
				165					170					175	
Gly	Ala	Leu	Ile	Thr	Ala	Ser	Gly	Asp	Ile	Ser	Leu	Thr	Phe	Lys	Gln
			180					185					190		
Val	Asp	Gly	Val	Asn	Asp	Val	Thr	Leu	Glu	Ser	Val	Lys	Val	Ser	Ser
		195					200					205			
Ser	Ala	Gly	Thr	Gly	Ile	Gly	Val	Leu	Ala	Glu	Val	Ile	Asn	Lys	Asn
	210					215					220				
Ser	Asn	Arg	Thr	Gly	Val	Lys	Ala	Tyr	Ala	Ser	Val	Ile	Thr	Thr	Ser
225					230					235					240
Asp	Val	Ala	Val	Gln	Ser	Gly	Ser	Leu	Ser	Asn	Leu	Thr	Leu	Asn	Gly
				245					250					255	
Ile	His	Leu	Gly	Asn	Ile	Ala	Asp	Ile	Lys	Lys	Asn	Asp	Ser	Asp	Gly
			260					265					270		
Arg	Leu	Val	Ala	Ala	Ile	Asn	Ala	Val	Thr	Ser	Glu	Thr	Gly	Val	Glu
		275					280						285		
Ala	Tyr	Thr	Asp	Gln	Lys	Gly	Arg	Leu	Asn	Leu	Arg	Ser	Ile	Asp	Gly
	290					295					300				
Arg	Gly	Ile	Glu	Ile	Lys	Thr	Asp	Ser	Val	Ser	Asn	Gly	Pro	Ser	Ala
305					310					315					320
Leu	Thr	Met	Val	Asn	Gly	Gly	Gln	Asp	Leu	Thr	Lys	Gly	Ser	Thr	Asn
				325					330					335	
Tyr	Gly	Arg	Leu	Ser	Leu	Thr	Arg	Leu	Asp	Ala	Lys	Ser	Ile	Asn	Val
			340					345					350		
Val	Ser	Ala	Ser	Asp	Ser	Gln	His	Leu	Gly	Phe	Thr	Ala	Ile	Gly	Phe
		355					360					365			
Gly	Glu	Ser	Gln	Val	Ala	Glu	Thr	Thr	Val	Asn	Leu	Arg	Asp	Val	Thr
	370					375					380				
Gly	Asn	Phe	Asn	Ala	Asn	Val	Lys	Ser	Ala	Ser	Gly	Ala	Asn	Tyr	Asn
385					390					395					400
Ala	Val	Ile	Ala	Ser	Gly	Asn	Gln	Ser	Leu	Gly	Ser	Gly	Val	Thr	Thr
				405					410					415	
Leu	Arg	Gly	Ala	Met	Val	Val	Ile	Asp	Ile	Ala	Glu	Ser	Ala	Met	Lys
			420					425					430		
Met	Leu	Asp	Lys	Val	Arg	Ser	Asp	Leu	Gly	Ser	Val	Gln	Asn	Gln	Met
		435					440					445			
Ile	Ser	Thr	Val	Asn	Asn	Ile	Ser	Ile	Thr	Gln	Val	Asn	Val	Lys	Ala
450						455					460				
Ala	Glu	Ser	Gln	Ile	Arg	Asp	Val	Asp	Phe	Ala	Glu	Glu	Ser	Ala	Asn
465					470				475						480
Phe	Asn	Lys	Asn	Asn	Ile	Leu	Ala	Gln	Ser	Gly	Ser	Tyr	Ala	Met	Ser
				485				490						495	
Gln	Ala	Asn	Thr	Val	Gln	Gln	Asn	Ile	Leu	Arg	Leu	Leu	Thr		
				500				505					510		

-continued

```

<210> SEQ ID NO 13
<211> LENGTH: 379
<212> TYPE: PRT
<213> ORGANISM: V. cholerae

<400> SEQUENCE: 13

Met Thr Ile Asn Val Asn Thr Asn Val Ser Ala Met Thr Ala Gln Arg
 1             5             10            15

Tyr Leu Thr Lys Ala Thr Gly Glu Leu Asn Thr Ser Met Glu Arg Leu
      20            25            30

Ser Ser Gly Asn Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Leu
      35            40            45

Gln Ile Ser Asn Arg Leu Thr Ala Gln Ser Arg Gly Leu Asp Val Ala
 50            55            60

Met Arg Asn Ala Asn Asp Gly Ile Ser Ile Ala Gln Thr Ala Glu Gly
 65            70            75            80

Ala Met Asn Glu Ser Thr Ser Ile Leu Gln Arg Met Arg Asp Leu Ala
      85            90            95

Leu Gln Ser Ala Asn Gly Thr Asn Ser Ala Ser Glu Arg Gln Ala Leu
      100           105           110

Asn Glu Glu Ser Val Ala Leu Gln Asp Glu Leu Asn Arg Ile Ala Glu
 115           120           125

Thr Thr Ser Phe Gly Gly Arg Lys Leu Leu Asn Gly Ser Phe Gly Glu
 130           135           140

Ala Ser Phe Gln Ile Gly Ser Ser Ser Gly Glu Ala Ile Ile Met Gly
 145           150           155           160

Leu Thr Ser Val Arg Ala Asp Asp Phe Arg Met Gly Gly Gln Ser Phe
      165           170           175

Ile Ala Glu Gln Pro Lys Thr Lys Glu Trp Gly Val Pro Pro Thr Ala
      180           185           190

Arg Asp Leu Lys Phe Glu Phe Thr Lys Lys Asp Gly Glu Ala Val Val
 195           200           205

Leu Asp Ile Ile Ala Lys Asp Gly Asp Asp Ile Glu Glu Leu Ala Thr
 210           215           220

Tyr Ile Asn Gly Gln Thr Asp Leu Phe Lys Ala Ser Val Asp Gln Glu
 225           230           235           240

Gly Lys Leu Gln Ile Phe Val Ala Glu Pro Asn Ile Glu Gly Asn Phe
      245           250           255

Asn Ile Ser Gly Gly Leu Ala Thr Glu Leu Gly Leu Asn Gly Gly Pro
      260           265           270

Gly Val Lys Thr Thr Val Gln Asp Ile Asp Ile Thr Ser Val Gly Gly
 275           280           285

Ser Gln Asn Ala Val Gly Ile Ile Asp Ala Ala Leu Lys Tyr Val Asp
 290           295           300

Ser Gln Arg Ala Asp Leu Gly Ala Lys Gln Asn Arg Leu Ser His Ser
 305           310           315           320

Ile Ser Asn Leu Ser Asn Ile Gln Glu Asn Val Glu Ala Ser Lys Ser
      325           330           335

Arg Ile Lys Asp Thr Asp Phe Ala Lys Glu Thr Thr Gln Leu Thr Lys
      340           345           350

Ser Gln Ile Leu Gln Gln Ala Gly Thr Ser Ile Leu Ala Gln Ala Lys
 355           360           365

Gln Leu Pro Asn Ser Ala Ile Ser Leu Leu Gln
 370           375

```

-continued

```

<210> SEQ ID NO 14
<211> LENGTH: 394
<212> TYPE: PRT
<213> ORGANISM: P. aeruginosa

<400> SEQUENCE: 14

Met Ala Leu Thr Val Asn Thr Asn Ile Ala Ser Leu Asn Thr Gln Arg
 1           5           10          15
Asn Leu Asn Asn Ser Ser Ala Ser Leu Asn Thr Ser Leu Gln Arg Leu
 20          25          30
Ser Thr Gly Ser Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Leu
 35          40          45
Gln Ile Ala Asn Arg Leu Thr Ser Gln Val Asn Gly Leu Asn Val Ala
 50          55          60
Thr Lys Asn Ala Asn Asp Gly Ile Ser Leu Ala Gln Thr Ala Glu Gly
 65          70          75          80
Ala Leu Gln Gln Ser Thr Asn Ile Leu Gln Arg Met Arg Asp Leu Ser
 85          90          95
Leu Gln Ser Ala Asn Gly Ser Asn Ser Asp Ser Glu Arg Thr Ala Leu
100         105        110
Asn Gly Glu Ala Lys Gln Leu Gln Lys Glu Leu Asp Arg Ile Ser Asn
115        120        125
Thr Thr Thr Phe Gly Gly Arg Lys Leu Leu Asp Gly Ser Phe Gly Val
130        135        140
Ala Ser Phe Gln Val Gly Ser Ala Ala Asn Glu Ile Ile Ser Val Gly
145        150        155        160
Ile Asp Glu Met Ser Ala Glu Ser Leu Asn Gly Thr Tyr Phe Lys Ala
165        170        175
Asp Gly Gly Gly Ala Val Thr Ala Ala Thr Ala Ser Gly Thr Val Asp
180        185        190
Ile Ala Ile Gly Ile Thr Gly Gly Ser Ala Val Asn Val Lys Val Asp
195        200        205
Met Lys Gly Asn Glu Thr Ala Glu Gln Ala Ala Ala Lys Ile Ala Ala
210        215        220
Ala Val Asn Asp Ala Asn Val Gly Ile Gly Ala Phe Ser Asp Gly Asp
225        230        235        240
Thr Ile Ser Tyr Val Ser Lys Ala Gly Lys Asp Gly Ser Gly Ala Ile
245        250        255
Thr Ser Ala Val Ser Gly Val Val Ile Ala Asp Thr Gly Ser Thr Gly
260        265        270
Val Gly Thr Ala Ala Gly Val Ala Pro Ser Ala Thr Ala Phe Ala Lys
275        280        285
Thr Asn Asp Thr Val Ala Lys Ile Asp Ile Ser Thr Ala Lys Ala Leu
290        295        300
Ser Arg Arg Ala Gly Asp Arg Thr Thr Ala Ile Lys Gln Ile Asp Ala
305        310        315        320
Ser Val Pro Thr Ser Val Ala Val Gln Asn Arg Phe Asp Asn Thr Ile
325        330        335
Asn Asn Leu Lys Asn Ile Gly Glu Asn Val Ser Ala Ala Arg Gly Arg
340        345        350
Ile Glu Asp Thr Asp Phe Ala Ala Glu Thr Ala Asn Leu Thr Lys Asn
355        360        365
Gln Val Leu Gln Gln Ala Gly Thr Ala Ile Leu Ala Gln Ala Asn Gln
370        375        380

```

-continued

Leu Pro Gln Ser Val Leu Ser Leu Leu Arg
385 390

<210> SEQ ID NO 15
<211> LENGTH: 170
<212> TYPE: PRT
<213> ORGANISM: R. sphaeroides

<400> SEQUENCE: 15

Met Thr Thr Ile Asn Thr Asn Ile Gly Ala Ile Ala Ala Gln Ala Asn
1 5 10 15
Met Thr Lys Val Asn Asp Gln Phe Asn Thr Ala Met Thr Arg Leu Ser
20 25 30
Thr Gly Leu Arg Ile Asn Ala Ala Lys Asp Asp Ala Ala Gly Met Ala
35 40 45
Ile Gly Glu Lys Met Thr Ala Gln Val Met Gly Leu Asn Gln Ala Ile
50 55 60
Arg Asn Ala Gln Asp Gly Lys Asn Leu Val Asp Thr Thr Glu Gly Ala
65 70 75 80
His Val Glu Val Ser Ser Met Leu Gln Arg Leu Arg Glu Leu Ala Val
85 90 95
Gln Ser Ser Asn Asp Thr Asn Thr Ala Ala Asp Arg Gly Ser Leu Ala
100 105 110
Ala Glu Gly Lys Gln Leu Ile Ala Glu Ile Asn Arg Val Ala Glu Ser
115 120 125
Thr Thr Phe Asn Gly Met Lys Val Leu Asp Gly Ser Phe Thr Gly Lys
130 135 140
Gln Leu Gln Ile Gly Ala Asp Ser Gly Gln Thr Met Ala Ile Asn Val
145 150 155 160
Asp Ser Ala Ala Ala Thr Asp Ile Gly Ala
165 170

<210> SEQ ID NO 16
<211> LENGTH: 365
<212> TYPE: PRT
<213> ORGANISM: P. mirabilis1

<400> SEQUENCE: 16

Met Ala Gln Val Ile Asn Thr Asn Tyr Leu Ser Leu Val Thr Gln Asn
1 5 10 15
Asn Leu Asn Lys Ser Gln Gly Thr Leu Gly Ser Ala Ile Glu Arg Leu
20 25 30
Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln
35 40 45
Ala Ile Ala Asn Arg Phe Thr Ser Asn Val Asn Gly Leu Thr Gln Ala
50 55 60
Ser Arg Asn Ala Asn Asp Gly Ile Ser Ile Ala Gln Thr Thr Glu Gly
65 70 75 80
Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln Arg Ile Arg Glu Leu Thr
85 90 95
Val Gln Ala Lys Asn Gly Thr Asn Ser Asn Ser Asp Ile Thr Ser Ile
100 105 110
Gln Asn Glu Val Lys Asn Val Leu Asp Glu Ile Asn Arg Ile Ser Glu
115 120 125
Gln Thr Gln Phe Asn Gly Val Lys Val Leu Ser Gly Glu Lys Ser Glu
130 135 140

-continued

```

Met Val Ile Gln Val Gly Thr Asn Asp Asn Glu Thr Ile Lys Phe Asn
145          150          155          160

Leu Asp Lys Val Asp Asn Asp Thr Leu Gly Val Ala Ser Asp Lys Leu
          165          170          175

Phe Asp Thr Lys Thr Glu Lys Lys Gly Val Thr Ala Ala Gly Ala Gly
          180          185          190

Val Thr Asp Ala Lys Lys Ile Asn Ala Ala Ala Thr Leu Asp Met Met
          195          200          205

Val Ser Leu Val Lys Glu Phe Asn Leu Asp Gly Lys Pro Val Thr Asp
210          215          220

Lys Phe Ile Val Thr Lys Gly Gly Lys Asp Tyr Val Ala Thr Lys Ser
225          230          235          240

Asp Phe Glu Leu Asp Ala Thr Gly Thr Lys Leu Gly Leu Lys Ala Ser
          245          250          255

Ala Thr Thr Glu Phe Lys Val Asp Ala Gly Lys Asp Val Lys Thr Leu
          260          265          270

Asn Val Lys Asp Asp Ala Leu Ala Thr Leu Asp Lys Ala Ile Asn Thr
          275          280          285

Ile Asp Glu Ser Arg Ser Lys Leu Gly Ala Ile Gln Asn Arg Phe Glu
290          295          300

Ser Thr Ile Asn Asn Leu Asn Asn Thr Val Asn Asn Leu Ser Ala Ser
305          310          315          320

Arg Ser Arg Ile Leu Asp Ala Asp Tyr Ala Thr Glu Val Ser Asn Met
          325          330          335

Ser Arg Gly Gln Ile Leu Gln Gln Ala Gly Thr Ser Val Leu Ala Gln
          340          345          350

Ala Asn Gln Val Pro Gln Thr Val Leu Ser Leu Leu Arg
          355          360          365

```

<210> SEQ ID NO 17

<211> LENGTH: 367

<212> TYPE: PRT

<213> ORGANISM: P. mirabilis2

<400> SEQUENCE: 17

```

Met Ala Gln Val Ile Asn Thr Asn Tyr Leu Ser Leu Val Thr Gln Asn
 1          5          10          15

Asn Leu Asn Arg Ser Gln Ser Ala Leu Gly Asn Ala Ile Glu Arg Leu
20          25          30

Ser Ser Gly Met Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln
35          40          45

Ala Ile Ala Asn Arg Phe Thr Ser Asn Ile Asn Gly Leu Thr Gln Ala
50          55          60

Ser Arg Asn Ala Asn Asp Gly Ile Ser Val Ser Gln Thr Thr Glu Gly
65          70          75          80

Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln Arg Ile Arg Glu Leu Thr
85          90          95

Val Gln Ala Lys Asn Gly Thr Asn Ser Asn Ser Asp Ile Asn Ser Ile
100         105         110

Gln Asn Glu Val Asn Gln Arg Leu Asp Glu Ile Asn Arg Val Ser Glu
115         120         125

Gln Thr Gln Phe Asn Gly Val Lys Val Leu Ser Gly Glu Lys Ser Lys
130         135         140

Met Thr Ile Gln Val Gly Thr Asn Asp Asn Glu Val Ile Glu Phe Asn

```

-continued

145	150	155	160
Leu Asp Lys Ile Asp Asn Asp Thr Leu Gly Val Ala Ser Asp Lys Leu	165	170	175
Phe Asp Ala Lys Thr Glu Lys Lys Gly Val Thr Ala Ala Gly Asp Ala	180	185	190
Ile Asp Ala Asn Ala Leu Gly Ile Ser Gly Ser Lys Lys Tyr Val Thr	195	200	205
Gly Ile Ser Val Lys Glu Tyr Lys Val Asp Gly Lys Val Ser Ser Asp	210	215	220
Lys Val Val Leu Asn Asp Gly Ser Asp Asp Tyr Ile Val Ser Lys Ser	225	230	235
Asp Phe Thr Leu Lys Ser Gly Thr Thr Thr Gly Glu Val Glu Phe Thr	245	250	255
Gly Ser Lys Thr Thr Lys Phe Thr Ala Asp Ala Gly Lys Asp Val Lys	260	265	270
Val Leu Asn Val Lys Asp Asp Ala Leu Ala Thr Leu Asp Asn Ala Ile	275	280	285
Ser Lys Val Asp Glu Ser Arg Ser Lys Leu Gly Ala Ile Gln Asn Arg	290	295	300
Phe Gln Ser Thr Ile Asn Asn Leu Asn Asn Thr Val Asn Asn Leu Ser	305	310	315
Ala Ser Arg Ser Arg Ile Leu Asp Ala Asp Tyr Ala Thr Glu Val Ser	325	330	335
Asn Met Ser Lys Asn Gln Ile Leu Gln Gln Ala Gly Thr Ala Val Leu	340	345	350
Ala Gln Ala Asn Gln Val Pro Gln Thr Val Leu Ser Leu Leu Arg	355	360	365

<210> SEQ ID NO 18
 <211> LENGTH: 506
 <212> TYPE: PRT
 <213> ORGANISM: S. typhimurium2

<400> SEQUENCE: 18

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Leu Thr Gln Asn	1	5	10	15
Asn Leu Asn Lys Ser Gln Ser Ala Leu Gly Thr Ala Ile Glu Arg Leu	20	25	30	
Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln	35	40	45	
Ala Ile Ala Asn Arg Phe Thr Ala Asn Ile Lys Gly Leu Thr Gln Ala	50	55	60	
Ser Arg Asn Ala Asn Asp Gly Ile Ser Ile Ala Gln Thr Thr Glu Gly	65	70	75	80
Ala Leu Asn Glu Ile Asn Asn Asn Leu Gln Arg Val Arg Glu Leu Ala	85	90	95	
Val Gln Ser Ala Asn Ser Thr Asn Ser Gln Ser Asp Leu Asp Ser Ile	100	105	110	
Gln Ala Glu Ile Thr Gln Arg Leu Asn Glu Ile Asp Arg Val Ser Gly	115	120	125	
Gln Thr Gln Phe Asn Gly Val Lys Val Leu Ala Gln Asp Asn Thr Leu	130	135	140	
Thr Ile Gln Val Gly Ala Asn Asp Gly Glu Thr Ile Asp Ile Asp Leu	145	150	155	160

Lys	Gln	Ile	Asn	Ser	Gln	Thr	Leu	Gly	Leu	Asp	Ser	Leu	Asn	Val	Gln
				165					170					175	
Lys	Ala	Tyr	Asp	Val	Lys	Asp	Thr	Ala	Val	Thr	Thr	Lys	Ala	Tyr	Ala
			180					185					190		
Asn	Asn	Gly	Thr	Thr	Leu	Asp	Val	Ser	Gly	Leu	Asp	Asp	Ala	Ala	Ile
			195				200					205			
Lys	Ala	Ala	Thr	Gly	Gly	Thr	Asn	Gly	Thr	Ala	Ser	Val	Thr	Gly	Gly
						215					220				
Ala	Val	Lys	Phe	Asp	Ala	Asp	Asn	Asn	Lys	Tyr	Phe	Val	Thr	Ile	Gly
225					230					235					240
Gly	Phe	Thr	Gly	Ala	Asp	Ala	Ala	Lys	Asn	Gly	Asp	Tyr	Glu	Val	Asn
				245					250					255	
Val	Ala	Thr	Asp	Gly	Thr	Val	Thr	Leu	Ala	Ala	Gly	Ala	Thr	Lys	Thr
			260					265					270		
Thr	Met	Pro	Ala	Gly	Ala	Thr	Thr	Lys	Thr	Glu	Val	Gln	Glu	Leu	Lys
			275				280					285			
Asp	Thr	Pro	Ala	Val	Val	Ser	Ala	Asp	Ala	Lys	Asn	Ala	Leu	Ile	Ala
			290			295					300				
Gly	Gly	Val	Asp	Ala	Thr	Asp	Ala	Asn	Gly	Ala	Glu	Leu	Val	Lys	Met
305					310					315					320
Ser	Tyr	Thr	Asp	Lys	Asn	Gly	Lys	Thr	Ile	Glu	Gly	Gly	Tyr	Ala	Leu
				325					330					335	
Lys	Ala	Gly	Asp	Lys	Tyr	Tyr	Ala	Ala	Asp	Tyr	Asp	Glu	Ala	Thr	Gly
			340					345					350		
Ala	Ile	Lys	Ala	Lys	Thr	Thr	Ser	Tyr	Thr	Ala	Ala	Asp	Gly	Thr	Thr
			355				360					365			
Lys	Thr	Ala	Ala	Asn	Gln	Leu	Gly	Gly	Val	Asp	Gly	Lys	Thr	Glu	Val
						375					380				
Val	Thr	Ile	Asp	Gly	Lys	Thr	Tyr	Asn	Ala	Ser	Lys	Ala	Ala	Gly	His
385					390					395					400
Asp	Phe	Lys	Ala	Gln	Pro	Glu	Leu	Ala	Glu	Ala	Ala	Ala	Lys	Thr	Thr
				405				410						415	
Glu	Asn	Pro	Leu	Gln	Lys	Ile	Asp	Ala	Ala	Leu	Ala	Gln	Val	Asp	Ala
			420					425					430		
Leu	Arg	Ser	Asp	Leu	Gly	Ala	Val	Gln	Asn	Arg	Phe	Asn	Ser	Ala	Ile
			435				440					445			
Thr	Asn	Leu	Gly	Asn	Thr	Val	Asn	Asn	Leu	Ser	Glu	Ala	Arg	Ser	Arg
						455					460				
Ile	Glu	Asp	Ser	Asp	Tyr	Ala	Thr	Glu	Val	Ser	Asn	Met	Ser	Arg	Ala
465					470					475					480
Gln	Ile	Leu	Gln	Gln	Ala	Gly	Thr	Ser	Val	Leu	Ala	Gln	Ala	Asn	Gln
				485					490					495	
Val	Pro	Gln	Asn	Val	Leu	Ser	Leu	Leu	Arg						
			500					505							

<400> SEQUENCE: 19

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Leu Thr Gln Asn
1 5 10 15
Asn Leu Asn Lys Ser Gln Ser Ala Leu Gly Thr Ala Ile Glu Arg Leu
20 25 30

-continued

Ser	Ser	Gly	Leu	Arg	Ile	Asn	Ser	Ala	Lys	Asp	Asp	Ala	Ala	Gly	Gln
		35						40				45			
Ala	Ile	Ala	Asn	Arg	Phe	Thr	Ala	Asn	Ile	Lys	Gly	Leu	Thr	Gln	Ala
	50					55					60				
Ser	Arg	Asn	Ala	Asn	Asp	Gly	Ile	Ser	Ile	Ala	Gln	Thr	Thr	Glu	Gly
65				70						75				80	
Ala	Leu	Asn	Glu	Ile	Asn	Asn	Asn	Leu	Gln	Arg	Val	Arg	Glu	Leu	Ala
			85					90					95		
Val	Gln	Ser	Ala	Asn	Ser	Thr	Asn	Ser	Gln	Ser	Asp	Leu	Asp	Ser	Ile
			100					105					110		
Gln	Ala	Glu	Ile	Thr	Gln	Arg	Leu	Asn	Glu	Ile	Asp	Arg	Val	Asn	Gly
	115						120					125			
Gln	Thr	Gln	Phe	Ser	Gly	Val	Lys	Val	Leu	Ala	Gln	Asp	Asn	Thr	Leu
	130					135					140				
Thr	Ile	Gln	Val	Gly	Ala	Asn	Asp	Gly	Glu	Thr	Ile	Asp	Ile	Asp	Leu
145					150					155					160
Lys	Gln	Ile	Asn	Ser	Gln	Thr	Leu	Gly	Leu	Asp	Thr	Leu	Asn	Val	Gln
			165					170						175	
Gln	Lys	Tyr	Lys	Val	Ser	Asp	Thr	Ala	Ala	Thr	Val	Thr	Gly	Tyr	Ala
			180					185					190		
Asp	Thr	Thr	Ile	Ala	Leu	Asp	Asn	Ser	Thr	Phe	Lys	Ala	Ser	Ala	Thr
		195					200					205			
Gly	Leu	Gly	Gly	Thr	Asp	Glu	Lys	Ile	Asp	Gly	Asp	Leu	Lys	Phe	Asp
	210					215					220				
Asp	Thr	Thr	Gly	Lys	Tyr	Tyr	Ala	Lys	Val	Thr	Val	Thr	Gly	Gly	Thr
225					230					235					240
Gly	Lys	Asp	Gly	Tyr	Tyr	Glu	Val	Ser	Val	Asp	Lys	Thr	Asn	Gly	Glu
			245					250						255	
Val	Thr	Leu	Ala	Ala	Val	Thr	Pro	Ala	Thr	Val	Thr	Thr	Ala	Thr	Ala
		260						265					270		
Leu	Ser	Gly	Lys	Met	Tyr	Ser	Ala	Asn	Pro	Asp	Ser	Asp	Ile	Ala	Lys
		275					280					285			
Ala	Ala	Leu	Thr	Ala	Ala	Gly	Val	Thr	Gly	Thr	Ala	Ser	Val	Val	Lys
	290					295					300				
Met	Ser	Tyr	Thr	Asp	Asn	Asn	Gly	Lys	Thr	Ile	Asp	Gly	Gly	Leu	Ala
305					310					315					320
Val	Lys	Val	Gly	Asp	Asp	Tyr	Tyr	Ser	Ala	Thr	Gln	Asp	Lys	Asp	Gly
			325					330						335	
Ser	Ile	Ser	Ile	Asp	Thr	Thr	Lys	Tyr	Thr	Ala	Asp	Asn	Gly	Thr	Ser
			340					345					350		
Lys	Thr	Ala	Leu	Asn	Lys	Leu	Gly	Gly	Ala	Asp	Gly	Lys	Thr	Glu	Val
		355				360						365			
Val	Thr	Ile	Asp	Gly	Lys	Thr	Tyr	Asn	Ala	Ser	Lys	Ala	Ala	Gly	His
	370					375					380				
Asp	Phe	Lys	Ala	Glu	Pro	Glu	Leu	Ala	Glu	Gln	Ala	Ala	Lys	Thr	Thr
385					390					395					400
Glu	Asn	Pro	Leu	Gln	Lys	Ile	Asp	Ala	Ala	Leu	Ala	Gln	Val	Asp	Thr
			405					410						415	
Leu	Arg	Ser	Asp	Leu	Gly	Ala	Val	Gln	Asn	Arg	Phe	Asn	Ser	Ala	Ile
			420					425					430		
Thr	Asn	Leu	Gly	Asn	Thr	Val	Asn	Asn	Leu	Ser	Ser	Ala	Arg	Ser	Arg
		435					440					445			

-continued

```

Ile Glu Asp Ser Asp Tyr Ala Thr Glu Val Ser Asn Met Ser Arg Ala
 450                      455                      460

Gln Ile Leu Gln Gln Ala Gly Thr Ser Val Leu Ala Gln Ala Asn Gln
465                      470                      475                      480

Val Pro Gln Asn Val Leu Ser Leu Leu Arg
      485                      490

```

```

<210> SEQ ID NO 20
<211> LENGTH: 351
<212> TYPE: PRT
<213> ORGANISM: S. marcesens

```

```

<400> SEQUENCE: 20

```

```

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Met Ala Gln Asn
 1              5              10              15

Asn Leu Asn Lys Ser Gln Ser Ser Leu Gly Thr Ala Ile Glu Arg Leu
20              25              30

Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln
35              40              45

Ala Ile Ser Asn Arg Phe Thr Ala Asn Ile Lys Gly Leu Thr Gln Ala
50              55              60

Ser Arg Asn Ala Asn Asp Gly Ile Ser Leu Ala Gln Thr Thr Glu Gly
65              70              75              80

Ala Leu Asn Glu Val Asn Asp Asn Leu Gln Asn Ile Arg Arg Leu Thr
85              90              95

Val Gln Ala Gln Asn Gly Ser Asn Ser Thr Ser Asp Leu Lys Ser Ile
100             105             110

Gln Asp Glu Ile Thr Gln Arg Leu Ser Glu Ile Asn Arg Ile Ser Glu
115             120             125

Gln Thr Asp Phe Asn Gly Val Lys Val Leu Ser Ser Asp Gln Lys Leu
130             135             140

Thr Ile Gln Val Gly Ala Asn Asp Gly Glu Thr Thr Asp Ile Asp Leu
145             150             155             160

Lys Lys Ile Asp Ala Lys Gln Leu Gly Met Asp Thr Phe Asp Val Thr
165             170             175

Thr Lys Ser Ala Lys Ala Gly Ala Glu Ile Ala Thr Gly Thr Lys Ile
180             185             190

Thr Val Asp Ser Asp Ala Thr Lys Gln Ala Asp Ala Asp Val Thr Gly
195             200             205

Leu Ala Lys Gly Gln Thr Leu Val Ser Gly Thr Asp Ala Asp Gly Lys
210             215             220

Ser Ala Tyr Phe Ile Ala Thr Lys Asp Asp Ala Thr Gly Asp Val Ala
225             230             235             240

Tyr Thr Lys Ala Lys Val Ala Asp Asp Gly Lys Val Thr Asp Ser Gly
245             250             255

Thr Asp Ala Gly Val Lys Asn Pro Leu Ala Thr Leu Asp Lys Ala Leu
260             265             270

Ala Gln Val Asp Gly Leu Arg Ser Ser Leu Gly Ala Val Gln Asn Arg
275             280             285

Phe Asp Ser Val Ile Asn Asn Leu Asn Ser Thr Val Asn Asn Leu Ser
290             295             300

Ala Ser Gln Ser Arg Ile Gln Asp Ala Asp Tyr Ala Thr Glu Val Ser
305             310             315             320

Asn Met Ser Arg Ala Asn Ile Leu Gln Gln Ala Gly Thr Ser Val Leu
325             330             335

```


-continued

Ala Gln Ala Asn Gln Ser Thr Gln Asn Val Leu Ser Leu Leu Arg
 340 345 350

<210> SEQ ID NO 21
 <211> LENGTH: 554
 <212> TYPE: PRT
 <213> ORGANISM: E. coli

<400> SEQUENCE: 21

Met Ala Gln Val Ile Asn Thr Asn Ser Leu Ser Leu Ile Thr Gln Asn
 1 5 10 15

Asn Ile Asn Lys Asn Gln Ser Ala Leu Ser Ser Ser Ile Glu Arg Leu
 20 25 30

Ser Ser Gly Leu Arg Ile Asn Ser Ala Lys Asp Asp Ala Ala Gly Gln
 35 40 45

Ala Ile Ala Asn Arg Phe Thr Ser Asn Ile Lys Gly Leu Thr Gln Ala
 50 55 60

Ala Arg Asn Ala Asn Asp Gly Ile Ser Val Ala Gln Thr Thr Glu Gly
 65 70 75 80

Ala Leu Ser Glu Ile Asn Asn Asn Leu Gln Arg Ile Arg Glu Leu Thr
 85 90 95

Val Gln Ala Thr Thr Gly Thr Asn Ser Asp Ser Asp Leu Asp Ser Ile
 100 105 110

Gln Asp Glu Ile Lys Ser Arg Leu Asp Glu Ile Asp Arg Val Ser Gly
 115 120 125

Gln Thr Gln Phe Asn Gly Val Asn Val Leu Ser Lys Asp Gly Ser Met
 130 135 140

Lys Ile Gln Val Gly Ala Asn Asp Gly Glu Thr Ile Thr Ile Asp Leu
 145 150 155 160

Lys Lys Ile Asp Ser Asp Thr Leu Asn Leu Ala Gly Phe Asn Val Asn
 165 170 175

Gly Glu Gly Glu Thr Ala Asn Thr Ala Ala Thr Leu Lys Asp Met Val
 180 185 190

Gly Leu Lys Leu Asp Asn Thr Gly Val Thr Thr Ala Gly Val Asn Arg
 195 200 205

Tyr Ile Ala Asp Lys Ala Val Ala Ser Ser Thr Asp Ile Leu Asn Ala
 210 215 220

Val Ala Gly Val Asp Gly Ser Lys Val Ser Thr Glu Ala Asp Val Gly
 225 230 235 240

Phe Gly Ala Ala Ala Pro Gly Thr Pro Val Glu Tyr Thr Tyr His Lys
 245 250 255

Asp Thr Asn Thr Tyr Thr Ala Ser Ala Ser Val Asp Ala Thr Gln Leu
 260 265 270

Ala Ala Phe Leu Asn Pro Glu Ala Gly Gly Thr Thr Ala Ala Thr Val
 275 280 285

Ser Ile Gly Asn Gly Thr Thr Ala Gln Glu Gln Lys Val Ile Ile Ala
 290 295 300

Lys Asp Gly Ser Leu Thr Ala Ala Asp Asp Gly Ala Ala Leu Tyr Leu
 305 310 315 320

Asp Asp Thr Gly Asn Leu Ser Lys Thr Asn Ala Gly Thr Asp Thr Gln
 325 330 335

Ala Lys Leu Ser Asp Leu Met Ala Asn Asn Ala Asn Ala Lys Thr Val
 340 345 350

Ile Thr Thr Asp Lys Gly Thr Phe Thr Ala Asn Thr Thr Lys Phe Asp

-continued

355					360					365					
Gly	Val	Asp	Ile	Ser	Val	Asp	Ala	Ser	Thr	Phe	Ala	Asn	Ala	Val	Lys
370					375					380					
Asn	Glu	Thr	Tyr	Thr	Ala	Thr	Val	Gly	Val	Thr	Leu	Pro	Ala	Thr	Tyr
385					390					395					400
Thr	Val	Asn	Asn	Gly	Thr	Ala	Ala	Ser	Ala	Tyr	Leu	Val	Asp	Gly	Lys
				405					410					415	
Val	Ser	Lys	Thr	Pro	Ala	Glu	Tyr	Phe	Ala	Gln	Ala	Asp	Gly	Thr	Ile
			420					425					430		
Thr	Ser	Gly	Glu	Asn	Ala	Ala	Thr	Ser	Lys	Ala	Ile	Tyr	Val	Ser	Ala
		435					440					445			
Asn	Gly	Asn	Leu	Thr	Thr	Asn	Thr	Thr	Ser	Glu	Ser	Glu	Ala	Thr	Thr
	450					455					460				
Asn	Pro	Leu	Ala	Ala	Leu	Asp	Asp	Ala	Ile	Ala	Ser	Ile	Asp	Lys	Phe
465				470					475					480	
Arg	Ser	Ser	Leu	Gly	Ala	Ile	Gln	Asn	Arg	Leu	Asp	Ser	Ala	Val	Thr
			485					490						495	
Asn	Leu	Asn	Asn	Thr	Thr	Thr	Asn	Leu	Ser	Glu	Ala	Gln	Ser	Arg	Ile
		500					505						510		
Gln	Asp	Ala	Asp	Tyr	Ala	Thr	Glu	Val	Ser	Asn	Met	Ser	Lys	Ala	Gln
	515						520					525			
Ile	Ile	Gln	Gln	Ala	Gly	Asn	Ser	Val	Leu	Ala	Lys	Ala	Asn	Gln	Val
	530					535					540				
Pro	Gln	Gln	Val	Leu	Ser	Leu	Gln	Gln	Gly						
545				550											

<210> SEQ ID NO 22

<211> LENGTH: 550

<212> TYPE: PRT

<213> ORGANISM: S. flexneri

<400> SEQUENCE: 22

Met	Ala	Gln	Val	Ile	Asn	Thr	Asn	Ser	Leu	Ser	Leu	Ile	Thr	Gln	Asn
1				5					10					15	
Asn	Ile	Asn	Lys	Asn	Gln	Ser	Ala	Leu	Ser	Ser	Ser	Ile	Glu	Arg	Leu
		20						25					30		
Ser	Ser	Gly	Leu	Arg	Ile	Asn	Ser	Ala	Lys	Asp	Asp	Ala	Ala	Gly	Gln
		35				40						45			
Ala	Ile	Ala	Asn	Arg	Phe	Thr	Ser	Asn	Ile	Lys	Gly	Leu	Thr	Gln	Ala
	50					55					60				
Ala	Arg	Asn	Ala	Asn	Asp	Gly	Ile	Ser	Val	Ala	Gln	Thr	Thr	Glu	Gly
65				70					75					80	
Ala	Leu	Ser	Glu	Ile	Asn	Asn	Asn	Leu	Gln	Arg	Ile	Arg	Glu	Leu	Thr
			85					90					95		
Val	Gln	Ala	Ser	Thr	Gly	Thr	Asn	Ser	Asp	Ser	Asp	Leu	Asp	Ser	Ile
		100						105					110		
Gln	Asp	Glu	Ile	Lys	Ser	Arg	Leu	Asp	Glu	Ile	Asp	Arg	Val	Ser	Gly
		115					120					125			
Gln	Thr	Gln	Phe	Asn	Gly	Val	Asn	Val	Leu	Ala	Lys	Asp	Gly	Ser	Met
	130					135						140			
Lys	Ile	Gln	Val	Gly	Ala	Asn	Asp	Gly	Gln	Thr	Ile	Thr	Ile	Asp	Leu
145				150					155						160
Lys	Lys	Ile	Asp	Ser	Asp	Thr	Leu	Gly	Leu	Asn	Gly	Phe	Asn	Val	Asn
				165				170						175	

-continued

Gly	Gly	Gly	Ala	Val	Ala	Asn	Thr	Ala	Ala	Ser	Lys	Ala	Asp	Leu	Val
			180					185					190		
Ala	Ala	Asn	Ala	Thr	Val	Val	Gly	Asn	Lys	Tyr	Thr	Val	Ser	Ala	Gly
		195					200					205			
Tyr	Asp	Ala	Ala	Lys	Ala	Ser	Asp	Leu	Leu	Ala	Gly	Val	Ser	Asp	Gly
	210					215					220				
Asp	Thr	Val	Gln	Ala	Thr	Ile	Asn	Asn	Gly	Phe	Gly	Thr	Ala	Ala	Ser
	225				230					235					240
Ala	Thr	Asn	Tyr	Lys	Tyr	Asp	Ser	Ala	Ser	Lys	Ser	Tyr	Ser	Phe	Asp
			245						250					255	
Thr	Thr	Thr	Ala	Ser	Ala	Ala	Asp	Val	Gln	Lys	Tyr	Leu	Thr	Pro	Gly
			260					265					270		
Val	Gly	Asp	Thr	Ala	Lys	Gly	Thr	Ile	Thr	Ile	Asp	Gly	Ser	Ala	Gln
		275					280					285			
Asp	Val	Gln	Ile	Ser	Ser	Asp	Gly	Lys	Ile	Thr	Ala	Ser	Asn	Gly	Asp
	290					295					300				
Lys	Leu	Tyr	Ile	Asp	Thr	Thr	Gly	Arg	Leu	Thr	Lys	Asn	Gly	Ser	Gly
	305				310					315					320
Ala	Ser	Leu	Thr	Glu	Ala	Ser	Leu	Ser	Thr	Leu	Ala	Ala	Asn	Asn	Thr
				325					330					335	
Lys	Ala	Thr	Thr	Ile	Asp	Ile	Gly	Gly	Thr	Ser	Ile	Ser	Phe	Thr	Gly
			340					345					350		
Asn	Ser	Thr	Thr	Pro	Asp	Thr	Ile	Thr	Tyr	Ser	Val	Thr	Gly	Ala	Lys
		355					360					365			
Val	Asp	Gln	Ala	Ala	Phe	Asp	Lys	Ala	Val	Ser	Thr	Ser	Gly	Asn	Asn
	370					375					380				
Val	Asp	Phe	Thr	Thr	Ala	Gly	Tyr	Ser	Val	Asn	Gly	Thr	Thr	Gly	Ala
	385				390					395					400
Val	Thr	Lys	Gly	Val	Asp	Ser	Val	Tyr	Val	Asp	Asn	Asn	Glu	Ala	Leu
			405					410						415	
Thr	Thr	Ser	Asp	Thr	Val	Asp	Phe	Tyr	Leu	Gln	Asp	Asp	Gly	Ser	Val
			420					425					430		
Thr	Asn	Gly	Ser	Gly	Lys	Ala	Val	Tyr	Lys	Asp	Ala	Asp	Gly	Lys	Leu
		435					440					445			
Thr	Thr	Asp	Ala	Glu	Thr	Lys	Ala	Ala	Thr	Thr	Ala	Asp	Pro	Leu	Lys
	450					455					460				
Ala	Leu	Asp	Glu	Ala	Ile	Ser	Ser	Ile	Asp	Lys	Phe	Arg	Ser	Ser	Leu
	465				470					475					480
Gly	Ala	Val	Gln	Asn	Arg	Leu	Asp	Ser	Ala	Val	Thr	Asn	Leu	Asn	Asn
				485					490					495	
Thr	Thr	Thr	Asn	Leu	Ser	Glu	Ala	Gln	Ser	Arg	Ile	Gln	Asp	Ala	Asp
			500					505					510		
Tyr	Ala	Thr	Glu	Val	Ser	Asn	Met	Ser	Lys	Ala	Gln	Ile	Ile	Gln	Gln
		515					520					525			
Ala	Gly	Asn	Ser	Val	Leu	Ala	Lys	Ala	Asn	Gln	Val	Pro	Gln	Gln	Val
	530					535					540				
Leu	Ser	Leu	Leu	Gln	Gly										
	545				550										

<210> SEQ ID NO 23

<211> LENGTH: 286

<212> TYPE: PRT

<213> ORGANISM: T. pallidumA

<400> SEQUENCE: 23

-continued

```

Met Ile Ile Asn His Asn Met Ser Ala Met Phe Ala Gln Arg Thr Leu
 1             5             10             15
Gly His Thr Asn Val Gln Val Gly Lys Gly Ile Glu Lys Leu Ser Ser
          20             25             30
Gly Tyr Arg Ile Asn Arg Ala Gly Asp Asp Ala Ser Gly Leu Ala Val
          35             40             45
Ser Glu Lys Met Arg Ser Gln Ile Arg Gly Leu Asn Gln Ala Ser Thr
 50             55             60
Asn Ala Ser Asn Gly Val Asn Phe Ile Gln Val Thr Glu Ala Tyr Leu
65             70             75             80
Gln Glu Thr Thr Asp Ile Met Gln Arg Ile Arg Glu Leu Ala Ile Gln
          85             90             95
Ala Ala Asn Gly Ile Tyr Ser Ala Glu Asp Arg Met Gln Ile Gln Val
          100             105             110
Glu Val Ser Gln Leu Val Ala Glu Val Asp Arg Ile Ala Ser Ser Ala
          115             120             125
Gln Phe Asn Gly Met Asn Leu Leu Thr Gly Arg Phe Ser Arg Thr Glu
          130             135             140
Gly Glu Asn Val Ile Gly Gly Ser Met Trp Phe His Ile Gly Ala Asn
          145             150             155             160
Met Asp Gln Arg Met Arg Val Tyr Ile Gly Thr Met Thr Ala Val Ala
          165             170             175
Leu Gly Val Arg Asn Gly Val Asp Glu Ser Ile Met Ser Ile Glu Thr
          180             185             190
Ala Asp Ser Ala Asn Lys Ser Ile Gly Thr Ile Asp Ala Ala Leu Lys
          195             200             205
Arg Ile Asn Lys Gln Arg Ala Asp Leu Gly Gly Tyr Gln Asn Arg Met
          210             215             220
Glu Tyr Thr Val Val Gly Leu Asp Ile Ala Ala Glu Asn Leu Gln Ala
          225             230             235             240
Ala Glu Ser Arg Ile Arg Asp Ala Asn Ile Ala Lys Gln Met Val Glu
          245             250             255
Tyr Thr Lys Asn Gln Val Leu Thr Gln Ser Gly Thr Ala Met Leu Ala
          260             265             270
Gln Ala Asn Thr Ser Ala Gln Ser Ile Leu Ser Ile Leu Arg
          275             280             285

```

<210> SEQ ID NO 24

<211> LENGTH: 286

<212> TYPE: PRT

<213> ORGANISM: T. pallidumB

<400> SEQUENCE: 24

```

Met Ile Ile Asn His Asn Met Ser Ala Met Phe Ala Gln Arg Thr Leu
 1             5             10             15
Gly Asn Thr Asn Leu Ser Val Gln Lys Asn Met Glu Lys Leu Ser Ser
          20             25             30
Gly Leu Arg Ile Asn Arg Ala Gly Asp Asp Ala Ser Gly Leu Ala Val
          35             40             45
Ser Glu Lys Met Arg Ser Gln Ile Arg Gly Leu Asn Gln Ala Ser Thr
 50             55             60
Asn Ala Gln Asn Gly Ile Ser Phe Ile Gln Val Ala Glu Ser Tyr Leu
65             70             75             80
Gln Glu Thr Thr Asp Val Ile Gln Arg Ile Arg Glu Leu Ser Val Gln

```

-continued

85	90	95
Ser Ala Asn Gly Ile Tyr	Ser Ala Glu Asp Arg Met Tyr Ile Gln Val	
100	105	110
Glu Val Ser Gln Leu Val Ala Glu Ile Asp Arg Ile Ala Ser His Ala		
115	120	125
Gln Phe Asn Gly Met Asn Met Leu Thr Gly Arg Phe Ala Arg Glu Thr		
130	135	140
Gly Glu Asn Thr Val Thr Ala Ser Met Trp Phe His Ile Gly Ala Asn		
145	150	155
Met Asp Gln Arg Thr Arg Ala Tyr Ile Gly Thr Met Thr Ala Ala Ala		
165	170	175
Leu Gly Val Arg Asp Val Gly Asp Glu Ser Ile Leu Asn Ile Asp Asp		
180	185	190
Pro Glu Lys Ala Asn Arg Ala Ile Gly Thr Leu Asp Glu Ala Ile Lys		
195	200	205
Lys Ile Asn Lys Gln Arg Ala Asp Leu Gly Ala Tyr Gln Asn Arg Leu		
210	215	220
Glu Tyr Thr Val Ile Gly Val Asn Val Ala Ala Glu Asn Leu Gln Ala		
225	230	235
Ala Glu Ser Arg Ile Arg Asp Val Asp Met Ala Lys Glu Met Val Asp		
245	250	255
Tyr Thr Lys Asn Gln Ile Leu Val Gln Ser Gly Thr Ala Met Leu Ala		
260	265	270
Gln Ala Asn Gln Ala Thr Gln Ser Val Leu Ser Leu Leu Arg		
275	280	285

<210> SEQ ID NO 25

<211> LENGTH: 283

<212> TYPE: PRT

<213> ORGANISM: L. pneumophila

<400> SEQUENCE: 25

Met Ile Ile Asn His Asn Leu Ser Ala Val Asn Ala His Arg Ser Leu		
1	5	10
Lys Phe Asn Glu Leu Ala Val Asp Lys Thr Met Lys Ala Leu Ser Ser		
20	25	30
Gly Met Arg Ile Asn Ser Ala Ala Asp Asp Ala Ser Gly Leu Ala Val		
35	40	45
Ser Glu Lys Leu Arg Thr Gln Val Asn Gly Leu Arg Gln Ala Glu Arg		
50	55	60
Asn Thr Glu Asp Gly Met Ser Phe Ile Gln Thr Ala Glu Gly Phe Leu		
65	70	75
Glu Gln Thr Ser Asn Ile Ile Gln Arg Ile Arg Val Leu Ala Ile Gln		
85	90	95
Thr Ser Asn Gly Ile Tyr Ser Asn Glu Asp Arg Gln Leu Val Gln Val		
100	105	110
Glu Val Ser Ala Leu Val Asp Glu Val Asp Arg Ile Ala Ser Gln Ala		
115	120	125
Glu Phe Asn Lys Phe Lys Leu Phe Glu Gly Gln Phe Ala Arg Gly Ser		
130	135	140
Arg Val Ala Ser Met Trp Phe His Met Gly Pro Asn Gln Asn Gln Arg		
145	150	155
Glu Arg Phe Tyr Ile Gly Thr Met Thr Ser Lys Ala Leu Lys Leu Val		
165	170	175

Lys	Ala	Asp	Gly 180	Arg	Pro	Ile	Ala	Ile 185	Ser	Ser	Pro	Gly	Glu 190	Ala	Asn
Asp	Val	Ile 195	Gly	Leu	Ala	Asp	Ala 200	Ala	Leu	Thr	Lys	Ile 205	Met	Lys	Gln
Arg	Ala 210	Asp	Met	Gly	Ala	Tyr 215	Tyr	Asn	Arg	Leu	Glu 220	Tyr	Thr	Ala	Lys
Gly 225	Leu	Met	Gly	Ala	Tyr 230	Glu	Asn	Met	Gln	Ala 235	Ser	Glu	Ser	Arg	Ile 240
Arg	Asp	Ala	Asp 245	Met	Ala	Glu	Glu	Val 250	Val	Ser	Leu	Thr	Thr	Lys 255	Gln
Ile	Leu	Val	Gln 260	Ser	Gly	Thr	Ala	Met 265	Leu	Ala	Arg	Ala	Asn 270	Met	Lys
Pro	Asn	Ser 275	Val	Leu	Lys	Leu	Leu 280	Gln	His	Ile					

```
<210> SEQ ID NO 26
<211> LENGTH: 336
<212> TYPE: PRT
<213> ORGANISM: B. burgdorferi
```

<400> SEQUENCE: 26

Met 1	Ile	Ile	Asn	His 5	Asn	Thr	Ser	Ala	Ile 10	Asn	Ala	Ser	Arg	Asn 15	Asn
Gly	Ile	Asn	Ala 20	Ala	Asn	Leu	Ser	Lys 25	Thr	Gln	Glu	Lys	Leu 30	Ser	Ser
Gly	Tyr	Arg 35	Ile	Asn	Arg	Ala	Ser 40	Asp	Asp	Ala	Ala	Gly 45	Met	Gly	Val
Ser	Gly 50	Lys	Ile	Asn	Ala	Gln 55	Ile	Arg	Gly	Leu	Ser 60	Gln	Ala	Ser	Arg
Asn 65	Thr	Ser	Lys	Ala 70	Ile	Asn	Phe	Ile	Gln	Thr 75	Thr	Glu	Gly	Asn	Leu 80
Asn	Glu	Val	Glu	Lys 85	Val	Leu	Val	Arg	Met 90	Lys	Glu	Leu	Ala	Val	Gln
Ser	Gly	Asn	Gly 100	Thr	Tyr	Ser	Asp	Ala 105	Asp	Arg	Gly	Ser	Ile 110	Gln	Ile
Glu	Ile	Glu	Gln 115	Leu	Thr	Asp	Glu 120	Ile	Asn	Arg	Ile	Ala 125	Asp	Gln	Ala
Gln	Tyr 130	Asn	Gln	Met	His 135	Met	Leu	Ser	Asn	Lys 140	Ser	Ala	Ser	Gln	Asn
Val 145	Arg	Thr	Ala	Glu	Glu 150	Leu	Gly	Met	Gln	Pro 155	Ala	Lys	Ile	Asn	Thr 160
Pro	Ala	Ser	Leu 165	Ser	Gly	Ser	Gln	Ala	Ser 170	Trp	Thr	Leu	Arg	Val	His 175
Val	Gly	Ala	Asn 180	Gln	Asp	Glu	Ala	Ile 185	Ala	Val	Asn	Ile 190	Tyr	Ala	Ala
Asn	Val 195	Ala	Asn	Leu	Phe	Ser	Gly 200	Glu	Gly	Ala	Gln	Ala 205	Ala	Gln	Thr
Ala 210	Pro	Val	Gln	Glu	Gly 215	Ala	Gln	Gln	Glu	Gly	Ala 220	Gln	Gln	Pro	Ala
Pro 225	Val	Thr	Ala	Pro	Ser 230	Gln	Gly	Gly	Val	Asn 235	Ser	Pro	Val	Asn	Val 240
Thr	Thr	Thr	Val 245	Asp	Ala	Asn	Thr	Ser	Leu 250	Ala	Lys	Ile	Glu	Asn	Ala
Ile	Arg	Met	Ile 260	Ser	Asp	Gln	Arg	Ala 265	Asn	Leu	Gly	Ala 270	Phe	Gln	Asn

Arg	Leu	Glu	Ser	Ile	Lys	Asp	Ser	Thr	Glu	Tyr	Ala	Ile	Glu	Asn	Leu
	275						280					285			
Lys	Ala	Ser	Tyr	Ala	Gln	Ile	Lys	Asp	Ala	Thr	Met	Thr	Asp	Glu	Val
	290					295					300				
Val	Ala	Ala	Thr	Thr	Asn	Ser	Ile	Leu	Thr	Gln	Ser	Ala	Met	Ala	Met
305					310					315					320
Ile	Ala	Gln	Ala	Asn	Gln	Val	Pro	Gln	Tyr	Val	Leu	Ser	Leu	Leu	Arg
				325					330					335	

```
<210> SEQ ID NO 27
<211> LENGTH: 304
<212> TYPE: PRT
<213> ORGANISM: B. subtilus
```

<400> SEQUENCE: 27

Met 1	Arg	Ile	Asn	His 5	Asn	Ile	Ala	Ala	Leu 10	Asn	Thr	Leu	Asn	Arg 15	Leu
Ser	Ser	Asn	Asn	Ser	Ala	Ser	Gln	Lys 25	Asn	Met	Glu	Lys	Leu	Ser	Ser
Gly	Leu	Arg	Ile	Asn	Arg	Ala	Gly 40	Asp	Asp	Ala	Ala	Gly 45	Leu	Ala	Ile
Ser	Glu	Lys	Met	Arg	Gly	Gln	Ile	Arg	Gly	Leu	Glu	Met	Ala	Ser	Lys
Asn 65	Ser	Gln	Asp	Gly	Ile 70	Ser	Leu	Ile	Gln	Thr 75	Ala	Glu	Gly	Ala	Leu
Thr	Glu	Thr	His 85	Ala	Ile	Leu	Gln	Arg	Val 90	Arg	Glu	Leu	Val	Val	Gln
Ala	Gly	Asn	Thr	Gly	Thr	Gln	Asp	Lys 105	Ala	Thr	Asp	Leu	Gln	Ser	Ile
Gln	Asp	Glu	Ile	Ser	Ala	Leu	Thr	Asp	Glu	Ile	Asp	Gly 125	Ile	Ser	Asn
Arg	Thr 130	Glu	Phe	Asn	Gly	Lys 135	Lys	Leu	Leu	Asp	Gly 140	Thr	Tyr	Lys	Val
Asp 145	Thr	Ala	Thr	Pro	Ala 150	Asn	Gln	Lys	Asn	Leu 155	Val	Phe	Gln	Ile	Gly 160
Ala	Asn	Ala	Thr	Gln	Gln	Ile	Ser	Val	Asn	Ile	Glu	Asp	Met	Gly	Ala 175
Asp	Ala	Leu	Gly 180	Ile	Lys	Glu	Ala	Asp 185	Gly	Ser	Ile	Ala	Ala	Leu	His
Ser	Val	Asn	Asp	Leu	Asp	Val	Thr 200	Lys	Phe	Ala	Asp	Asn 205	Ala	Ala	Asp
Thr 210	Ala	Asp	Ile	Gly	Phe	Asp 215	Ala	Gln	Leu	Lys	Val	Val	Asp	Glu	Ala
Ile 225	Asn	Gln	Val	Ser	Ser 230	Gln	Arg	Ala	Lys	Leu 235	Gly	Ala	Val	Gln	Asn 240
Arg	Leu	Glu	His 245	Thr	Ile	Asn	Asn	Leu	Ser 250	Ala	Ser	Gly	Glu	Asn 255	Leu
Thr	Ala	Ala	Glu 260	Ser	Arg	Ile	Arg	Asp 265	Val	Asp	Met	Ala	Lys	Glu	Met
Ser	Glu	Phe	Thr	Lys	Asn	Asn	Ile 280	Leu	Ser	Gln	Ala	Ser 285	Gln	Ala	Met
Leu 290	Ala	Gln	Ala	Asn	Gln	Gln	Pro 295	Gln	Asn	Val	Leu	Gln	Leu	Leu	Arg

-continued

<210> SEQ ID NO 28
 <211> LENGTH: 281
 <212> TYPE: PRT
 <213> ORGANISM: C. difficile

<400> SEQUENCE: 28

```

Met Arg Val Asn Thr Asn Val Ser Ala Leu Ile Ala Asn Asn Gln Met
 1             5             10             15
Gly Arg Asn Val Ser Gly Gln Ser Lys Ser Met Glu Lys Leu Ser Ser
          20             25             30
Gly Leu Arg Ile Lys Arg Ala Ala Asp Asp Ala Ala Gly Leu Ala Ile
          35             40             45
Ser Glu Lys Met Arg Ala Gln Leu Lys Gly Leu Asp Gln Ala Gly Arg
          50             55             60
Asn Val Gln Asp Gly Ile Ser Val Val Gln Thr Ala Glu Gly Ala Leu
          65             70             75             80
Glu Glu Thr Gly Asn Ile Leu Thr Arg Met Arg Thr Leu Ala Val Gln
          85             90             95
Ala Ser Asn Glu Thr Asn Ser Lys Asp Glu Arg Ala Lys Ile Ala Gly
          100            105            110
Glu Met Glu Gln Leu Arg Ser Glu Val Asp Arg Ile Ala Asp Ser Thr
          115            120            125
Lys Phe Asn Gly Glu Asn Leu Leu Ser Ser Asp Lys Lys Ile Ala Leu
          130            135            140
Gln Val Gly Ala Glu Ala Val Ser Asn Asn Val Ile Glu Val Ser Leu
          145            150            155            160
Ile Asn Thr Lys Gly Val Leu Thr Thr Arg Asn Val Asn Ser Ala Asn
          165            170            175
Ile Asp Ala Met Ser Val Ser Gly Ser Ile Gly Thr Glu Ala Ala Ser
          180            185            190
Lys Met Ile Val Asn Leu Asp Ser Ser Leu Ala Asp Ile Asn Ser Ala
          195            200            205
Arg Ala Leu Leu Gly Ala Gln Gln Asn Arg Leu Glu Ser Thr Gln Asn
          210            215            220
Asn Leu Asn Asn Thr Val Glu Asn Val Thr Ala Ala Glu Ser Arg Ile
          225            230            235            240
Arg Asp Thr Asp Val Ala Ser Glu Met Val Asn Leu Ser Lys Met Asn
          245            250            255
Ile Leu Val Gln Ala Ser Gln Ser Met Leu Ser Gln Ala Asn Gln Gln
          260            265            270
Pro Gln Gly Val Leu Gln Leu Leu Gly
          275            280

```

<210> SEQ ID NO 29
 <211> LENGTH: 394
 <212> TYPE: PRT
 <213> ORGANISM: R. meliloti

<400> SEQUENCE: 29

```

Met Thr Ser Ile Leu Thr Asn Asn Ser Ala Met Ala Ala Leu Ser Thr
 1             5             10             15
Leu Arg Ser Ile Ser Ser Ser Met Glu Asp Thr Gln Ser Arg Ile Ser
          20             25             30
Ser Gly Leu Arg Val Gly Ser Ala Ser Asp Asn Ala Ala Tyr Trp Ser
          35             40             45
Ile Ala Thr Thr Met Arg Ser Asp Asn Gln Ala Leu Ser Ala Val Gln

```


-continued

50	55	60
Asp Ala Leu Gly Leu Gly	Ala Ala Lys Val Asp	Thr Ala Tyr Ser Gly
65	70	75 80
Met Glu Ser Ala Ile Glu Val Val Lys Glu Ile Lys Ala Lys Leu Val		
	85	90 95
Ala Ala Thr Glu Asp Gly Val Asp Lys Ala Lys Ile Gln Glu Glu Ile		
	100	105 110
Thr Gln Leu Lys Asp Gln Leu Thr Ser Ile Ala Glu Ala Ala Ser Phe		
	115	120 125
Ser Gly Glu Asn Trp Leu Gln Ala Asp Leu Ser Gly Gly Pro Val Thr		
	130	135 140
Lys Ser Val Val Gly Gly Phe Val Arg Asp Ser Ser Gly Ala Val Ser		
	145	150 155 160
Val Lys Lys Val Asp Tyr Ser Leu Asn Thr Asp Thr Val Leu Phe Asp		
	165	170 175
Thr Thr Gly Asn Thr Gly Ile Leu Asp Lys Val Tyr Asn Val Ser Gln		
	180	185 190
Ala Ser Val Thr Leu Pro Val Asn Val Asn Gly Thr Thr Ser Glu Tyr		
	195	200 205
Thr Val Gly Ala Tyr Asn Val Asp Asp Leu Ile Asp Ala Ser Ala Thr		
	210	215 220
Phe Asp Gly Asp Tyr Ala Asn Val Gly Ala Gly Ala Leu Ala Gly Asp		
	225	230 235 240
Tyr Val Lys Val Gln Gly Ser Trp Val Lys Ala Val Asp Val Ala Ala		
	245	250 255
Thr Gly Gln Glu Val Val Tyr Asp Asp Gly Thr Thr Lys Trp Gly Val		
	260	265 270
Asp Thr Thr Val Thr Gly Ala Pro Ala Thr Asn Val Ala Ala Pro Ala		
	275	280 285
Ser Ile Ala Thr Ile Asp Ile Thr Ile Ala Ala Gln Ala Gly Asn Leu		
	290	295 300
Asp Ala Leu Ile Ala Gly Val Asp Glu Ala Leu Thr Asp Met Thr Ser		
	305	310 315 320
Ala Ala Ala Ser Leu Gly Ser Ile Ser Ser Arg Ile Asp Leu Gln Ser		
	325	330 335
Asp Phe Val Asn Lys Leu Ser Asp Ser Ile Asp Ser Gly Val Gly Arg		
	340	345 350
Leu Val Asp Ala Asp Met Asn Glu Glu Ser Thr Arg Leu Lys Ala Leu		
	355	360 365
Gln Thr Gln Gln Gln Leu Ala Ile Gln Ala Leu Ser Ile Ala Asn Ser		
	370	375 380
Asp Ser Gln Asn Val Leu Ser Leu Phe Arg		
	385	390

<210> SEQ ID NO 30

<211> LENGTH: 306

<212> TYPE: PRT

<213> ORGANISM: A. tumefaciens

<400> SEQUENCE: 30

Met Ala Ser Ile Leu Thr Asn Asn Asn Ala Met Ala Ala Leu Ser Thr
1 5 10 15
Leu Arg Ser Ile Ala Ser Asp Leu Ser Thr Thr Gln Asp Arg Ile Ser
20 25 30

[illegible]

```
<210> SEQ ID NO 31
<211> LENGTH: 410
<212> TYPE: PRT
<213> ORGANISM: R. lupini
```

<400> SEQUENCE: 31

Met	Ala	Ser	Val	Leu	Thr	Asn	Ile	Asn	Ala	Met	Ser	Ala	Leu	Gln	Thr
1				5					10					15	
Leu	Arg	Ser	Ile	Ser	Ser	Asn	Met	Glu	Asp	Thr	Gln	Ser	Arg	Ile	Ser
			20					25					30		
Ser	Gly	Met	Arg	Val	Gly	Ser	Ala	Ser	Asp	Asn	Ala	Ala	Tyr	Trp	Ser
		35					40					45			
Ile	Ala	Thr	Thr	Met	Arg	Ser	Asp	Asn	Ala	Ser	Leu	Ser	Ala	Val	Gln
	50					55					60				
Asp	Ala	Ile	Gly	Leu	Gly	Ala	Ala	Lys	Val	Asp	Thr	Ala	Ser	Ala	Gly
65				70					75					80	
Met	Asp	Ala	Val	Ile	Asp	Val	Val	Lys	Gln	Ile	Lys	Asn	Lys	Leu	Val
			85					90					95		

-continued

Thr Ala Gln Glu Ser Ser Ala Asp Lys Thr Lys Ile Gln Gly Glu Val
 100 105 110
 Lys Gln Leu Gln Glu Gln Leu Lys Gly Ile Val Asp Ser Ala Ser Phe
 115 120 125
 Ser Gly Glu Asn Trp Leu Lys Gly Asp Leu Ser Thr Thr Thr Thr Lys
 130 135 140
 Ser Val Val Gly Ser Phe Val Arg Glu Gly Gly Thr Val Ser Val Lys
 145 150 155 160
 Thr Ile Asp Tyr Ala Leu Asn Ala Ser Lys Val Leu Val Asp Thr Arg
 165 170 175
 Ala Thr Gly Thr Lys Thr Gly Ile Leu Asp Thr Ala Tyr Thr Gly Leu
 180 185 190
 Asn Ala Asn Thr Val Thr Val Asp Ile Asn Lys Gly Gly Val Ile Thr
 195 200 205
 Gln Ala Ser Val Arg Ala Tyr Ser Thr Asp Glu Met Leu Ser Leu Gly
 210 215 220
 Ala Lys Val Asp Gly Ala Asn Ser Asn Val Ala Val Gly Gly Gly Ser
 225 230 235 240
 Ala Phe Val Lys Val Asp Gly Ser Trp Val Lys Gly Ser Val Asp Ala
 245 250 255
 Ala Ala Ser Ile Thr Ala Ser Thr Pro Val Ala Gly Lys Phe Ala Ala
 260 265 270
 Ala Tyr Thr Ala Ala Glu Ala Gly Thr Ala Ala Ala Ala Gly Asp Ala
 275 280 285
 Ile Ile Val Asp Glu Thr Asn Ser Gly Ala Gly Ala Val Asn Leu Thr
 290 295 300
 Gln Ser Val Leu Thr Met Asp Val Ser Ser Met Ser Ser Thr Asp Val
 305 310 315 320
 Gly Ser Tyr Leu Thr Gly Val Glu Lys Ala Leu Thr Ser Leu Thr Ser
 325 330 335
 Ala Gly Ala Glu Leu Gly Ser Ile Lys Gln Arg Ile Asp Leu Gln Val
 340 345 350
 Asp Phe Ala Ser Lys Leu Gly Asp Ala Leu Ala Lys Gly Ile Gly Arg
 355 360 365
 Leu Val Asp Ala Asp Met Asn Glu Glu Ser Thr Lys Leu Lys Ala Leu
 370 375 380
 Gln Thr Gln Gln Gln Leu Ala Ile Gln Ser Leu Ser Ile Ala Asn Ser
 385 390 395 400
 Asp Ser Gln Asn Ile Leu Ser Leu Phe Arg
 405 410

<210> SEQ ID NO 32

<211> LENGTH: 287

<212> TYPE: PRT

<213> ORGANISM: L. monocytogenes

<400> SEQUENCE: 32

Met Lys Val Asn Thr Asn Ile Ile Ser Leu Lys Thr Gln Glu Tyr Leu
 1 5 10 15
 Arg Lys Asn Asn Glu Gly Met Thr Gln Ala Gln Glu Arg Leu Ala Ser
 20 25 30
 Gly Lys Arg Ile Asn Ser Ser Leu Asp Asp Ala Ala Gly Leu Ala Val
 35 40 45
 Val Thr Arg Met Asn Val Lys Ser Thr Gly Leu Asp Ala Ala Ser Lys

-continued

50	55	60
Asn Ser Ser Met Gly Ile Asp Leu Leu Gln Thr Ala Asp Ser Ala Leu		
65	70	75 80
Ser Ser Met Ser Ser Ile Leu Gln Arg Met Arg Gln Leu Ala Val Gln		
	85	90 95
Ser Ser Asn Gly Ser Phe Ser Asp Glu Asp Arg Lys Gln Tyr Thr Ala		
	100	105 110
Glu Phe Gly Ser Leu Ile Lys Glu Leu Asp His Val Ala Asp Thr Thr		
	115	120 125
Asn Tyr Asn Asn Ile Lys Leu Leu Asp Gln Thr Ala Thr Gly Ala Ala		
	130	135 140
Thr Gln Val Ser Ile Gln Ala Ser Asp Lys Ala Asn Asp Leu Ile Asn		
	145	150 155 160
Ile Asp Leu Phe Asn Ala Lys Gly Leu Ser Ala Gly Thr Ile Thr Leu		
	165	170 175
Gly Ser Gly Ser Thr Val Ala Gly Tyr Ser Ala Leu Ser Val Ala Asp		
	180	185 190
Ala Asp Ser Ser Gln Glu Ala Thr Glu Ala Ile Asp Glu Leu Ile Asn		
	195	200 205
Asn Ile Ser Asn Gly Arg Ala Leu Leu Gly Ala Gly Met Ser Arg Leu		
	210	215 220
Ser Tyr Asn Val Ser Asn Val Asn Asn Gln Ser Ile Ala Thr Lys Ala		
	225	230 235 240
Ser Ala Ser Ser Ile Glu Asp Ala Asp Met Ala Ala Glu Met Ser Glu		
	245	250 255
Met Thr Lys Tyr Lys Ile Leu Thr Gln Thr Ser Ile Ser Met Leu Ser		
	260	265 270
Gln Ala Asn Gln Thr Pro Gln Met Leu Thr Gln Leu Ile Asn Ser		
	275	280 285

<210> SEQ ID NO 33
 <211> LENGTH: 399
 <212> TYPE: PRT
 <213> ORGANISM: B. claridgeiae

<400> SEQUENCE: 33

Met Gly Thr Ser Leu Leu Thr Asn Lys Ser Ala Met Thr Ala Leu Gln
1 5 10 15
Thr Leu Arg Ser Ile Asp Ala Asn Leu Asp Arg Ser Lys Asp Arg Val
20 25 30
Ser Thr Gly Leu Arg Ile Ser Asn Ala Ser Glu Asn Thr Ala Tyr Trp
35 40 45
Ser Ile Ser Ser Met Met Arg His Asp Ser Asn Thr Met Ser Ala Ile
50 55 60
Val Asp Ala Ile Asn Leu Gly Lys Glu Gln Val Gly Ile Ala Asp Thr
65 70 75 80
Ala Ile Gly Leu Thr Lys Glu Ala Leu Asp Asp Ile Gln Lys Ser Met
85 90 95
Val Ser Ala Arg Glu Lys Gly Ser Asp Asp Ile Ala Lys Ile Gln Asp
100 105 110
Ser Ile Ile Gly Asn Met Lys Asn Ile Ser Asn Ala Val Gln Ser Ala
115 120 125
Ser Phe Gly Gly Lys Asn Ile Leu Ser Asn Gly Gly Gln Thr Val Gly
130 135 140

-continued

```

Met Ala Ala Gly Tyr Arg Arg Glu Gly Thr Ala Val Tyr Val Asp Met
145                150                155                160

Ile Asp Val Gly Gly Ser Glu Leu Asn Phe Gly Thr Ile Gly Ser Asp
                165                170                175

Gly Thr Ile Asp Met Ser Gln Gly Val Leu Gly Gly Ile Phe Gly Thr
                180                185                190

Ser Lys Gly Asp Glu Gly Glu Asp Val Val Gly Lys Gly Ile Gly Ala
195                200                205

Phe Ser Ala Ala His Ala Thr Tyr Lys Gly Leu Glu Asp Thr Leu Arg
210                215                220

Asn Ala Glu Ala Asp Leu Ala Lys Ala Ile Ala Lys Tyr Gly Glu Ser
225                230                235                240

Pro Glu Asp Glu Pro Gly Lys Ala Ile Ile Glu Lys Ala Lys Gln Ala
                245                250                255

Val Glu Thr Ala Lys Thr Gly Leu Lys Asp Gly Gln Glu Ala Tyr Asn
                260                265                270

Lys Ala Lys Gly Glu Phe Gln Thr Val Leu Asp Gly Met Thr Leu Ala
275                280                285

Asp Phe Thr Glu Leu Lys Gly Leu Gly Glu Leu His Ser Asp Ile Gln
290                295                300

Arg Met Ile Met Thr Ser Val Gln Asn Thr Val Arg Asp Ala Val Asn
305                310                315                320

Val Thr Leu Thr Ala Gly Ser Lys Ile Gly Ala Ala Val Asn Leu Val
                325                330                335

Asn Ile Gln Leu Asn Phe Val Lys Lys Leu Leu Asp Asn Val Glu Val
                340                345                350

Gly Ile Gly Ala Leu Val Asp Ala Asp Met Asn Ala Glu Ser Ala Lys
355                360                365

Leu Ala Ala Leu Gln Val Gln Gln Gln Leu Gly Ile Gln Ala Leu Ser
370                375                380

Ile Ala Asn Gln Gly Ser Gln Asn Ile Leu Ala Leu Phe Arg Asn
385                390                395

```

<210> SEQ ID NO 34

<211> LENGTH: 181

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: consensus sequence

<400> SEQUENCE: 34

```

Met Ile Asn Thr Asn Val Ala Leu Ala Gln Asn Leu Lys Gln Leu Ser
 1                5                10                15

Leu Glu Arg Leu Ser Ser Gly Leu Arg Ile Asn Ser Ala Asp Asp Ala
20                25                30

Ala Gly Met Ala Ile Ala Arg Leu Ser Gln Val Arg Gly Leu Gln Ala
35                40                45

Thr Arg Asn Ala Asn Asp Gly Ile Ser Ile Leu Gln Thr Ala Glu Gly
50                55                60

Ala Leu Glu Ile Leu Gln Arg Ile Arg Asp Leu Val Gln Ala Asn Gly
65                70                75                80

Thr Gln Ser Asp Arg Ile Gln Glu Ile Gln Leu Met Glu Glu Ile Asp
85                90                95

Arg Ile Ala Thr Phe Asn Gly Met Lys Leu Leu Gly Gln Ile Gly Val
100               105               110

```

-continued

```

Ile Val Ile Gly Leu Leu Met Met Ile Asp Ala Met Leu Arg Ala Leu
    115                      120                      125

Gly Ala Val Gln Asn Arg Val Asp Ile Asn Leu Glu Asn Leu Ala Ala
    130                      135                      140

Ser Arg Ile Asp Ala Asp Ala Glu Val Thr Asn Leu Ser Lys Gln Ile
    145                      150                      155                      160

Leu Gln Gln Gly Ser Ile Leu Ala Gln Ala Asn Gln Pro Gln Asn Val
    165                      170                      175

Leu Ser Leu Leu Arg
    180

```

```

<210> SEQ ID NO 35
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

```

```

<400> SEQUENCE: 35

```

```

ttaaagtggg accagttctc ccttttcatt gtatgcact 39

```

```

<210> SEQ ID NO 36
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

```

```

<400> SEQUENCE: 36

```

```

cgggatcccg ttaggagatg gttgctacag tttagc 35

```

```

<210> SEQ ID NO 37
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic construct

```

```

<400> SEQUENCE: 37

```

```

Ala Asp Thr Arg Asp Leu Gly Ala Val Gln Asn Arg Phe Asn Ser Ala
  1           5           10           15

```

```

Ile Thr

```

```

<210> SEQ ID NO 38
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic construct

```

```

<400> SEQUENCE: 38

```

```

Val Asp Ala Arg Asp Leu Gly Ala Val Gln Asn Arg Phe Asn Ser Ala
  1           5           10           15

```

```

Ile Thr

```

```

<210> SEQ ID NO 39
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic construct

```

```

<400> SEQUENCE: 39

```

-continued

Val	Asp	Thr	Ala	Asp	Leu	Gly	Ala	Val	Gln	Asn	Arg	Phe	Asn	Ser	Ala
1				5					10					15	

Ile Thr

<210> SEQ ID NO 40
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic construct

<400> SEQUENCE: 40

Arg	Ser	Asp	Leu	Gly	Ala	Val	Gln	Asn	Arg	Phe	Asn	Ser	Ala	Ile
1			5					10					15	

<210> SEQ ID NO 41
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic construct

<400> SEQUENCE: 41

Asp	Leu	Gly	Ala	Val	Gln	Asn	Arg	Phe	Asn	Ser	Ala	Ile	Thr	Asn
1			5				10					15		

<210> SEQ ID NO 42
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic construct

<400> SEQUENCE: 42

Gly	Ala	Val	Gln	Asn	Arg	Phe	Asn	Ser	Ala	Ile	Thr	Asn	Leu	Gly
1			5				10					15		

<210> SEQ ID NO 43
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic construct

<400> SEQUENCE: 43

Val	Gln	Asn	Arg	Phe	Asn	Ser	Ala	Ile	Thr	Asn	Leu	Gly	Asn	Thr
1			5					10				15		

The invention claimed is:

1. A method to stimulate a TLR-mediated enhancement of an antigen specific immune response in subject which method comprises administering to said subject said antigen along with a flagellin polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:11-SEQ ID NO:34, and

wherein said flagellin polypeptide does not contain said antigen.

2. The method of claim 1 wherein said flagellin polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:11 - SEQ ID NO:34.

3. The method of claim 1 wherein the flagellin polypeptide further comprises an ADCC targeting molecule.

4. The method of claim 1 wherein said antigen is selected from the group consisting of polypeptides, polysaccharides,

50 pathologically aberrant cells, inactivated and attenuated viruses or bacteria, nucleic acids and toxoids.

5. The method of claim 1 wherein the flagellin polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:13 - SEQ ID NO:33.

55 6. The method of claim 5 wherein the flagellin polypeptide further comprises an ADCC targeting molecule.

7. The method of claim 5 wherein said antigen is selected from the group consisting of polypeptides, polysaccharides, pathologically aberrant cells, inactivated and attenuated viruses or bacteria, nucleic acids and toxoids.

60 8. The method of claim 1 wherein the flagellin polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:13 - SEQ ID NO:33.

* * * * *